Amide compounds and their uses
By providing a new amide compound of formula (I), the problem of the lack of CSF-1R inhibitors in the prior art is solved, and effective inhibition of CSF-1R is achieved, providing a treatment option for a variety of diseases.
Patent Information
- Application Number
- CN202311688364.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-03-30
- Filing Date
- 2021-03-29
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2041-03-29
AI Technical Summary
There is a lack of effective CSF-1R inhibitors in the current technology, especially novel amide compounds for the treatment of cancer, autoimmune diseases and inflammatory diseases.
A novel amide compound, specifically represented by formula (I), is provided that can inhibit the activity of CSF-1R and can be used to prepare pharmaceutical compositions for treating related diseases.
This compound can effectively inhibit CSF-1R activity, providing a new treatment approach for cancer, autoimmune diseases, inflammatory diseases, metabolic diseases, neurodegenerative diseases, obesity or obesity-related diseases.
Smart Images

Figure CN117720519B_ABST
Abstract
Description
[0001] This application is a divisional application of the international application filed on March 29, 2021, with application number PCT / CN2021 / 083664 and the invention title "Amide Compounds and Their Uses". The international application entered the Chinese national phase on September 22, 2022, with application number 202180023506.2. Technical Field
[0002] This invention relates to novel amide compounds, pharmaceutical compositions comprising them, and methods for their preparation and use. Background Technology
[0003] The type III tyrosine kinase receptor family includes CSF-1R, PDGFRα, PDGFRβ, FLT3, and c-KIT. All members of this family consist of an extracellular immunoglobulin-like domain, a transmembrane domain, a juxtamembrane domain, and a protein kinase domain, with the kinase domain being highly conserved (Nat Rev Cancer. 2012, 12(11):753-66). Their mediated phosphorylation signaling participates in numerous cellular biological functions and plays a crucial role in disease development. Among these, mutations in the PDGFRα and c-KIT kinase domains have been reported to lead to gastrointestinal tumors (J Pathol. 2011, 223(2):251-261). Furthermore, tandem duplication of FLT-3 (FLT3-ITD) has been identified as a key pathogenic factor in approximately 20% of patients with acute lymphoblastic leukemia (Biomark Insights. 2015, 10(Suppl 3):1-14).
[0004] CSF-1R, or CSF-1 receptor (Colony stimulating factor 1 receptor), is encoded by the oncogene c-fms. The human c-fms gene is located on chromosome 5, 5q33.3, downstream of the PDGF-Rβ gene, with the two linked end-to-end. Human CSF-1R is a single-chain, transmembrane receptor tyrosine kinase, a transmembrane glycoprotein composed of 972 amino acids with a molecular weight of 150 kDa. It consists of a 512-amino acid extracellular domain, a 25-amino acid transmembrane domain, and a 435-amino acid intracellular cytoplasmic domain. Its extracellular region has 5 disulfide bonds and 11 possible glycosylation sites, and its intracellular region has a Gly-X-Gly-XX-Gly motif. The lysine at position 616 is the ATP binding site. There is a 72-amino acid kinase insertion region on the flanking side of this site, which is speculated to have the function of recognizing specific substrates (ColdSpring Harb Perspect Biol. 2014, 6(6)).
[0005] CSF-1, also known as M-CSF (macrophage colony stimulating factor), is encoded by the CSF-1 gene. CSF-1 exerts its biological effects by binding to its unique cell surface receptor, CSF-1R. After binding to CSF-1, CSF-1R undergoes a conformational change, forming a dimer or higher polymer. After dimerization, the tyrosine kinase activity of the receptor is activated, and tyrosine residues at positions 544, 559, 699, 708, 723, 809, and 923 are phosphorylated. Subsequently, these residues interact with multiple intracellular signaling pathways, such as Ras, MAPK, PI3K, and JAK, leading to various biological effects in the cell (J Cell Biochem. 1988, 38(3):179-87).
[0006] The tumor microenvironment is a complex ecosystem that supports tumor development, growth, and metastasis. Macrophages are particularly abundant among immune cells that migrate to the tumor site and are present at all stages of tumor development. Studies have shown that tumor-associated macrophages (TAMs) play an important role in tumor development, growth, and metastasis. For primary tumors, macrophages can stimulate angiogenesis, assist in the extravasation, survival, and sustained growth of tumor cells, thereby promoting tumor cell metastasis. TAMs also play an immunosuppressive role, preventing natural killer cells and T cells from attacking tumor cells (Immunity. 2014, 41(1):49-61). CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depend on the CSF-1 / CSF-1R signaling pathway. The CSF-1 / CSF-1R signaling pathway intervenes in tumor progression by regulating TAMs, reducing tumor invasiveness and proliferation, so the CSF1 / CSF1R signaling pathway is a potential target for cancer therapy. Overexpression of CSF-1 or CSF-1R is associated with malignant invasiveness and poor prognosis in tumors. Studies have shown that the application of CSF-1R inhibitors can affect the exchange of inflammatory factors between TAMs and glioma cells, significantly reducing the volume of glioblastoma and decreasing tumor invasiveness and proliferation (Nat Med. 2013, 19(10): 1264-72). In addition, abnormally high expression of CSF-1 is a major pathogenesis of tenosynovial giant cell tumor (a rare non-metastatic tumor of the tendon sheath that presents as a giant cell tumor and pigmented villonodular synovitis). Patients with tenosynovial giant cell tumor have shown significant clinical benefits after using CSF-1R inhibitors (NEngl J Med. 2015, 373(5): 428-37).
[0007] Besides tumors, the CSF-1R signaling pathway plays an important role in autoimmune and inflammatory diseases, including systemic lupus erythematosus, arthritis, atherosclerosis, and obesity (Arthritis Res Ther. 2016, 18:75; Nat Rev Immunol. 2008, 8(7):533-44; J Immunother Cancer. 2017, 5(1):53). Therefore, the development of CSF-1R inhibitors may also be used to treat these diseases.
[0008] Currently, the CSF-1R and c-KIT inhibitor Pexidartinib have been approved by the FDA for the treatment of adult patients with tenosynovial giant cell tumors. However, there remains a need to develop new type III tyrosine kinase receptor inhibitors, particularly CSF-1R inhibitors, for the treatment of diseases such as cancer, autoimmune diseases, or inflammatory diseases. This invention addresses these needs. Invention Summary
[0009] This invention provides compounds of formula (I):
[0010]
[0011] Or its pharmaceutically acceptable salts, and / or its deuterated compounds, solvates, racemic mixtures, enantiomers, diastereomers and tautomers, wherein:
[0012] X is either N or CR5;
[0013] Z1 and Z2 are either N or CR6 independently;
[0014] Y1 is N or CR7; Y2 is N or CR8; Y3 is N or CR9;
[0015] L can be NH, O, S, or CH2;
[0016] W is absent or is NH, O, S or CH2;
[0017] R1 is a phenyl group, a 5-12-membered heteroaryl group, a 4-6-membered heterocyclic group, or a C-membered heterocyclic group. 3-8 Cycloalkyl groups, each optionally substituted with one or more groups selected from: halogen, -CN, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Halogenated groups, -(C 1-6 Alkylene) n -NH2、-(C 1-6 Alkylene) n -NH(C 1-6 alkyl), -(C1-6 Alkylene) n -N(C 1-6 alkyl)2、-(C 1-6 Alkylene) n -OH, -(C 1-6 Alkylene) n -O-(C 1-6 alkyl) or -(C 1-6 Alkylene) n -O-(C 1-6 (Halogenated groups);
[0018] R2 represents hydrogen, -CN, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Halogenated groups, -(C 1-6 alkylene)-NH2, -(C 1-6 alkylene)-NH(C 1-6 alkyl), -(C 1-6 alkylene)-N(C 1-6 alkyl)2、-(C 1-6 alkylene)-O-(C 1-6 alkyl), -(C 1-6 alkylene)-O-(C 1-6 Halogenated alkyl groups), -(C 1-6 alkylene)-OH, C 3-8 Cycloalkyl or 4-6 membered heterocyclic groups;
[0019] R3, R4, R5, R6, R7, and R8 are independently selected from: hydrogen, halogen, -CN, and C, respectively. 1-6 Alkyl, C 1-6 Halogenated groups, -O(C) 1-6 Alkyl), -O(C) 1-6 (haloalkyl) or -OH;
[0020] R9 represents hydrogen, halogen, -CN, or C. 1-6 Alkyl, C 1-6 Halogenated groups, -O(C) 1-6 Alkyl), -O(C) 1-6 Halogenated groups), -OH, -(C 1-6 alkylene)-OH, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl)2 or C 3-8 cycloalkyl;
[0021] n is 0 or 1;
[0022] Alternatively, when Y3 is CR9, R2, R9, together with the N and C atoms attached to them, form a 5-6 membered heteroaromatic ring or a 5-6 membered heterocyclic ring.
[0023] Alternatively, when Y2 is CR8 and Y3 is CR9, R8 and R9 together with the C atoms they are attached to form a benzene ring;
[0024] or for Where R 10 It is hydrogen or C 1-6 alkyl;
[0025] The condition is that when X is CH, Z1 is not N.
[0026] The present invention also provides a pharmaceutical composition comprising a compound of formula (I) of the present invention (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof, and optionally comprising at least one pharmaceutically acceptable excipient (e.g., a pharmaceutically acceptable carrier).
[0027] The present invention also provides a method for inhibiting CSF-1R activity in vivo or in vitro, comprising contacting an effective amount of at least one compound of formula (I) of the present invention (e.g., any of the examples herein) and / or at least one pharmaceutically acceptable salt thereof with CSF-1R.
[0028] The present invention also provides the use of compounds of formula (I) of the present invention (e.g., compounds of any of the examples herein) and / or pharmaceutically acceptable salts thereof for the inhibition of CSF-1R activity in vivo or in vitro.
[0029] The present invention also provides the use of compounds of formula (I) of the present invention (e.g., compounds of any of the embodiments herein) and / or pharmaceutically acceptable salts thereof in the preparation of medicaments for inhibiting CSF-1R activity in vivo or in vitro.
[0030] The present invention also provides a method for treating an individual with cancer, autoimmune disease, inflammatory disease, metabolic disease, neurodegenerative disease, obesity or obesity-related disease, comprising administering to the individual in need an effective amount of at least one compound of formula (I) of the present invention (e.g., any compound described herein) and / or at least one pharmaceutically acceptable salt thereof.
[0031] The present invention also provides the use of compounds of formula (I) of the present invention (e.g., compounds of any of the embodiments herein) and / or pharmaceutically acceptable salts thereof in treating individuals with cancer, autoimmune diseases, inflammatory diseases, metabolic diseases, neurodegenerative diseases, obesity, or obesity-related diseases.
[0032] The present invention also provides compounds of formula (I) of the present invention (e.g., compounds of any example herein) and / or pharmaceutically acceptable salts thereof for treating individuals with cancer, autoimmune diseases, inflammatory diseases, metabolic diseases, neurodegenerative diseases, obesity, or obesity-related diseases.
[0033] The present invention also provides the use of compounds of formula (I) of the present invention (e.g., compounds of any of the embodiments herein) and / or pharmaceutically acceptable salts thereof in the preparation of medicaments for treating individuals with cancer, autoimmune diseases, inflammatory diseases, metabolic diseases, neurodegenerative diseases, obesity, or obesity-related diseases. Invention Details
[0034] definition
[0035] The following words, phrases and symbols used in this application have the meanings described below, unless otherwise stated in the context.
[0036] A hyphen ("-") not between two letters or symbols indicates the connection site of a substituent. For example, -O(C 1-6 Alkyl groups are carbon atoms that are attached to the rest of the molecule via an oxygen atom. 1-6 Alkyl groups. When the linking site of the substituent is well known to those skilled in the art, the "-" may be omitted, for example, in halogen substituents.
[0037] As used herein, the term "alkyl" refers to a straight-chain or branched saturated hydrocarbon group containing 1-18 carbon atoms, preferably 1-10 carbon atoms, particularly preferably 1-6 carbon atoms, and even more preferably 1-4 carbon atoms. For example, "C 1-6 "Alkyl" means an alkyl group having 1 to 6 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl ("Me"), ethyl ("Et"), n-propyl ("n-Pr"), isopropyl ("i-Pr"), n-butyl ("n-Bu"), isobutyl ("i-Bu"), sec-butyl ("s-Bu"), and tert-butyl ("t-Bu").
[0038] As used herein, the term "alkylene" refers to a straight-chain or branched saturated divalent hydrocarbon group containing 1-18 carbon atoms, preferably 1-10 carbon atoms, particularly preferably 1-6 carbon atoms, and even more preferably 1-4 carbon atoms. For example, "C 1-6 "alkylene" refers to a straight-chain or branched alkylene chain having 1-6 carbon atoms, such as a straight-chain alkylene chain -(CH2). n - where n is an integer from 1 to 6, or a branched alkylene group, such as -CH2-CH(CH3)-CH2-, -CH(CH3)-CH2-, -CH(CH3)-CH2-, etc. Straight-chain C is preferred.1-6 Alkylene, more preferably -CH2- and -CH 2- CH2-.
[0039] As used herein, the term "alkenyl" refers to a straight-chain or branched unsaturated hydrocarbon group containing one or more, for example, 1, 2, or 3 carbon-carbon double bonds (C=C), and containing 2 to 10 carbon atoms, preferably 2 to 6 carbon atoms, more preferably 2 to 4 carbon atoms. For example, "C 2-6 "Alkenyl" refers to an alkenyl group having 2 to 6 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl, 2-propenyl, and 2-butenyl. The alkenyl group may or may not be attached to a double bond.
[0040] As used herein, the term "alkynyl" refers to a straight-chain or branched unsaturated hydrocarbon group containing one or more, for example, 1, 2, or 3 carbon-carbon triple bonds (C≡C), and containing 2 to 10 carbon atoms, preferably 2 to 6 carbon atoms, more preferably 2 to 4 carbon atoms. For example, "C 2-6 "Alynyl" indicates an alkynyl group having 2-6 carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl, 2-propynyl, and 2-butynyl. The alkynyl group may or may not be attached to a triple bond.
[0041] As used herein, the term "halogen" or "halogenated" refers to fluorine, chlorine, bromine, and iodine, preferably fluorine, chlorine, and bromine, and more preferably fluorine and chlorine.
[0042] As used herein, the term "haloalkyl" or "haloalkyl" refers to an alkyl group as defined herein in which one or more hydrogen atoms, such as 1, 2, 3, 4, or 5 hydrogen atoms, are replaced by halogen atoms, and when more than one hydrogen atom is replaced by a halogen atom, the halogen atoms may be the same as or different from each other. In one embodiment, the term "haloalkyl" or "haloalkyl" as used herein refers to an alkyl group as defined herein in which two or more hydrogen atoms, such as 2, 3, 4, or 5 hydrogen atoms, are replaced by halogen atoms, wherein the halogen atoms are the same as each other. In another embodiment, the term "haloalkyl" or "haloalkyl" as used herein refers to an alkyl group as defined herein in which two or more hydrogen atoms, such as 2, 3, 4, or 5 hydrogen atoms, are replaced by halogen atoms, wherein the halogen atoms are different from each other. Examples of haloalkyl groups include, but are not limited to, -CF3, -CHF2, -CH2CF3, -CH(CF3)2, etc.
[0043] As used herein, the term "cycloalkyl" refers to a saturated or partially unsaturated cyclic hydrocarbon group containing 3-12 ring carbon atoms (e.g., 3-8 ring carbon atoms, 5-7 ring carbon atoms, 4-7 ring carbon atoms, 5-6 ring carbon atoms, or 3-6 ring carbon atoms); it may have one or more rings, such as 1, 2, or 3, preferably 1 or 2 rings. For example, "C3-8 "Cycloalkyl" refers to a cycloalkyl group having 3-8 ring carbon atoms. Cycloalkyl groups may include fused or bridged rings and spirocyclic rings. The ring of a cycloalkyl group may be saturated and may contain one or more double bonds, such as one or two (i.e., partially unsaturated), but it is not fully conjugated and is not an "aryl" group as defined in this invention. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[4.1.0]heptyl, bicyclo[3.1.1]heptyl, spiro[3.3]heptyl, spiro[2.2]pentyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and bicyclo[3.1.1]hept-2-ene. In one embodiment of the invention, the ring of the cycloalkyl group is saturated.
[0044] As used herein, the term "heterocyclic group" or "heterocycle" refers to a saturated or partially unsaturated monocyclic, bicyclic, or tricyclic ring having 3-12 ring atoms (e.g., 3-8, 4-7, 5-7, 4-6, 3-6, or 5-6 ring atoms), wherein the ring contains one or more (e.g., 1, 2, or 3, preferably 1 or 2) cyclic heteroatoms independently selected from N, O, and S, and the remaining ring atoms are carbon atoms. N and S may optionally be oxidized to various oxidation states, and the junction of the heterocyclic group may be on an N heteroatom or a carbon atom. For example, "3-12 membered heterocyclic group" or "3-12 membered heterocycle" refers to a heterocyclic group having 3-12 ring atoms, containing at least one heteroatom selected from N, O, and S; "4-6 membered heterocyclic group" or "4-6 membered heterocycle" refers to a heterocyclic group having 4-6 ring atoms, containing at least one heteroatom selected from N, O, and S; "5-6 membered heterocyclic group" or "5-6 membered heterocycle" refers to a heterocyclic group having 5 or 6 ring atoms, containing at least one heteroatom selected from N, O, and S. Heterocyclic rings or heterocyclic groups may include fused or bridged rings and spirocyclic rings, wherein at least one ring contains at least one cyclic heteroatom independently selected from N, O, and S and the connection point with the rest of the molecule is located on the ring containing the cyclic heteroatom, and the remaining rings are not "aryl" or "heteroaryl" as defined in this invention. The ring of the heterocyclic or heterocyclic group may be saturated and may contain one or more double bonds, such as one or two double bonds (i.e., partially unsaturated), but it is not fully conjugated and is not a "heteroaryl" as defined in this invention. In one embodiment of the invention, the ring of the heterocyclic or heterocyclic group is saturated. Examples of heterocyclic groups include, but are not limited to, 4-6 membered heterocyclic groups or 5-6 membered heterocyclic groups such as oxobutyranyl, azabutyranyl, pyrrolidinyl, tetrahydrofuranyl, dioxolane, morpholinyl, thiomorpholinyl, piperidinyl, piperazine, pyrazolyl, dihydro Diazolyl and oxazolo[3.3]heptyl.
[0045] As used herein, the term "aryl" or "aromatic ring" refers to a carbocyclic hydrocarbon group containing 6-14 carbon atoms, consisting of one or more fused rings, wherein at least one ring is an aromatic ring. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, indenyl, indanyl, azulel, with phenyl and naphthyl being preferred.
[0046] As used herein, the term "heteroaryl" or "heteroary ring" refers to an aromatic hydrocarbon group (i.e., a 5-12-membered heteroaryl, 5-10-membered heteroaryl, 5-6-membered heteroaryl, or 6-membered heteroaryl) having 5-12 ring atoms (e.g., 5-10 ring atoms, 5-6 ring atoms, or 6 ring atoms), wherein the ring contains one or more (e.g., 1, 2, 3, or 4, preferably 1, 2, or 3, more preferably 1 or 2) cyclic heteroatoms independently selected from N, O, and S, and the remaining ring atoms are carbon atoms; it may have one or more rings, such as 1, 2, or 3, preferably 1 or 2 rings, for example, the heteroaryl includes:
[0047] A monocyclic aromatic hydrocarbon group having 5, 6, or 7 ring atoms (preferably 5 or 6 ring atoms, i.e., 5-6 membered heteroaryl groups), wherein the ring contains one or more, for example 1, 2, 3, or 4, preferably 1, 2, or 3, more preferably 1 or 2 cyclic heteroatoms independently selected from N, O, and S (preferably N and O), and the remaining ring atoms are carbon atoms; and
[0048] A bicyclic aromatic hydrocarbon group having 8-12 ring atoms (preferably 9 or 10 ring atoms), comprising one or more, for example 1, 2, 3 or 4, preferably 1, 2 or 3, cyclic heteroatoms independently selected from N, O and S (preferably N) in at least one ring, the remaining ring atoms being carbon atoms, wherein at least one ring is an aromatic ring and the connection point to the rest of the molecule is located on the aromatic ring. For example, a bicyclic heteroaryl group comprises a 5-6 membered heteroaryl ring fused to a 5-6 membered alkyl ring.
[0049] When the total number of S and O atoms in a heteroaryl group exceeds 1, these S and O heteroatoms are not adjacent to each other.
[0050] Heteroaryl groups also include those in which the N-ring atom is in the form of an N-oxide, such as N-pyridine oxide.
[0051] Examples of heteroaryl groups include, but are not limited to, 5-6 membered heteroaryl groups, such as pyridyl, N-pyridyl oxide, pyrazinyl, pyrimidinyl, triazine (e.g., 1,3,5-triazine), pyrazolyl, imidazoleyl, etc. azole group, iso azole group, Diazole groups (e.g., 1,2,4-) Diazolyl, 1,2,5- Diazole group and 1,3,4- Diazolyl, thiazolyl, isothiazolyl, thiadiazolyl, tetrazolyl, triazolyl (e.g., 1,2,3-triazolyl and 1,2,4-triazolyl), thiophene, furanyl, pyranyl, pyrrolithyl, pyridazinyl, and bicyclic heteroaryl groups such as benzo[a]-dioxacyclopentenyl, benzo[a]-dioxacyclopentenyl, etc. azole group, benzo[a] Azolyl, benzothiophene, benzothiazolyl, benzoisothiazolyl, imidazopyridyl (e.g., imidazo[1,2-a]pyridyl), imidazopyridazinyl (e.g., imidazo[1,2-b]pyridazinyl), pyrrolopyridyl (e.g., 1H-pyrrolo[2,3-b]pyridyl), pyrrolopyrimidinyl (e.g., pyrrolo[3,4-d]pyrimidinyl), pyrazolopyridyl (e.g., 1H-pyrazolo[3,4-b]pyridyl), pyrazolopyrimidinyl (e.g., pyrazolyl), [1,5-a]pyrimidinyl), triazolopyridyl (e.g., [1,2,4]triazolo[4,3-a]pyridyl and [1,2,4]triazolo[1,5-a]pyridyl), triazolopyridinyl (e.g., [1,2,4]triazolo[4,3-b]pyridinyl), tetraazolopyridyl (e.g., tetraazolo[1,5-a]pyridyl), benzofuranyl, benzimidazolinyl, indolyl, indazole, purinyl, quinolinyl, isoquinolinyl, and quinazolinyl.
[0052] The term "hydroxyl group" as used in this article refers to the -OH group.
[0053] The term "oxo" as used in this article refers to the =O group.
[0054] As used herein, the terms “optional,” “optional,” or “optionally” mean that the event or situation described below may or may not occur, and the description includes both scenarios in which the event or situation occurs and scenarios in which the event or situation does not occur. For example, “optionally substituted alkyl” includes both “unsubstituted alkyl” and “substituted alkyl” as defined herein. Those skilled in the art will understand that, for any group containing one or more substituents, the group does not include any substitution pattern that is spatially impractical, chemically incorrect, synthetically infeasible, and / or inherently unstable.
[0055] As used herein, the terms “substituted” or “replaced by” mean that one or more hydrogen atoms on a given atom or group are replaced by one or more substituents selected from a given group of substituents, provided that the substitution does not exceed the normal valence of the given atom. When the substituent is oxo (i.e., =O), two hydrogen atoms on a single atom are replaced. Such combinations are permitted only if the combination of substituents and / or variables results in a chemically correct and stable compound. A chemically correct and stable compound means that the compound is stable enough to be isolated from the reaction mixture and subsequently formulated into an agent with at least practical utility.
[0056] Unless otherwise stated, substituents are named within the core structure. For example, it should be understood that when (cycloalkyl)alkyl is listed as a possible substituent, it indicates that the substituent is attached to the core structure at the alkyl moiety.
[0057] As used herein, the term "substituted by one or more substituents" means that one or more hydrogen atoms on a given atom or group are independently replaced by one or more substituents selected from the given group. In some embodiments, "substituted by one or more substituents" means that a given atom or group is replaced by 1, 2, 3 or 4 substituents independently selected from the given group.
[0058] Those skilled in the art will understand that some compounds of formula (I) may contain one or more chiral centers, and thus have two or more stereoisomers. Racemic mixtures of these isomers, mixtures of single isomers and enantiomer-enriched mixtures, and mixtures of diastereomers and specific diastereomer-enriched mixtures when there are two chiral centers are all within the scope of this invention. Those skilled in the art will also understand that this invention includes all single stereoisomers (e.g., enantiomers), racemic mixtures, or partially separated mixtures of compounds of formula (I), and, where appropriate, single tautomers thereof.
[0059] Racemic mixtures can be used in their original form or can be resolved into their individual isomers. Resolution yields stereochemically pure compounds or mixtures enriched with one or more isomers. Methods for isomer separation are well known (see Allinger NL and Eliel EL, "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971), including physical methods such as chromatography using chiral adsorbents. Individual isomers in chiral form can be prepared from chiral precursors. Alternatively, individual isomers can be chemically separated from the mixture by forming diastereomeric salts with chiral acids (e.g., individual enantiomers of 10-camphorsulfonic acid, camphoric acid, α-bromocamphoric acid, tartaric acid, diacetyl tartaric acid, malic acid, pyrrolidone-5-carboxylic acid, etc.), fractionally crystallizing the salts, and then freeing one or both of the resolved bases. Optionally, this process is repeated to obtain one or two isomers that substantially do not contain the other isomer, i.e., isomers with optical purity >95%. Alternatively, the racemic compound can be covalently attached to a chiral compound (auxiliary compound) to obtain diastereomers, which can be separated by chromatography or fractional crystallization. The chiral auxiliary compound can then be chemically removed to obtain pure enantiomers.
[0060] The term "tautomer" refers to a functional group isomer resulting from the rapid movement of an atom between two positions in a molecule. Tautomers can interconvert; for example, enol and keto forms are typical tautomers. Furthermore, some compounds of the present invention, when R2 is hydrogen, may also exist in the structural form of formula (II) shown below; that is, compounds of formula (II) may be tautomers of compounds of formula (I) of the present invention; such tautomers belong to the compounds of the present invention.
[0061]
[0062] "Pharmaceutical-acceptable salts" refer to salts of free acids or bases of formula (I) that are non-toxic, biologically tolerable, or otherwise biologically suitable for administration to a therapeutic individual. For example, pharmaceutically acceptable salts are acid addition salts, including, for example, addition salts derived from inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and nitric acid, and such organic acids as p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, etc. For a general description of pharmaceutically acceptable salts, see, for example: SMBerge et al., "Pharmaceutical Salts", J. Pharm. Sci., 1977, 66: 1-19; and Handbook of Pharmaceutical Salts, Properties, Selection, and Use, Stahl and Wermuth eds., Wiley-VCH and VHCA, Zurich, 2002.
[0063] Furthermore, if the compound described herein is obtained as an acid addition salt, its free base form can be obtained by alkalizing the solution of the acid addition salt. Conversely, if the product is in the form of a free base, its acid addition salt, particularly a pharmaceutically acceptable acid addition salt, can be obtained by following the conventional procedure for preparing acid addition salts from basic compounds, by dissolving the free base in a suitable solvent and treating the solution with acid. Those skilled in the art can determine various synthetic methods for preparing non-toxic, pharmaceutically acceptable acid or base addition salts without extensive experimentation.
[0064] The term "solvate" refers to a solvation form containing stoichiometric or non-stoichiometric solvents. Some compounds have a tendency to engulf solvent molecules in a fixed molar ratio in the solid state, thus forming solvates. If the solvent is water, the formed solvate is a hydrate; when the solvent is ethanol, the formed solvate is an ethanolate. Hydrates are formed by one or more molecules of water with one molecule of the substance in which the water retains its H₂O molecular state; such combinations can form one or more hydrates, such as hemihydrates, monohydrates, and dihydrates.
[0065] The terms “group” and “base” used in this article are synonyms and are used to refer to functional groups or molecular segments that can be linked to other molecular segments.
[0066] The term "active ingredient" is used to refer to a biologically active chemical substance. In some implementations, the "active ingredient" is a chemical substance intended for pharmaceutical use. In the United States, actual drug activity can be determined through appropriate preclinical trials, whether in vitro or in vivo. However, drug activity sufficient for acceptance by regulatory agencies (such as the FDA in the United States) requires a higher standard than that achieved through preclinical trials. The success of achieving such a higher standard of drug activity cannot generally be reasonably expected from preclinical trial results, but can be established through appropriate and effective randomized, double-blind, controlled clinical trials conducted in humans.
[0067] The term "treatment" or "treatment" of a disease or disorder refers to the administration of one or more pharmaceutical substances, particularly compounds of formula (I) or pharmaceutically acceptable salts thereof, to an individual suffering from, or having symptoms of, the disease or disorder, or being susceptible to, the disease or disorder, in order to cure, heal, alleviate, reduce, alter, treat, improve, enhance, or influence the disease or disorder, its symptoms, or the individual's susceptibility to it. In some embodiments, the disease or disorder is cancer. In some embodiments, the disease or disorder is an autoimmune disease or an inflammatory disease.
[0068] When referring to chemical reactions, the terms “treatment,” “contact,” and “reaction” mean the addition or mixing of two or more reagents under appropriate conditions to produce the shown and / or desired product. It should be understood that the reaction producing the shown and / or desired product may not necessarily originate directly from the combination of the two initially added reagents; that is, one or more intermediates may be present in the mixture that ultimately lead to the formation of the shown and / or desired product.
[0069] As used herein, the term "effective amount" refers to the amount or dose of the compound of the present invention that is generally sufficient to produce a beneficial therapeutic effect for a patient requiring treatment of a disease or disorder mediated or at least partially mediated by CSF-1R activity. The effective amount or dose of the active ingredient in the present invention can be determined by conventional methods (e.g., modeling, dose-escalation studies, or clinical trials) combined with conventional influencing factors (e.g., the manner or route of administration, pharmacokinetics of the drug component, severity and duration of the disease or disorder, prior or ongoing treatment of the individual, the individual's health condition and response to the drug, and the judgment of the attending physician). In the United States, the determination of the effective dose is generally difficult to predict from preclinical trials. In fact, the dose is entirely unpredictable, and new, unpredictable dosing regimens may develop after the initial randomized, double-blind, controlled clinical trials.
[0070] Typical dosage ranges are from about 0.0001 to about 200 mg of active ingredient per kilogram of individual body weight per day, for example, from about 0.001 to 100 mg / kg / day, or about 0.01 to 35 mg / kg / day, or about 0.1 to 10 mg / kg, taken once daily or in divided doses (e.g., twice daily, three times daily, or four times daily). For a 70 kg person, an appropriate dosage range is typically from about 0.05 to about 7 g / day, or about 0.2 to about 5 g / day. Once the patient's condition or impairment improves, the dosage can be adjusted to maintain treatment. For example, the dosage or frequency of administration may be adjusted according to changes in symptoms, or the dosage and frequency may be reduced to maintain the desired therapeutic effect. Of course, treatment can be discontinued if symptoms have improved to an appropriate level. However, for recurrence of symptoms, patients may require intermittent long-term treatment.
[0071] The term "inhibition" refers to a reduction in the baseline activity of a biological activity or process. The term "inhibition of CSF-1R activity" is the actual pharmaceutical activity used for the purposes of this invention, referring to a reduction in CSF-1R activity resulting from a direct or indirect response to the presence of a compound of formula (I) and / or its pharmaceutically acceptable salt, relative to the CSF-1R activity in the absence of the compound of formula (I) and / or its pharmaceutically acceptable salt. The reduction in activity may be caused by a direct interaction between the compound of formula (I) and / or its pharmaceutically acceptable salt and CSF-1R, or by the interaction of the compound of formula (I) and / or its pharmaceutically acceptable salt with one or more other factors, thereby affecting CSF-1R activity. For example, the presence of the compound of formula (I) and / or its pharmaceutically acceptable salt may reduce CSF-1R activity by directly binding to CSF-1R, by directly or indirectly affecting another factor, or by directly or indirectly reducing the amount of CSF-1R present in cells or the body.
[0072] As used herein, the term "individual" refers to both mammals and non-mammals. Mammals include any member of the mammalian class, including but not limited to: humans; non-human primates such as chimpanzees and other ape and monkey species; farm animals such as cattle, horses, sheep, goats, and pigs; livestock such as rabbits, dogs, and cats; laboratory animals, including rodents such as rats, mice, and guinea pigs; etc. Examples of non-mammals include, but are not limited to, birds. The term "individual" is not limited to a specific age or sex. In some implementations, an individual is a human being.
[0073] Generally, the term "about" is used in this article to adjust the given value to be 20% higher or lower than that value.
[0074] Undefined technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which this invention pertains.
[0075] This invention provides compounds of formula (I):
[0076]
[0077] Or its pharmaceutically acceptable salts, and / or its deuterated compounds, solvates, racemic mixtures, enantiomers, diastereomers and tautomers, wherein:
[0078] X is either N or CR5;
[0079] Z1 and Z2 are either N or CR6 independently;
[0080] Y1 is N or CR7; Y2 is N or CR8; Y3 is N or CR9;
[0081] L can be NH, O, S, or CH2;
[0082] W is absent or is NH, O, S or CH2;
[0083] R1 is a phenyl group, a 5-12-membered heteroaryl group, a 4-6-membered heterocyclic group, or a C-membered heterocyclic group. 3-8 Cycloalkyl groups, each optionally substituted with one or more groups selected from: halogen, -CN, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Halogenated groups, -(C 1-6 Alkylene) n -NH2、-(C 1-6 Alkylene) n -NH(C 1-6 alkyl), -(C 1-6 Alkylene) n -N(C 1-6 alkyl)2、-(C 1-6 Alkylene) n -OH, -(C 1-6 Alkylene) n -O-(C 1-6 alkyl) or -(C 1-6 Alkylene) n -O-(C 1-6 (Halogenated groups);
[0084] R2 represents hydrogen, -CN, or C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Halogenated groups, -(C 1-6alkylene)-NH2, -(C 1-6 alkylene)-NH(C 1-6 alkyl), -(C 1-6 alkylene)-N(C 1-6 alkyl)2、-(C 1-6 alkylene)-O-(C 1-6 alkyl), -(C 1-6 alkylene)-O-(C 1-6 Halogenated alkyl groups), -(C 1-6 alkylene)-OH, C 3-8 Cycloalkyl or 4-6 membered heterocyclic groups;
[0085] R3, R4, R5, R6, R7, and R8 are independently selected from: hydrogen, halogen, -CN, and C, respectively. 1-6 Alkyl, C 1-6 Halogenated groups, -O(C) 1-6 Alkyl), -O(C) 1-6 (haloalkyl) or -OH;
[0086] R9 represents hydrogen, halogen, -CN, or C. 1-6 Alkyl, C 1-6 Halogenated groups, -O(C) 1-6 Alkyl), -O(C) 1-6 Halogenated groups), -OH, -(C 1-6 alkylene)-OH, -NH2, -NH(C 1-6 alkyl), -N(C) 1-6 Alkyl)2 or C 3-8 cycloalkyl;
[0087] n is 0 or 1;
[0088] Alternatively, when Y3 is CR9, R2, R9, together with the N and C atoms attached to them, form a 5-6 membered heteroaromatic ring or a 5-6 membered heterocyclic ring.
[0089] Alternatively, when Y2 is CR8 and Y3 is CR9, R8 and R9 together with the C atoms they are attached to form a benzene ring;
[0090] or for Where R 10 It is hydrogen or C 1-6 alkyl;
[0091] The condition is that when X is CH, Z1 is not N.
[0092] In some embodiments of the compound of formula (I), X is N.
[0093] In some embodiments of the compound of formula (I), X is CR5.
[0094] In some embodiments of the compound of formula (I), R5 is hydrogen, halogen, C 1-6 Alkyl or -O(C) 1-6 alkyl).
[0095] In some embodiments of the compound of formula (I), X is CH.
[0096] In some embodiments of the compound of formula (I), Z1 and Z2 are independently CR6.
[0097] In some embodiments of the compound of formula (I), Z1 is N; Z2 is CR6.
[0098] In some embodiments of the compound of formula (I), Z1 is CR6; Z2 is N.
[0099] In some embodiments of the compound of formula (I), R6 is hydrogen.
[0100] In some embodiments of the compound of formula (I), Z1 and Z2 are both CH.
[0101] In some embodiments of the compound of formula (I), Y1 is CR7, Y2 is CR8, and Y3 is CR9.
[0102] In some embodiments of the compound of formula (I), Y1 is CR7, Y2 is N, and Y3 is CR9.
[0103] In some embodiments of the compound of formula (I), Y1 is N, Y2 is CR8, and Y3 is CR9.
[0104] In some embodiments of the compound of formula (I), Y1 is CR7, Y2 is CR8, and Y3 is N.
[0105] In some embodiments of the compound of formula (I), L is O or CH2.
[0106] In some embodiments of the compound of formula (I), L is O.
[0107] In some embodiments of the compound of formula (I), R7 is selected from: hydrogen, C 1-6 Alkyl or -O(C) 1-6 alkyl).
[0108] In some embodiments of the compound of formula (I), R7 is hydrogen.
[0109] In some embodiments of the compound of formula (I), R8 is selected from hydrogen, halogen, or C. 1-6 alkyl.
[0110] In some embodiments of the compound of formula (I), R8 is selected from hydrogen, fluorine or methyl.
[0111] In some embodiments of the compound of formula (I), R9 is hydrogen, C 1-6 Alkyl, C 1-6 Halogenated groups, -O(C) 1-6 Alkyl groups, -NH2, -NH(C) 1-6 alkyl), -N(C) 1-6 Alkyl)2 or C 3-6 Cycloalkyl.
[0112] In some embodiments of the compound of formula (I), R9 is hydrogen or methyl.
[0113] In some embodiments of the compound of formula (I), Y1 is CR7, Y2 is CR8, and Y3 is CR9; R7 and R8 are independently selected from: hydrogen, halogen, C 1-6 Alkyl or -O(C) 1-6 Alkyl); R9 is hydrogen, C 1-6 Alkyl, C 1-6 Halogenated groups, -O(C) 1-6 Alkyl groups, -NH2, -NH(C) 1-6 alkyl) or -N(C) 1-6 Alkyl)2.
[0114] In some embodiments of the compound of formula (I), Y1 is CR7, Y2 is CR8, and Y3 is CR9; R7 is hydrogen or -O(C 1-6 Alkyl); R8 is hydrogen, halogen, or C. 1-6 Alkyl; R9 is hydrogen, C 1-6 Alkyl, C 1-6 Halogenated groups, -O(C) 1-6 Alkyl groups, -NH2, -NH(C) 1-6 alkyl) or -N(C) 1-6 Alkyl)2.
[0115] In some embodiments of the compound of formula (I), Y1 is CR7, Y2 is CR8, Y3 is CR9; R7 is hydrogen; R8 is hydrogen or halogen; R9 is hydrogen or C 1-6 alkyl.
[0116] In some embodiments of the compound of formula (I), Y1 is CR7, Y2 is CR8, Y3 is CR9; R7 is hydrogen; R8 is hydrogen or fluorine; R9 is hydrogen or methyl.
[0117] In some embodiments of the compound of formula (I), Y1 is CR7, Y2 is CR8, and Y3 is CR9; R7, R8, and R9 are all hydrogen.
[0118] In some embodiments of the compound of formula (I), Y1 is CR7, Y2 is N, and Y3 is CR9; R7 is hydrogen, C 1-6 Alkyl or -O(C) 1-6 Alkyl); R9 is hydrogen, C 1-6 Alkyl, C 1-6 Halogenated or C 3-6 Cycloalkyl.
[0119] In some embodiments of the compound of formula (I), Y1 is CR7, Y2 is N, and Y3 is CR9; R7 is hydrogen or C. 1-6 Alkyl; R9 is hydrogen, C 1-6 Alkyl or C 3-6 Cycloalkyl.
[0120] In some embodiments of the compound of formula (I), Y1 is CR7, Y2 is N, Y3 is CR9; R7 is hydrogen; R9 is hydrogen, C 1-6 Alkyl or C 3-6 Cycloalkyl.
[0121] In some embodiments of the compound of formula (I), Y1 is CR7, Y2 is N, Y3 is CR9; R7 is hydrogen; R9 is C. 1-6 alkyl.
[0122] In some embodiments of the compound of formula (I), Y1 is CR7, Y2 is N, Y3 is CR9; R7 is hydrogen; R9 is methyl.
[0123] In some embodiments of the compound of formula (I), Y1 is CR7, Y2 is N, and Y3 is CR9; R7 and R9 are both hydrogen.
[0124] In some embodiments of the compound of formula (I), Y1 is N, Y2 is CR8, Y3 is CR9; R8 and R9 are both hydrogen.
[0125] In some embodiments of the compound of formula (I), Y1 is CR7, Y2 is CR8, and Y3 is N; R7 and R8 are both hydrogen.
[0126] In some embodiments of the compound of formula (I), W is absent or is NH.
[0127] In some embodiments of the compound of formula (I), W is absent.
[0128] In some embodiments of the compound of formula (I), W is NH.
[0129] In some embodiments of compounds of formula (I), R1 is a phenyl, a 5-12-membered heteroaryl, a 4-6-membered heterocyclic group, or a C-membered heterocyclic group. 3-8 Cycloalkyl groups, each optionally substituted with one or more groups selected from: halogen, C1-6 Alkyl, C 1-6 Halogenated groups, -(C 1-6 Alkylene) n -NH2、-(C 1-6 Alkylene) n -NH(C 1-6 alkyl), -(C 1-6 Alkylene) n -N(C 1-6 alkyl)2 or -(C 1-6 Alkylene) n -OH.
[0130] In some embodiments of compounds of formula (I), R1 is a phenyl, a 5-10-membered heteroaryl, a 4-6-membered heterocyclic group, or a C-membered heterocyclic group. 3-8 Cycloalkyl groups, each optionally substituted with one or more groups selected from: halogen, C 1-6 Alkyl, C 1-6 Halogenated groups, -(C 1-6 Alkylene) n -NH2、-(C 1-6 Alkylene) n -NH(C 1-6 alkyl), -(C 1-6 Alkylene) n -N(C 1-6 alkyl)2 or -(C 1-6 Alkylene) n -OH.
[0131] In some embodiments of compounds of formula (I), R1 is a phenyl, a 5-6 membered monocyclic heteroaryl, a 9-10 membered bicyclic heteroaryl, a 4-6 membered heterocyclic group, or a C-membered heterocyclic group. 3-8 Cycloalkyl groups, each optionally substituted with one or more groups selected from: halogen, C 1-6 Alkyl, C 1-6 Halogenated groups, -(C 1-6 Alkylene) n -NH2、-(C 1-6 Alkylene) n -NH(C 1-6 alkyl), -(C 1-6 Alkylene) n -N(C 1-6 alkyl)2 or -(C 1-6 Alkylene) n -OH.
[0132] In some embodiments of the compound of formula (I), R1 is phenyl, pyrazolyl, pyrroleyl, furanyl, thiophenyl, pyridyl, thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, imidazolyl, imidazo[1,2-a]pyridyl, piperazineyl, or cyclohexenyl, each optionally substituted by one or more groups selected from: halogen, C 1-6 Alkyl, C 1-6 Halogenated groups, -(C 1-6 Alkylene) n -NH2、-(C 1-6 Alkylene) n -NH(C 1-6 alkyl), -(C 1-6 Alkylene) n -N(C 1-6 alkyl)2 or -(C 1-6 Alkylene) n -OH.
[0133] In some embodiments of the compound of formula (I), R1 is phenyl, pyrazolyl, pyrroleyl, furanyl, thiophenyl, pyridyl, thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, imidazolyl, imidazo[1,2-a]pyridyl, piperazineyl, or cyclohexenyl, each optionally substituted by one or more groups selected from: halogen, C 1-6 Alkyl, C 1-6 Halogenated groups, -(C 1-6 alkylene)-NH2, -(C 1-6 alkylene)-NH(C 1-6 alkyl), -(C 1-6 alkylene)-N(C 1-6 alkyl)2 or -(C 1-6 (alkylene)-OH.
[0134] In some embodiments of the compound of formula (I), R1 is a pyrazolyl or pyrroleyl group, each optionally substituted with one or more groups selected from: C 1-6 Alkyl, C 1-6 Halogenated groups, -(C 1-6 alkylene)-NH2, -(C 1-6 alkylene)-NH(C 1-6 alkyl), -(C 1-6 alkylene)-N(C 1-6 alkyl)2 or -(C 1-6 (alkylene)-OH.
[0135] In some embodiments of the compound of formula (I), R1 is a pyrazolyl or pyrroleyl group, each optionally substituted with one or more groups selected from: methyl, ethyl, isopropyl, -CHF2, -CF3, -(CH2CH2)-NH2, -(CH2CH2)-NH(C 1-6 Alkyl), -(CH2CH2)-N(C 1-6 Alkyl)2 or -(CH2CH2)-OH.
[0136] In some embodiments of the compound of formula (I), R1 is a pyrazolyl or pyrroleyl group, each optionally surrounded by one or more C1 groups. 1-6 Alkyl substitution.
[0137] In some embodiments of the compound of formula (I), R1 is pyrazolyl or pyrroleyl, each optionally substituted with one or more methyl groups.
[0138] In some embodiments of the compound of formula (I), R1 is... Each of them is replaced by one or more methyl groups.
[0139] In some embodiments of the compound of formula (I), R1 is... It is substituted with one or more methyl groups.
[0140] In some embodiments of the compound of formula (I), R1 is a phenyl group, which is optionally substituted with one or more halogens.
[0141] In some embodiments of the compound of formula (I), R1 is a phenyl group, which is optionally substituted with one or more F groups.
[0142] In some embodiments of the compound of formula (I), R1 is furanyl, thienyl, pyridyl, thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, imidazolyl, imidazo[1,2-a]pyridyl, piperazinel, or cyclohexenyl, each optionally constituting one or more C 1-6 Alkyl substitution.
[0143] In some embodiments of the compound of formula (I), R1 is furanyl, thiophene, pyridinyl, thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, imidazolyl, or imidazo[1,2-a]pyridinyl, each optionally substituted with one or more methyl groups.
[0144] In some embodiments of the compound of formula (I), R1 is piperazine group, which is optionally substituted with one or more ethyl groups.
[0145] In some embodiments of the compound of formula (I), W is NH; R1 is pyrazolyl, pyridyl, or thiazolyl, each optionally substituted by one or more groups selected from: halogen, C1-6 Alkyl, C 1-6 Halogenated groups, -(C 1-6 alkylene)-NH2, -(C 1-6 alkylene)-NH(C 1-6 alkyl), -(C 1-6 alkylene)-N(C 1-6 alkyl)2 or -(C 1-6 (alkylene)-OH.
[0146] In some embodiments of the compound of formula (I), W is NH; R1 is pyrazolyl, pyridyl, or thiazolyl, each optionally substituted by one or more groups selected from: C 1-6 Alkyl or C 1-6 Halogenated groups.
[0147] In some embodiments of the compound of formula (I), W is NH; R1 is a pyrazolyl group, which is optionally substituted with one or more methyl groups.
[0148] In some embodiments of the compound of formula (I), W is NH; R1 is Each of them is replaced by one or more methyl groups.
[0149] In some embodiments of the compound of formula (I), W is absent; R1 is a pyrazolyl or pyrroleyl group, each optionally substituted with one or more methyl groups.
[0150] In some embodiments of the compound of formula (I), W is absent; R1 is... Each of them is replaced by one or more methyl groups.
[0151] In some embodiments of the compound of formula (I), W is absent; R1 is... It is substituted with one or more methyl groups.
[0152] In some embodiments of the compound of formula (I), R2 is hydrogen, C 1-6 Alkyl, C 2-6 alkenyl, C 1-6 Halogenated groups, -(C 1-6 alkylene)-N(C 1-6 alkyl)2、-(C 1-6 alkylene)-O-(C 1-6 alkyl), -(C 1-6 alkylene)-OH, C 3-6 Cycloalkyl or 4-6 membered heterocyclic groups.
[0153] In some embodiments of the compound of formula (I), R2 is hydrogen, C 1-6 Alkyl, C 2-6 alkenyl, C 1-6Halogenated groups, -(CH2CH2)-N(C) 1-6 Alkyl)2、-(CH2CH2)-O-(C 1-6 Alkyl), -(CH2CH2)-OH, C 3-6 Cycloalkyl or 4-6 membered heterocyclic groups.
[0154] In some embodiments of the compound of formula (I), R2 is hydrogen, C 1-6 Alkyl, C 2-6 alkenyl, C 1-6 Halogenated groups, -(CH2CH2)-N(C) 1-6 Alkyl)2、-(CH2CH2)-O-(C 1-6 Alkyl), -(CH2CH2)-OH, C 3-6 Cycloalkyl or oxobutyric.
[0155] In some embodiments of the compound of formula (I), R2 is C 1-6 Alkyl, C 2-6 alkenyl, -(CH2CH2)-O-(C 1-6 Alkyl), -(CH2CH2)-OH, cyclopropyl, cyclobutyl or oxetane.
[0156] In some embodiments of the compound of formula (I), R2 is C 1-6 alkyl.
[0157] In some embodiments of the compound of formula (I), R2 is methyl, ethyl or isopropyl.
[0158] In some embodiments of the compound of formula (I), R2 is methyl.
[0159] In some embodiments of the compound of formula (I), R2 is isopropyl.
[0160] In some embodiments of the compound of formula (I), R3 and R4 are independently selected from: hydrogen, halogen, -CN, C 1-6 Alkyl or -O(C) 1-6 alkyl).
[0161] In some embodiments of the compound of formula (I), R3 and R4 are independently selected from: hydrogen, halogen, -CN, C 1-6 Alkyl or -O(C) 1-6 Alkyl); and when X is CH, at least one of R3 and R4 is hydrogen.
[0162] In some embodiments of the compound of formula (I), R3 is hydrogen, halogen, -CN, C 1-6 Alkyl or -O(C) 1-6 Alkyl); R4 is hydrogen or C 1-6alkyl.
[0163] In some embodiments of the compound of formula (I), both R3 and R4 are hydrogen.
[0164] In some embodiments of the compound of formula (I), X is CH; R3 and R4 are independently selected from: hydrogen, halogen, C 1-6 Alkyl or -O(C) 1-6 Alkyl group), and at least one of R3 and R4 is hydrogen.
[0165] In some embodiments of the compound of formula (I), X is CH; R3 is hydrogen, halogen, C 1-6 Alkyl or -O(C) 1-6 Alkyl); R4 is hydrogen.
[0166] In some embodiments of the compound of formula (I), n is 1.
[0167] In some embodiments of the compound of formula (I), Y3 is CR9; R2, R9 together with the N and C atoms attached to them form pyridine or pyrrolidine.
[0168] In some embodiments of the compound of formula (I), Y3 is CR9; R2, R9 together with the N and C atoms to which they are attached form pyridine.
[0169] In some embodiments of the compound of formula (I), Y3 is CR9; R2, R9 together with the N and C atoms attached to them form pyrrolidine.
[0170] In some embodiments of the compound of formula (I), for Where R 10 C 1-6 alkyl.
[0171] In some embodiments of the compound of formula (I), for Where R 10 It is a methyl group.
[0172] In some embodiments of compounds of formula (I), X is CR5; Z1 and Z2 are independently CR6; Y1 is CR7; Y2 is N or CR8; Y3 is CR9; W is absent; R1 is a 5-6 membered heteroaryl group, optionally bounded by one or more C1 groups. 1-6 Alkyl substitution; R2 is C 1-6 Alkyl group; R3, R4, R5, R6, R7, and R8 are each independently selected from: hydrogen, halogen, C 1-6 Alkyl or -O(C) 1-6 Alkyl group), and at least one of R3 and R4 is hydrogen; R9 is hydrogen or C 1-6 alkyl.
[0173] In some embodiments of compounds of formula (I), X is CH; Z1 and Z2 are both CH; Y1 is CH; Y2 is N or CH; Y3 is CR9; W is absent; R1 is a pyrazolyl group, optionally surrounded by one or more C groups. 1-6 Alkyl substitution; R2 is C 1-6 Alkyl group; R3 is hydrogen, halogen, or C. 1-6 Alkyl or -O(C) 1-6 (alkyl); R4 is hydrogen; R9 is hydrogen or C 1-6 alkyl.
[0174] In some embodiments of compounds of formula (I), X is N; Z1 and Z2 are both CH; Y1 is CH; Y2 is N or CR8; Y3 is CR9; W is absent; R1 is pyrazolyl or pyrroleyl, optionally surrounded by one or more C 1-6 Alkyl substitution; R2 is C 1-6 Alkyl group; R3 is hydrogen, halogen, or C. 1-6 Alkyl or -O(C) 1-6 (alkyl); R4 is hydrogen; R8 is hydrogen or halogen; R9 is hydrogen or C 1-6 alkyl.
[0175] In some embodiments of the compound of formula (I), X is N; Z1 and Z2 are both CH; Y1 is CH; Y2 is N or CR8; Y3 is CR9; W is absent; R1 is pyrazolyl or pyrroleyl, which is substituted by one or more methyl groups; R2 is methyl or isopropyl; R3 is hydrogen; R4 is hydrogen; R8 is hydrogen or F; R9 is hydrogen or methyl.
[0176] In some embodiments of the compound of formula (I), X is N; Z1 and Z2 are both CH; Y1 is CH; Y2 is N or CR8; Y3 is CR9; W is NH; R1 is a pyrazolyl group, optionally surrounded by one or more C groups. 1-6 Alkyl substitution; R2 is C 1-6 Alkyl group; R3 is hydrogen, halogen, or C. 1-6 Alkyl or -O(C) 1-6 (alkyl); R4 is hydrogen; R8 is hydrogen or halogen; R9 is hydrogen or C 1-6 alkyl.
[0177] In some embodiments of the compound of formula (I), X is N; Z1 and Z2 are both CH; Y1 is CH; Y2 is N or CR8; Y3 is CR9; W is NH; R1 is pyrazolyl group, which is substituted by one or more methyl groups; R2 is methyl or isopropyl; R3 is hydrogen; R4 is hydrogen; R8 is hydrogen or F; R9 is hydrogen or methyl.
[0178] The present invention also provides the example compounds selected from compounds numbered 1-135 in the experimental section, and / or their pharmaceutically acceptable salts:
[0179]
[0180]
[0181]
[0182]
[0183]
[0184]
[0185]
[0186]
[0187]
[0188] On the other hand, the present invention also provides a pharmaceutical composition comprising a compound of formula (I) (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof, and optionally comprising at least one pharmaceutically acceptable excipient (e.g., a pharmaceutically acceptable carrier).
[0189] On the other hand, the present invention also provides a method for inhibiting CSF-1R activity in vivo or in vitro, comprising contacting an effective amount of a compound of formula (I) (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof with CSF-1R.
[0190] On the other hand, the present invention also provides a method for treating a disease mediated or at least partially mediated by CSF-1R in an individual, comprising administering to the individual in need an effective amount of a compound of formula (I) (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof.
[0191] On the other hand, the present invention also provides a method for treating cancer, autoimmune diseases, inflammatory diseases, metabolic diseases, neurodegenerative diseases, obesity or obesity-related diseases in an individual, comprising administering to the individual in need an effective amount of a compound of formula (I) (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof.
[0192] On the other hand, the present invention also provides a method for treating cancer, autoimmune disease or inflammatory disease in an individual, comprising administering to the individual in need an effective amount of a compound of formula (I) (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof.
[0193] On the other hand, the present invention also provides a method for treating a disease mediated or at least partially mediated by CSF-1R in an individual, comprising administering an effective amount of a pharmaceutical composition to the individual in need of it, said pharmaceutical composition comprising a compound of formula (I) (e.g., any compound described herein) and / or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient (e.g., a pharmaceutically acceptable carrier).
[0194] On the other hand, the present invention also provides a method for treating cancer, autoimmune diseases, inflammatory diseases, metabolic diseases, neurodegenerative diseases, obesity or obesity-related diseases in an individual, comprising administering an effective amount of a pharmaceutical composition to the individual in need of it, said pharmaceutical composition comprising a compound of formula (I) (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient (e.g., a pharmaceutically acceptable carrier).
[0195] On the other hand, the present invention also provides a method for treating cancer, autoimmune disease or inflammatory disease in an individual, comprising administering an effective amount of a pharmaceutical composition to an individual in need of it, said pharmaceutical composition comprising a compound of formula (I) (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient (e.g., a pharmaceutically acceptable carrier).
[0196] On the other hand, the present invention also provides the use of a compound of formula (I) described herein (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof in treating an individual with a disease mediated by or at least partially mediated by CSF-1R.
[0197] On the other hand, the present invention also provides the use of a compound of formula (I) described herein (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof in treating individuals with cancer, autoimmune diseases, inflammatory diseases, metabolic diseases, neurodegenerative diseases, obesity, or obesity-related diseases.
[0198] On the other hand, the present invention also provides the use of a compound of formula (I) described herein (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof in the treatment of individuals with cancer, autoimmune diseases, or inflammatory diseases.
[0199] On the other hand, the present invention also provides the use of a compound of formula (I) described herein (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating an individual with a disease mediated by or at least partially mediated by CSF-1R.
[0200] On the other hand, the present invention also provides the use of a compound of formula (I) described herein (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating an individual with cancer, an autoimmune disease, an inflammatory disease, a metabolic disease, a neurodegenerative disease, obesity, or an obesity-related disease.
[0201] On the other hand, the present invention also provides the use of a compound of formula (I) described herein (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating cancer, autoimmune disease, or inflammatory disease in an individual.
[0202] On the other hand, the present invention also provides a combination comprising a compound of formula (I) (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof, and at least one additional therapeutic agent.
[0203] On the other hand, the present invention also provides a method for treating a disease mediated or at least partially mediated by CSF-1R in an individual, comprising administering to the individual in need an effective amount of a compound of formula (I) (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof, as well as additional therapeutic agents.
[0204] On the other hand, the present invention also provides a method for treating cancer, autoimmune disease or inflammatory disease in an individual, comprising administering to the individual in need an effective amount of a compound of formula (I) (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof, as well as additional therapeutic agents.
[0205] On the other hand, the present invention also provides the use of a compound of formula (I) described herein (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof with an additional therapeutic agent in the preparation of a combination medicament for treating an individual with a disease mediated by or at least partially mediated by CSF-1R.
[0206] On the other hand, the present invention also provides the use of a compound of formula (I) described herein (e.g., any of the examples herein) and / or a pharmaceutically acceptable salt thereof with an additional therapeutic agent in the preparation of a combination medicament for the treatment of cancer, autoimmune diseases, or inflammatory diseases.
[0207] In some implementations, the additional therapeutic agent is an antitumor agent.
[0208] In some implementations, the antitumor agent is selected from chemotherapeutic agents, immune checkpoint inhibitors or agonists, and targeted therapeutic agents.
[0209] In some implementations, the diseases mediated by or at least partially mediated by CSF-1R are cancer, autoimmune diseases, inflammatory diseases, metabolic diseases, neurodegenerative diseases, obesity, or obesity-related diseases.
[0210] In some implementations, the disease mediated by CSF-1R or at least partially mediated by CSF-1R is cancer, an autoimmune disease, or an inflammatory disease.
[0211] In some implementations, the cancer is a solid tumor or a hematologic malignancy (such as leukemia, lymphoma, or myeloma).
[0212] In some implementations, the cancer is selected from ovarian cancer, lung cancer (including non-small cell lung cancer), brain tumors (including glioblastoma (GBM)), giant cell tenosynovitis, gastrointestinal stromal tumors (GIST), gastric cancer, esophageal cancer, colon cancer, colorectal cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, melanoma, mesothelioma, mesothelial endometrial carcinoma, kidney cancer, liver cancer, thyroid cancer, head and neck cancer, urothelial carcinoma, bladder cancer, endometrial cancer, choriocarcinoma, adrenal carcinoma, sarcoma, leukemia, lymphoma, or myeloma.
[0213] In some implementations, the cancer is selected from ovarian cancer, lung cancer (including non-small cell lung cancer), glioblastoma (GBM), giant cell tenosynovitis, gastrointestinal stromal tumor (GIST), gastric cancer, esophageal cancer, colon cancer, colorectal cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, melanoma, mesothelioma, mesothelial endometrial carcinoma, kidney cancer, liver cancer, thyroid cancer, head and neck cancer, urothelial carcinoma, bladder cancer, endometrial cancer, choriocarcinoma, adrenal carcinoma, sarcoma, acute myeloid leukemia (AML) (including relapsed or refractory AML), acute lymphoblastic leukemia (ALL), B-cell lymphoma, T-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), or multiple myeloma (MM).
[0214] In some implementations, the autoimmune disease or inflammatory disease is selected from arthritis (including rheumatoid arthritis, collagen-induced arthritis), osteoarthritis, pigmented villonodular synovitis (PVNS), systemic lupus erythematosus, multiple sclerosis, autoimmune nephritis, Crohn's disease, asthma, or chronic obstructive pulmonary disease.
[0215] In some implementations, the metabolic diseases are selected from osteoporosis, diabetes, diabetic ketoacidosis, hyperglycemic hyperosmolar syndrome, hypoglycemia, gout, protein-energy malnutrition, vitamin A deficiency, scurvy, vitamin D deficiency, etc.
[0216] In some implementations, the neurodegenerative diseases are selected from Parkinson's disease (PD), multiple system atrophy, Alzheimer's disease (AD), frontotemporal dementia, Huntington's disease (HD), corticobasal degeneration, spinocerebellar ataxia, motor neuron disease (including amyotrophic lateral sclerosis (ALS)), and hereditary motor sensory neuropathy (CMT).
[0217] In some implementation schemes, the obesity-related diseases are selected from diabetes, hypertension, insulin resistance syndrome, dyslipidemia, heart disease, cardiovascular diseases (including atherosclerosis, arrhythmia, irregular heart rhythm, myocardial infarction, congestive heart failure, coronary heart disease, angina pectoris), cerebral infarction, cerebral hemorrhage, osteoarthritis, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, etc.
[0218] General synthesis method of publicly disclosed implementation scheme
[0219] The compounds of formula (I) described herein and / or their pharmaceutically acceptable salts can be synthesized from commercially available starting materials, by methods known in the art, or by methods disclosed in this patent application. The synthetic routes shown in routes 1-3 illustrate general synthetic methods for the compounds of the present invention.
[0220] Method 1:
[0221]
[0222] As shown in Route 1, under alkaline conditions (e.g., but not limited to potassium carbonate), the compound represented by molecular formula (1-1) undergoes a substitution reaction with the compound represented by molecular formula (1-2), or the compound represented by molecular formula (1-1') undergoes a substitution reaction with the compound represented by molecular formula (1-2'), to give the compound represented by molecular formula (1-3). The compound represented by molecular formula (1-3) undergoes a coupling reaction with the compound represented by molecular formula (1-4) under the catalysis of a palladium reagent (e.g., but not limited to Pd(dppf)Cl2), or a substitution reaction with the compound represented by molecular formula (1-4') under the catalysis of a palladium reagent (e.g., but not limited to Pd2(dba)3) and a ligand (e.g., but not limited to BINAP), to give the compound represented by molecular formula (1-5); further reduction reaction yields the compound represented by molecular formula (1-6). Compounds represented by molecular formulas (1-6) undergo a condensation reaction with compounds represented by molecular formulas (1-7) in the presence of a condensing agent (e.g., but not limited to HATU) to yield compounds of formula (I). Wherein, R1, R2, R3, R4, W, X, Y1, Y2, Y3, Z1, and Z2 are as defined herein; M is a borate ester, boric acid, or alkyltin; X1 is a halogen selected from Cl and Br; and X2 is a halogen selected from F and Cl.
[0223] Method 2:
[0224]
[0225] As shown in route 2, the compound represented by molecular formula (1-3) undergoes a reduction reaction to obtain the compound represented by molecular formula (1-8), and then continues to undergo a condensation reaction with the compound represented by molecular formula (1-7) in the presence of a condensing agent (e.g., but not limited to HATU) to obtain the compound represented by molecular formula (1-9). The compound represented by molecular formula (1-9) undergoes a coupling reaction with the compound represented by molecular formula (1-4) under the catalysis of a palladium reagent (e.g., but not limited to Pd(dppf)Cl2), or a substitution reaction with the compound represented by molecular formula (1-4') under the catalysis of a palladium reagent (e.g., but not limited to Pd2(dba)3) and a ligand (e.g., but not limited to BINAP) to obtain the compound of formula (I). Wherein, R1, R2, R3, R4, W, X, Y1, Y2, Y3, Z1, and Z2 are as defined herein; M is a borate ester, boric acid, or alkyltin; X1 is a halogen selected from Cl and Br.
[0226] Method 3:
[0227]
[0228] As shown in route 3, the compound represented by molecular formula (1-1') undergoes a substitution reaction with the compound represented by molecular formula (1-10) under basic conditions (e.g., but not limited to cesium carbonate) to give the compound represented by molecular formula (1-8). The compound represented by molecular formula (1-8) undergoes a coupling reaction with the compound represented by molecular formula (1-4) under the catalysis of a palladium reagent (e.g., but not limited to Pd(dppf)Cl2), or a substitution reaction with the compound represented by molecular formula (1-4') under the catalysis of a palladium reagent (e.g., but not limited to Pd2(dba)3) and a ligand (e.g., but not limited to BINAP) to give the compound represented by molecular formula (1-6). The compound represented by molecular formula (1-6) undergoes a condensation reaction with the compound represented by molecular formula (1-7) in the presence of a condensing agent (e.g., but not limited to HATU) to give the compound of formula (I). Wherein, R1, R2, R3, R4, W, X, Y1, Y2, Y3, Z1 and Z2 are as defined herein; M is a borate ester, boric acid or alkyltin; X1 is a halogen selected from Cl and Br; X2 is a halogen selected from F and Cl.
[0229] The substituents of the compounds obtained by the above methods can be further modified to obtain other desired compounds. For synthetic chemical transformation methods, see, for example: R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette (ed.), Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) and subsequent editions.
[0230] Prior to use, the compounds of formula (I) described herein and / or their pharmaceutically acceptable salts may be purified by column chromatography, high performance liquid chromatography, crystallization or other suitable methods.
[0231] Pharmaceutical Compositions and Practical Uses
[0232] Compounds of formula (I) described herein (e.g., any of the examples herein) and / or their pharmaceutically acceptable salts may be formulated into pharmaceutical compositions, alone or in combination with one or more additional active ingredients. A pharmaceutical composition comprises: (a) an effective amount of a compound of formula (I) described herein and / or a pharmaceutically acceptable salt thereof, and optionally, an additional active ingredient; and (b) a pharmaceutically acceptable excipient (e.g., a pharmaceutically acceptable carrier).
[0233] A pharmaceutically acceptable carrier is one that is compatible with (and in some embodiments, stabilizes) the active ingredient in a composition and is harmless to the individual being treated. For example, solubilizers such as cyclodextrins (which can form specific, more soluble complexes with compounds of formula (I) described herein and / or their pharmaceutically acceptable salts) can be used as pharmaceutical excipients to deliver the active ingredient. Other examples of carriers include colloidal silica, magnesium stearate, cellulose, sodium dodecyl sulfate, and pigments such as D&C Yellow #10. Suitable pharmaceutically acceptable carriers are disclosed in a standard reference book in the art (Remington's Pharmaceutical Sciences, A.Osol).
[0234] Pharmaceutical compositions comprising compounds of formula (I) described herein (e.g., any of the examples herein) and / or pharmaceutically acceptable salts thereof may be administered in a variety of known manners, such as oral, topical, rectal, parenteral, inhalation, or implantation. The term “parenteral” as used herein includes subcutaneous, intradermal, intravenous, intramuscular, intra-articular, intra-articular, intrasynovial, intrasternal, intravertebral, intra-affective, and intracranial injections or infusions.
[0235] The pharmaceutical compositions described herein may be prepared in the form of tablets, capsules, sachets, sugar-coated pills, powders, granules, lozenges, powder for injection, liquid preparations, or suppositories. In some embodiments, pharmaceutical compositions comprising a compound of formula (I) and / or a pharmaceutically acceptable salt thereof may be formulated for intravenous infusion, topical administration, or oral administration.
[0236] Orally administered compositions can be in any orally acceptable dosage form, including but not limited to: tablets, capsules, emulsions, and aqueous suspensions, dispersants, and solutions. Common tablet carriers include lactose and corn starch. Lubricants such as magnesium stearate are also frequently incorporated into tablets. When administered orally in capsule form, useful diluents include lactose and dried corn starch. When administered orally in aqueous suspension or emulsion form, emulsifiers or suspending agents can be used to suspend or dissolve the active ingredient in the oil phase. If desired, certain sweeteners, flavoring agents, or colorings may be added.
[0237] In some embodiments, the amount of the compound of formula (I) and / or its pharmaceutically acceptable salt in the tablet may be 1, 5, 10, 15, 20, 25, 50, 75, 80, 85, 90, 95, 100, 125, 150, 200, 250, 300, 400, and 500 mg. In some embodiments, the amount of the compound of formula (I) and / or its pharmaceutically acceptable salt in the capsule may be 1, 5, 10, 15, 20, 25, 50, 75, 80, 85, 90, 95, 100, 125, 150, 200, 250, 300, 400, and 500 mg.
[0238] Sterile injectable compositions (such as aqueous or oily suspensions) can be formulated using suitable dispersants or wetting agents (e.g., Tween 80) and suspending agents according to techniques known in the art. Sterile injectable intermediates can also be sterile injectable solutions or suspensions in non-toxic, parenteral-acceptable diluents or solvents, such as solutions in 1,3-butanediol. Pharmaceutically acceptable carriers and solvents, particularly mannitol, water, Ringer's solution, and physiological saline, are commonly used. Furthermore, sterile, non-volatile oils, such as synthetic mono- or diglycerides, are often used as solvents or suspension media. Fatty acids, such as oleic acid and its glyceride derivatives, and natural, pharmaceutically acceptable oils, such as olive oil or castor oil (especially in their polyoxyethylated forms), are commonly used as injectable intermediates. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants, or carboxymethyl cellulose or similar dispersants.
[0239] Inhalation compositions can be prepared using benzyl alcohol or other suitable preservatives, absorption enhancers that improve bioavailability, fluorocarbons and / or other solubilizers or dispersants known in the art, according to techniques well known in the pharmaceutical formulation field, or they can be prepared as solutions in saline.
[0240] Topical compositions can be formulated as oils, creams, lotions, ointments, etc. Suitable carriers for the compositions include vegetable or mineral oils, white petrolatum (white paraffin), branched-chain fatty acids or oils, animal fats, and high molecular weight alcohols (i.e., alcohols with more than 12 carbon atoms). In some embodiments, pharmaceutically acceptable carriers are those in which the active ingredient can dissolve. If desired, the composition may also contain emulsifiers, stabilizers, wetting agents, and antioxidants, as well as substances that impart color or fragrance. Furthermore, transdermal penetration enhancers may be added to the topical formulation. Examples of such enhancers can be found in U.S. Patent Nos. 3,989,816 and 4,444,762.
[0241] Creams can be formulated from a mixture of mineral oil, self-emulsifying beeswax, and water, with an active ingredient dissolved in a small amount of oil, such as almond oil, incorporated therein. An example of a cream contains approximately 40 parts by weight of water, approximately 20 parts by weight of beeswax, approximately 40 parts by weight of mineral oil, and approximately 1 part by weight of almond oil. Ointments can be formulated by mixing a solution of the active ingredient in a vegetable oil, such as almond oil, with warm paraffin wax and then cooling the mixture. An example of an ointment contains approximately 30% by weight of almond oil and approximately 70% by weight of white paraffin wax.
[0242] Appropriate in vitro studies can be used to evaluate the practical use of compounds of formula (I) described herein and / or their pharmaceutically acceptable salts in inhibiting CSF-1R activity. Further in vivo studies can be conducted to investigate additional practical use of compounds of formula (I) described herein and / or their pharmaceutically acceptable salts in the treatment of cancer, autoimmune diseases, or inflammatory diseases, etc. For example, compounds of formula (I) described herein and / or their pharmaceutically acceptable salts can be administered to animals with cancer (e.g., mouse models), and their therapeutic effects can then be evaluated. If the preclinical trials are successful, the dosage range and route of administration in animals, such as humans, can also be predicted.
[0243] The compounds of formula (I) described herein and / or their pharmaceutically acceptable salts have shown sufficient preclinical practical use to warrant clinical trials and are expected to demonstrate beneficial therapeutic or preventative effects, for example, in individuals with cancer.
[0244] As used herein, the term "cancer" refers to a cellular disorder characterized by uncontrolled or disordered cell proliferation, reduced cell differentiation, inappropriate invasion of surrounding tissues, and / or the ability to establish new growth sites in other locations. The term "cancer" includes, but is not limited to, solid tumors and hematologic malignancies. The term "cancer" includes cancers of the skin, tissues, organs, bones, cartilage, blood, and blood vessels. The term "cancer" includes both primary and metastatic cancers.
[0245] Non-limiting examples of solid tumors include pancreatic cancer; bladder cancer; colorectal cancer; colon cancer; breast cancer, including metastatic breast cancer; prostate cancer, including androgen-dependent and androgen-independent prostate cancer; testicular cancer; kidney cancer, including, for example, metastatic renal cell carcinoma; urothelial carcinoma; liver cancer; hepatocellular carcinoma; lung cancer, including, for example, non-small cell lung cancer (NSCLC), bronchioloalveolar carcinoma (BAC), and lung adenocarcinoma; ovarian cancer, including, for example, progressive epithelial carcinoma or primary peritoneal carcinoma; cervical cancer; endometrial cancer; gastrointestinal stromal tumors (GIST); gastric cancer; esophageal cancer; head and neck cancer, including, for example, squamous cell carcinoma of the head and neck; skin cancer, including, for example, melanoma and basal carcinoma; neuroendocrine carcinoma, including metastatic neuroendocrine tumors; brain tumors, including, for example, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma; bone cancer; sarcomas, including, for example, Kaposi's sarcoma. Sarcoma; adrenal carcinoma; mesothelioma; mesothelial endometrial carcinoma; choriocarcinoma; myoma; connective tissue carcinoma; tenosynovial giant cell tumor; and thyroid carcinoma.
[0246] Non-limiting examples of hematologic malignancies include acute myeloid leukemia (AML); chronic myeloid leukemia (CML), including accelerated phase CML and CML blast crisis (CML-BP); acute lymphoblastic leukemia (ALL); chronic lymphocytic leukemia (CLL); Hodgkin lymphoma; non-Hodgkin lymphoma (NHL); follicular lymphoma; mantle cell lymphoma (MCL); B-cell lymphoma; T-cell lymphoma; diffuse large B-cell lymphoma (DLBCL); multiple myeloma (MM); Waldenström macroglobulinemia; myelodysplastic syndromes (MDS), including refractory anemia (RA), ringed sideroblastic refractory anemia (RARS), excessive budding cell refractory anemia (RAEB), and excessive budding cell refractory anemia with acute transformation (RAEB-T); and myeloproliferative syndrome.
[0247] In some implementations, solid tumors include ovarian cancer, lung cancer (including non-small cell lung cancer), glioblastoma (GBM), giant cell tenosynovitis, gastrointestinal stromal tumors (GIST), gastric cancer, esophageal cancer, colon cancer, colorectal cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, melanoma, mesothelioma, mesothelial endometrial carcinoma, kidney cancer, liver cancer, thyroid cancer, head and neck cancer, urothelial carcinoma, bladder cancer, endometrial cancer, choriocarcinoma, adrenal carcinoma, and sarcoma.
[0248] In some implementations, typical hematologic malignancies include leukemias such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML); multiple myeloma (MM); and lymphomas such as Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma, B-cell lymphoma, T-cell lymphoma, and diffuse large B-cell lymphoma (DLBCL).
[0249] The compounds of formula (I) described herein and / or their pharmaceutically acceptable salts may be used to achieve beneficial therapeutic or preventive effects, for example, in individuals with cancer.
[0250] The compounds of formula (I) described herein and / or their pharmaceutically acceptable salts may be used to achieve beneficial therapeutic or preventive effects, for example, in individuals suffering from autoimmune or inflammatory diseases.
[0251] The term "autoimmune disease" refers to a disease or condition caused by damage to one's own tissues or organs due to an immune response to self-antigens. Examples of autoimmune diseases include, but are not limited to: chronic obstructive pulmonary disease (COPD), allergic rhinitis, lupus erythematosus, myasthenia gravis, multiple sclerosis (MS), rheumatoid arthritis (RA), collagen-induced arthritis, psoriasis, inflammatory bowel disease (including Crohn's disease), asthma, autoimmune nephritis, idiopathic thrombocytopenic purpura (ITP), and myeloproliferative diseases, such as myelofibrosis and post-PV / ET myelofibrosis.
[0252] The term "inflammatory disease" or "inflammatory condition" refers to a pathological state that causes inflammation, particularly due to neutrophil chemotaxis. Non-limiting examples of inflammatory diseases include systemic and local inflammation, immunosuppression-related inflammation, organ transplant rejection, allergic reactions, inflammatory skin diseases (including psoriasis and atopic dermatitis); systemic scleroderma and sclerosis; reactions associated with inflammatory bowel diseases (IBD, such as Crohn's disease and ulcerative colitis); ischemia-reperfusion injury, including surgically induced tissue reperfusion injury, myocardial ischemia such as myocardial infarction, cardiac arrest, post-cardiac reperfusion and abnormal contractile responses of coronary vessels after percutaneous coronary angioplasty, tissue reperfusion injury after stroke and abdominal aortic aneurysm surgery; stroke-related cerebral edema; head trauma; hemorrhagic shock; asphyxia; adult respiratory distress syndrome; acute lung injury; Behcet's disease; dermatomyositis; polymyositis; multiple sclerosis (MS). Dermatitis; meningitis; encephalitis; uveitis; osteoarthritis; lupus nephritis; autoimmune diseases such as rheumatoid arthritis (RA), Sjorgen's syndrome, vasculitis; diseases involving leukocyte exudation; sepsis or trauma-induced inflammatory diseases of the central nervous system (CNS), multiple organ injury syndrome; alcoholic hepatitis; bacterial pneumonia; antigen-antibody complex-mediated diseases, including glomerulonephritis; sepsis; sarcoidosis; immunopathological reactions following tissue / organ transplantation; lung inflammation, including pleurisy, alveolitis, vasculitis, pneumonia, chronic bronchitis, bronchiectasis, diffuse panbronchiolitis, allergic pneumonia, idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, etc. Preferred indications include, but are not limited to, chronic inflammation, autoimmune diabetes, rheumatoid arthritis (RA), rheumatoid spondylitis, gouty arthritis and other joint diseases, multiple sclerosis (MS), asthma, systemic lupus erythematosus, adult respiratory distress syndrome, Behcet's disease, psoriasis, chronic inflammatory lung disease, graft-versus-host disease, Crohn's disease, ulcerative colitis, inflammatory bowel disease (IBD), Alzheimer's disease and pyresis, and any disease associated with inflammation and related conditions.
[0253] The term "metabolic disease" refers to a disease or condition caused by metabolic problems, including metabolic disorders and hypermetabolism. Examples of metabolic diseases include, but are not limited to: osteoporosis, diabetes, diabetic ketoacidosis, hyperglycemic hyperosmolar syndrome, hypoglycemia, gout, protein-energy malnutrition, vitamin A deficiency, scurvy, and vitamin D deficiency.
[0254] The term "neurodegenerative diseases" refers to neurodegenerative diseases or conditions caused by neuronal degeneration and apoptosis. Examples of neurodegenerative diseases include, but are not limited to: Parkinson's disease (PD), multiple system atrophy, Alzheimer's disease (AD), frontotemporal dementia, Huntington's disease (HD), corticobasal degeneration, spinocerebellar ataxia, motor neuron diseases (including amyotrophic lateral sclerosis (ALS)), and hereditary motor sensory neuropathy (CMT).
[0255] The term "obesity-related diseases" refers to diseases or conditions that are associated with, caused by, or resulting from obesity. Examples of obesity-related diseases include, but are not limited to: diabetes, hypertension, insulin resistance syndrome, dyslipidemia, heart disease, cardiovascular diseases (including atherosclerosis, arrhythmias, irregular heart rhythms, myocardial infarction, congestive heart failure, coronary artery disease, angina pectoris), cerebral infarction, cerebral hemorrhage, osteoarthritis, metabolic syndrome, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
[0256] Furthermore, compounds of formula (I) described herein (e.g., compounds of any of the embodiments herein) and / or pharmaceutically acceptable salts thereof may be used in combination with additional therapeutic agents for the treatment of cancer, autoimmune diseases, or inflammatory diseases. The additional therapeutic agent may be administered separately from the compounds of formula (I) described herein and / or pharmaceutically acceptable salts thereof, or may be included in a pharmaceutical composition, such as a fixed-dose combination drug, in accordance with this disclosure. In some embodiments, the additional therapeutic agent is an ingredient known or found to be effective in treating diseases mediated or at least partially mediated by CSF-1R, such as another CSF-1R inhibitor or a compound that effectively antagonizes another target associated with that particular disease. Combination therapy may be used to improve efficacy (e.g., by including a compound that enhances the potency or effectiveness of the compounds of formula (I) described herein and / or pharmaceutically acceptable salts thereof in the combination therapy), reduce one or more side effects, or reduce the required dose of the compounds of formula (I) described herein and / or pharmaceutically acceptable salts thereof.
[0257] In some embodiments, compounds of formula (I) described herein (e.g., compounds of any of the examples herein) and / or pharmaceutically acceptable salts thereof may be used in combination with antitumor agents. As used herein, the term "antitumor agent" refers to any agent administered to a subject suffering from cancer for the purpose of treating cancer, including but not limited to radiotherapy agents, chemotherapy agents, immune checkpoint inhibitors or agonists, targeted therapy agents, etc.
[0258] In some implementations, compounds of formula (I) described herein (e.g., any of the examples herein) and / or pharmaceutically acceptable salts thereof may be used in combination with immune checkpoint inhibitors or agonists, targeted therapies, or chemotherapeutic agents.
[0259] Non-limiting examples of immune checkpoint inhibitors or agonists include PD-1 inhibitors, such as anti-PD-1 antibodies, such as pembrolizumab, nivolumab, and spartalizumab; PD-L1 inhibitors, such as anti-PD-L1 antibodies, such as atezolizumab, durvalumab, and avelumab; CTLA-4 inhibitors, such as anti-CTLA-4 antibodies, such as ipilimumab; and BTLA inhibitors, LAG-3 inhibitors, TIM3 inhibitors, TIGIT inhibitors, VISTA inhibitors, OX-40 agonists, etc.
[0260] Non-limiting examples of chemotherapeutic agents include topoisomerase I inhibitors (e.g., irinotecan, topotecan, camptothecin and its analogues or metabolites, and doxorubicin); topoisomerase II inhibitors (e.g., etoposide, teniposide, mitoxantrone, demethoxydaunorubicin, and donomycin); alkylating agents (e.g., melphalan, chlorambucil, busulfan, thiotepa, ifosfamide, nitrosourea mustard, cyclohexanenitrosourea, methylcyclohexanenitrosourea, streptozotocin, aminoimide, methotrexate, mitomycin C, and... Cyclophosphamide; DNA intercalating agents (e.g., cisplatin, oxaliplatin, and carboplatin); DNA intercalating agents and free radical generating agents such as bleomycin; nucleoside analogs (e.g., 5-fluorouracil, capecitabine, gemcitabine, fludarabine, cytarabine, azacitidine, mercaptopurine, thioguanine, pentostatin, and hydroxyurea); paclitaxel, taxanes, and related analogs; vincristine, vinblastine, and related analogs; sedatives and related analogs (e.g., CC-5013 and CC-4047).
[0261] Non-limiting examples of targeted therapies include: protein tyrosine kinase inhibitors (e.g., imatinib mesylate and gefitinib); proteasome inhibitors (e.g., bortezomib); NF-κB inhibitors, including IκB kinase inhibitors; IDO inhibitors; A2AR inhibitors; BRAF inhibitors (e.g., dabrafenib); MEK inhibitors (e.g., trametinib); mTOR inhibitors (e.g., rapamycin); anti-CD40 antibodies (e.g., APX005M, RO7009789); and... Antibodies that bind to proteins overexpressed in cancer and thereby downregulate cell replication include anti-CD20 antibodies (such as rituximab, teimomab, and tosimob), anti-Her2 antibodies (such as trastuzumab), anti-EGFR antibodies (such as cetuximab), and anti-VEGF antibodies (such as bevacizumab); anti-angiogenic drugs, such as lenalidomide; and other protein or enzyme inhibitors known to be upregulated, overexpressed, or activated in cancer, and whose inhibition can downregulate cell replication. Example
[0262] The following examples are illustrative of the invention and do not limit the invention in any way. The data given (e.g., quantities, temperatures, etc.) are intended to be accurate; however, those skilled in the art will understand that some experimental errors and biases may occur. Unless otherwise stated, all parts are by weight, temperatures are in Celsius, and pressures are at or near atmospheric pressure. All mass spectrometry data were obtained using Agilent 6120 and 1100. All nuclear magnetic resonance data were obtained using a Varian 400MHz NMR. Except for synthetic intermediates, all reagents used in this invention were commercially available. All compound names, except for reagents, were generated using Chemdraw 18.0.
[0263] In any structural formula of this application, if there is a vacant valence on any atom, the vacant valence is actually for the sake of simplicity and is not specifically described as a hydrogen atom.
[0264] In this application, if both the name and structural formula of a compound are given, and the two are inconsistent, the structure of the compound shall prevail, unless the context indicates that the structure of the compound is incorrect while the name is correct.
[0265] The following list of abbreviations is used in the examples below:
[0266]
[0267]
[0268] Example 1
[0269] Preparation of intermediates
[0270] Intermediate 1
[0271] 5-Chloro-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid
[0272]
[0273] (A) Isopropyl 5-chloro-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid
[0274] In a reaction flask under nitrogen protection, 5-chloro-2-oxo-1,2-dihydropyridine-3-carboxylic acid (200 mg, 1.15 mmol), 2-iodopropane (784 mg, 4.61 mmol), potassium carbonate (637 mg, 4.61 mmol), and DMF (5 mL) were added sequentially, and the reaction was carried out at 80 °C for 5 h. The reaction solution was concentrated, and the residue was dissolved in water (10 mL), adjusted to pH 2 with 1N HCl solution, and then extracted with dichloromethane (50 mL × 3). The organic layers were combined, concentrated, and the residue was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0–0:100 gradient elution) to give 110 mg of the title product as a white solid. MS (m / z): 258.1 [M+H] + (B) 5-Chloro-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid
[0275] In a reaction flask, isopropyl 5-chloro-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxylate (110 mg, 0.43 mmol), lithium hydroxide monohydrate (36 mg, 0.86 mmol), methanol (3 mL), and water (1 mL) were added, and the reaction was carried out at room temperature for 2 hours. The reaction solution was concentrated, and the residue was dissolved in water (2 mL). The pH was adjusted to 4 with 1 N HCl solution. The precipitated solid was filtered, washed, and dried to give 74 mg of the title product as a white solid. MS (m / z): 216.0 [M+H] + .
[0276] Intermediate 2
[0277] 4-Methyl-3-oxo-3,4-dihydropyrazine-2-carboxylic acid
[0278]
[0279] (A) Methyl 4-methyl-3-oxo-3,4-dihydropyrazine-2-carboxylate
[0280] In a reaction flask under nitrogen protection, methyl 3-oxo-3,4-dihydropyrazine-2-carboxylate (250 mg, 1.6 mmol), methyl iodomethane (461 mg, 2.4 mmol), potassium carbonate (448 mg, 3.2 mmol), and DMF (5 mL) were added sequentially, and the reaction was carried out at 50 °C for 4 hours. The reaction solution was concentrated, and the residue was dissolved in water (10 mL). The pH was adjusted to 4 with 1N HCl solution, followed by extraction with dichloromethane (50 mL × 3). The organic layers were combined and concentrated. The crude product obtained could be used directly in the next reaction step.
[0281] (B) 4-Methyl-3-oxo-3,4-dihydropyrazine-2-carboxylic acid
[0282] In a reaction flask, methyl 4-methyl-3-oxo-3,4-dihydropyrazine-2-carboxylate (155 mg, 0.92 mmol), lithium hydroxide monohydrate (77 mg, 1.84 mmol), methanol (4 mL), and water (1 mL) were added, and the reaction was carried out at room temperature for 2 hours. The pH was adjusted to 4 with 1 N HCl solution, the mixture was concentrated, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 83 mg of the title product as a white solid. MS (m / z): 155.1 [M+H] + .
[0283] Intermediate 3
[0284] 4-Isopropyl-3-oxo-3,4-dihydropyrazine-2-carboxylic acid
[0285]
[0286] (A) Methyl 4-isopropyl-3-oxo-3,4-dihydropyrazine-2-carboxylate
[0287] In a reaction flask under nitrogen protection, methyl 3-oxo-3,4-dihydropyrazine-2-carboxylate (500 mg, 3.25 mmol), 2-iodopropane (827 mg, 4.87 mmol), potassium carbonate (1.4 g, 9.75 mmol), and DMF (10 mL) were added sequentially, and the reaction was carried out at 50 °C for 4 hours. The reaction solution was concentrated, and the residue was dissolved in water (50 mL). The pH was adjusted to 3 with 1 N HCl solution, followed by extraction with dichloromethane (50 mL × 3). The organic layers were combined, concentrated, and the residue was purified by rapid column chromatography (dichloromethane / methanol = 100:0–10:1 gradient elution) to give 263 mg of the title product as a colorless liquid. MS (m / z): 197.1 [M+H] + .
[0288] (B) 4-Isopropyl-3-oxo-3,4-dihydropyrazine-2-carboxylic acid
[0289] In a reaction flask, methyl 4-isopropyl-3-oxo-3,4-dihydropyrazine-2-carboxylate (263 mg, 1.34 mmol), lithium hydroxide monohydrate (113 mg, 2.68 mmol), methanol (3 mL), and water (1 mL) were added, and the reaction was carried out at room temperature for 2 hours. The reaction solution was concentrated, and the residue was dissolved in water (5 mL). The pH was adjusted to 4 with 1 N HCl solution. The precipitated solid was filtered, washed, and dried to give 200 mg of the title product as a white solid. MS (m / z): 183.1 [M+H] + .
[0290] Intermediate 4
[0291] 2-Isopropyl-3-oxo-2,3-dihydropyridazine-4-carboxylic acid
[0292]
[0293] (A) Isopropyl 2-isopropyl-3-oxo-2,3-dihydropyridazine-4-carboxylic acid isopropyl ester
[0294] In a reaction flask under nitrogen protection, 3-oxo-2,3-dihydropyridazine-4-carboxylic acid (500 mg, 3.57 mmol), 2-iodopropane (1.5 g, 8.92 mmol), potassium carbonate (1.5 g, 10.71 mmol), and DMF (10 mL) were added sequentially, and the reaction was carried out at 40 °C for 2 h. The reaction solution was concentrated, and the residue was dissolved in water (50 mL). The pH was adjusted to 3 with 1 N HCl solution, followed by extraction with dichloromethane (50 mL × 3). The organic layers were combined, concentrated, and the residue was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0–0:100 gradient elution) to give 90 mg of the yellow oil title product. MS (m / z): 225.1 [M+H] + .
[0295] (B) 2-Isopropyl-3-oxo-2,3-dihydropyridazine-4-carboxylic acid
[0296] In a reaction flask, add isopropyl 2-isopropyl-3-oxo-2,3-dihydropyridazine-4-carboxylate (90 mg, 0.4 mmol), lithium hydroxide monohydrate (34 mg, 0.8 mmol), methanol (3 mL), and water (1 mL), and react at room temperature for 1 hour. Adjust the pH of the reaction solution to 4 with 1N HCl solution, concentrate, and the resulting crude product can be used directly in the next reaction step.
[0297] Intermediate 5
[0298] 1-(difluoromethyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid
[0299]
[0300] (A) Methyl 1-(difluoromethyl)-2-oxo-1,2-dihydropyridine-3-carboxylate
[0301] In a reaction flask under nitrogen protection, methyl 2-oxo-1,2-dihydropyridine-3-carboxylate (153 mg, 1 mmol), 2,2-difluoro-2-(fluorosulfonyl)acetic acid (267 mg, 1.5 mmol), sodium bicarbonate (168 mg, 2 mmol), and acetonitrile (10 mL) were added sequentially, and the mixture was refluxed for 6 hours. The reaction solution was filtered, the mother liquor was concentrated, and the residue was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0–0:100 gradient elution) to give 146 mg of the title product as a white solid. MS (m / z): 204.1 [M+H] + .
[0302] (B) 1-(difluoromethyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid
[0303] In a reaction flask, methyl 1-(difluoromethyl)-2-oxo-1,2-dihydropyridine-3-carboxylate (146 mg, 0.72 mmol), lithium hydroxide monohydrate (60 mg, 1.44 mmol), methanol (2 mL), and water (0.5 mL) were added, and the mixture was reacted at room temperature for 30 min. The reaction solution was adjusted to pH 4 with 1N HCl solution, concentrated, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 84 mg of the title product as a white solid. MS (m / z): 190.1 [M+H] + .
[0304] Intermediate 6
[0305] 4-O-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid
[0306]
[0307] (A) Ethyl 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylate
[0308] In a reaction flask, 500 mg (5.31 mmol) of 2-aminopyridine and 1.206 g (5.58 mmol) of diethyl 2-(ethoxymethylene)malonate were added. The mixture was heated to 130 °C and reacted for 40 minutes. Then, 25 mL of acetic acid was added, and the mixture was refluxed for another 4 hours. The reaction solution was concentrated to obtain an oily substance, which was used directly in the next reaction without purification. MS (m / z): 219.0 [M+H] + .
[0309] (B) 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid
[0310] In a reaction flask, ethyl 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylate (1.16 g, 5.32 mmol), lithium hydroxide monohydrate (894 mg, 21.28 mmol), THF (20 mL), MeOH (8 mL), and water (8 mL) were added. The mixture was stirred overnight at room temperature. The pH was adjusted to 3.0 with 1 N hydrochloric acid, and a white solid precipitated. The solid was filtered and dried to give 828 mg of the title product. MS (m / z): 191.0 [M+H] + .
[0311] Intermediate 7
[0312] 5-O-1,2,3,5-Tetrahydroindoleazine-6-carboxylic acid
[0313]
[0314] (A)(3-bromopropoxy)(tert-butyl)dimethylsilane
[0315] In a reaction flask, 3-bromopropane-1-ol (4.0 g, 28.78 mmol), 1H-imidazole (3.92 g, 57.56 mmol), DCM (150 mL), and TBSCl (4.55 g, 30.22 mmol) were added sequentially, and the mixture was stirred overnight at room temperature. The reaction solution was washed with water, the organic phase was dried and concentrated, and the residue was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0-90:10 gradient elution) to give 6.5 g of the title product as a colorless liquid.
[0316] (B)2-(3-((tert-butyldimethylsilyl)oxy)propyl)-6-methoxypyridine
[0317] In a reaction flask, 4.83 g (25.67 mmol) of 2-bromo-6-methoxypyridine and 100 mL of dry THF were added. The reaction solution was cooled to -78 °C, and under nitrogen protection, 11.77 mL (28.24 mmol) of 2.4N n-BuLi was added dropwise. After reacting for 30 minutes, 6.5 g (25.67 mmol) of (3-bromopropoxy)(tert-butyl)dimethylsilane was slowly added dropwise. The reaction was continued at -78 °C for 1 hour, then raised to room temperature and allowed to react overnight. The reaction was quenched with water, extracted with ethyl acetate, and the organic phase was dried and concentrated to give a yellow oil. MS (m / z): 282.2 [M+H] + .
[0318] (C)3-(6-methoxypyridin-2-yl)propane-1-ol
[0319] The oily substance obtained in step (B) above was dissolved in THF (80 mL), and TBAF trihydrate (16.1 g, 51.34 mmol) was added. The mixture was stirred overnight at room temperature. Ethyl acetate was added to the reaction solution, and the mixture was washed with water. The organic phase was dried and concentrated. The residue was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0-0:100 gradient elution) to give 1.2 g of the title product as a colorless liquid.
[0320] (D) 3-(6-methoxypyridin-2-yl)propyl methanesulfonate
[0321] In a reaction flask, 1.0 g (5.98 mmol) of 3-(6-methoxypyridin-2-yl)propane-1-ol, 1.66 mL (11.96 mmol), and 50 mL of DCM were added. The reaction mixture was cooled in an ice bath, and then MsCl (822 mg, 7.18 mmol) was added dropwise. The reaction was allowed to proceed for half an hour. The mixture was washed with water, and the organic phase was dried and concentrated to obtain a colorless liquid. MS (m / z): 246.1 [M+H] + .
[0322] (E)2,3-Dihydroindoleazine-5(1H)-one
[0323] In a reaction flask, the crude product of 3-(6-methoxypyridin-2-yl)propyl methanesulfonate obtained in step (D) above and acetonitrile (25 mL) were added. The reaction mixture was reacted in a microwave oven at 125 °C for 15 min, then concentrated. The residue was purified by rapid column chromatography (H₂O / MeOH = 100:0–0:100 gradient elution) to give 400 mg of the pale yellow oil title product. MS (m / z): 136.1 [M+H] + .
[0324] (F)6-Bromo-2,3-dihydroindoleazine-5(1H)-one
[0325] In a reaction flask, 300 mg of 2,3-dihydroindolinazine-5(1H)-one, 5.0 mL of DMF, and 435 mg of NBS were added and stirred overnight at room temperature. The reaction mixture was purified by rapid column chromatography (H₂O / MeOH = 100:0–0:100 gradient elution) to give 120 mg of the pale yellow title product. MS (m / z): 214.0, 216.0 [M+H] + . 1 HNMR (400MHz, DMSO-d6) δ7.79 (d, J = 7.4 Hz, 1H), 6.12 (dt, J = 7.4, 1.2 Hz, 1H), 4.06-3.93 (m, 3H), 3.09-2.97 (m, 3H), 2.18-2.01 (m, 3H).
[0326] (G)5-Oxo-1,2,3,5-Tetrahydroindoleazine-6-carboxynitrile
[0327] In a reaction flask, 120 mg (0.56 mmol) of 6-bromo-2,3-dihydroindolinazine-5(1H)-one, 43 mg (0.365 mmol) of zinc cyanide, 65 mg (0.0561 mmol) of Pd(PPh3)4, and 5.0 mL of DMF were added. The mixture was heated to 100 °C and stirred overnight under nitrogen protection. The reaction solution was purified by rapid column chromatography (H2O / MeOH = 100:0–0:100 gradient elution) to give 60 mg of the white title product. MS (m / z): 161.1 [M+H] + .
[0328] (H)5-oxo-1,2,3,5-tetrahydroindoleazine-6-carboxylic acid
[0329] In a reaction flask, 60 mg (0.375 mmol) of 5-oxo-1,2,3,5-tetrahydroindoleazine-6-carboxynitrile and 1.0 mL (2.0 mmol) of 2N aqueous sodium hydroxide solution were added. The mixture was heated to 100 °C and stirred overnight. It was then cooled to room temperature, and the pH was adjusted to 3 with 1N hydrochloric acid. The mixture was filtered to give 60 mg of the white title product. MS (m / z): 180.1 [M+H] + .
[0330] Intermediate 8
[0331] 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid
[0332]
[0333] (A) Methyl 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
[0334] In a reaction flask, uracil-5-carboxylic acid (1 g, 6.4 mmol) was dissolved in DMF (15 mL), followed by the sequential addition of Cs₂CO₃ (12.5 g, 38.4 mmol) and CH₃I (4.6 g, 32 mmol). The reaction mixture was reacted at 60 °C for 16 h. Water was added to the reaction solution, and the mixture was extracted with ethyl acetate, washed with saturated brine, and dried over anhydrous sodium sulfate. The solution was concentrated to give 0.8 g of a light brown solid. MS (m / z): 199 [M+H] + .
[0335] (B) 1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid
[0336] In a reaction flask, methyl 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (500 mg, 2.5 mmol) was dissolved in methanol (6 mL) and water (1.5 mL). NaOH (200 mg, 5 mmol) was added, and the reaction was carried out at room temperature for 3 hours. Methanol was removed from the reaction solution by rotary evaporation, and the solution was neutralized to pH 3 with 1N hydrochloric acid. A solid precipitated, was filtered, and dried to give 300 mg of a white solid. MS (m / z): 185 [M+H] + .
[0337] Intermediate 9
[0338] 1-Methyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid
[0339]
[0340] (A) Diethyl 2-(2-nitrobenzylidene)malonate
[0341] In a reaction flask under nitrogen protection, 2-nitrobenzaldehyde (2.0 g, 13.2 mmol), diethyl malonate (2.0 mL, 13.2 mmol), potassium carbonate (2.74 g, 19.8 mmol), and acetic anhydride (5 mL) were added sequentially. The mixture was heated to 80 °C and stirred for 4 hours. After cooling to room temperature, the mixture was poured into ice water (100 mL) and extracted with ethyl acetate (100 mL). The organic phase was washed with saturated sodium bicarbonate (100 mL) and saturated brine (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated, and the residue was purified by rapid column chromatography (petroleum ether:ethyl acetate = 100:0-0:100 gradient elution) to give 3.2 g of the title product as a pale yellow solid. MS (m / z): 294.1 [M+H] + .
[0342] (B) Ethyl 2-oxo-1,2-dihydroquinoline-3-carboxylate
[0343] In a reaction flask, diethyl 2-(2-nitrobenzyl)malonate (3.2 g, 10.9 mmol), ethanol (50 mL), and Raney-Ni (1.0 g) were added sequentially. After purging with hydrogen using a hydrogen balloon, the mixture was stirred overnight at room temperature under normal pressure. Dichloromethane (30 mL) and methanol (30 mL) were added, followed by filtration. The filtrate was concentrated to give 2.87 g of the title product as a brown solid. MS (m / z): 218.1 [M+H] + .
[0344] (C) 1-Methyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid
[0345] In a reaction flask, ethyl 2-oxo-1,2-dihydroquinoline-3-carboxylate (500 mg, 2.3 mmol), methyl iodoform (430 μL, 6.9 mmol), potassium carbonate (636 mg, 4.6 mmol), and DMF (5 mL) were added sequentially, and the mixture was stirred overnight at room temperature. A sodium hydroxide aqueous solution (2N, 4 mL) was added dropwise, and the mixture was stirred at room temperature for 4 hours. Water (100 mL) was added, and the pH was adjusted to 4 with concentrated hydrochloric acid. The mixture was filtered, washed with water, and dried to give 350 mg of the title product as a white solid. MS (m / z): 204.1 [M+H] + .
[0346] Intermediate 10
[0347] 5-Fluoro-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid
[0348]
[0349] (A) Methyl 5-fluoro-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate
[0350] In a reaction flask under nitrogen protection, 720 mg of 5-fluoro-2-hydroxynicotinic acid (4.6 mmol), 860 μL of iodomethane (13.8 mmol), 2.74 g of potassium carbonate (19.8 mmol), and 10 mL of DMF were added sequentially. The mixture was heated to 50 °C and stirred overnight. After cooling to room temperature, the reaction solution was purified by rapid column chromatography (elution gradient of water (0.5% formic acid): methanol = 100:0-0:100) to give 750 mg of the title product as a pale yellow solid. MS (m / z): 186.1 [M+H] + .
[0351] (B) 5-Fluoro-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid
[0352] In a reaction flask, methyl 5-fluoro-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate (750 mg, 4.05 mmol), lithium hydroxide monohydrate (340 mg, 9.1 mmol), and methanol / water (15 mL / 5 mL) were added sequentially, and the mixture was stirred at room temperature for 2 hours. After concentration, water (40 mL) was added, and the pH was adjusted to 4 with aqueous hydrochloric acid (2N) before filtration. The solid was dried to give 600 mg of the white title product. MS (m / z): 172.0 [M+H] + .
[0353] Intermediate 11
[0354] 2-Isopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid
[0355]
[0356] (A) Methyl 2-isopropyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate
[0357] In a reaction flask under nitrogen protection, isopropylamine hydrochloride (1.23 g, 10 mmol), anhydrous methanol (20 mL), and sodium methoxide (504 mg, 10 mmol) were added sequentially. After stirring for half an hour, dimethyl 2-(methoxymethylene)malonate (1.74 g, 10 mmol) and sodium methoxide (504 mg, 10 mmol) were added sequentially under ice bath conditions. The mixture was then slowly heated to room temperature and stirred overnight. After concentration, the sample was mixed with silica gel and purified by rapid column chromatography (dichloromethane:methanol = 100:0-90:10 gradient elution) to obtain 700 mg of the title product as a pale yellow solid. MS (m / z): 197.1 [M+H] + .
[0358] (B) Methyl 2-isopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate
[0359] In a reaction flask under nitrogen protection, methyl 2-isopropyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate (700 mg, 3.6 mmol), methyl iodoformate (436 μL, 7 mmol), cesium carbonate (2.28 g, 7 mmol), and DMF (10 mL) were added sequentially. The mixture was heated to 80 °C and stirred overnight. After cooling to room temperature, the reaction solution was purified by rapid column chromatography (elution gradient of water (0.5% formic acid): methanol = 100:0–0:100) to give 250 mg of the title product as a white solid. MS (m / z): 211.1 [M+H] + .
[0360] (C)2-Isopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid
[0361] In a reaction flask, methyl 2-isopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate (250 mg, 1.2 mmol), sodium hydroxide (96 mg, 2 mmol), and methanol / water (10 mL / 2 mL) were added sequentially, and the mixture was stirred at room temperature for 2 hours. The pH was adjusted to 4 with 2N hydrochloric acid aqueous solution, and the mixture was concentrated. The residue was purified by rapid column chromatography (water (0.5% formic acid):methanol = 100:0–0:100 gradient elution) to give 180 mg of the white title product. MS (m / z): 197.1 [M+H] + .
[0362] Intermediate 12
[0363] 2-Cyclopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid
[0364]
[0365] (A) Methyl 2-cyclopropyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate
[0366] The title compound was prepared using cyclopropanedin hydrochloride and appropriate reagents, following the preparation procedure for intermediate 11(A). MS (m / z): 195.1 [M+H] + .
[0367] (B) Methyl 2-cyclopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate
[0368] The title compound was prepared using the same intermediates and reagents as intermediate 11(B). MS (m / z): 209.1 [M+H] + .
[0369] (C)2-Cyclopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid
[0370] In a reaction flask, methyl 2-cyclopropyl-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate (750 mg, 3.6 mmol), sodium hydroxide (288 mg, 7.2 mmol), and methanol / water (20 mL / 4 mL) were added sequentially, and the mixture was stirred at room temperature for 2 hours. After concentration, water (40 mL) was added, and the pH was adjusted to 4 with hydrochloric acid aqueous solution (2N), followed by filtration. The solid was dried to give 450 mg of the yellow title product. MS (m / z): 195.1 [M+H] + .
[0371] Intermediate 13
[0372] 5-Fluoro-1,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid
[0373]
[0374] (A) 5-Fluoro-1,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxynitrile
[0375] In a reaction flask, 500 mg (3.38 mmol) of 1,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxynitrile, 1.19 g (3.38 mmol) of Selectfluor (fluorine reagent), and 10 mL of acetonitrile were added sequentially, and the reaction was carried out at room temperature for 15 hours under nitrogen protection. The concentrated reaction solution was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0–0:100 gradient elution) to give 133 mg of the title product as a white solid. MS (m / z): 166.7 [M+H] + .
[0376] (B) 5-Fluoro-1,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid
[0377] In a reaction flask, 133 g (0.80 mmol) of 5-fluoro-1,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxynitrile and 2 mL of concentrated hydrochloric acid were added sequentially, and the mixture was refluxed for 3 h. The reaction solution was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 60 mg of the title product as a white solid. MS (m / z): 186.0 [M+H] + .
[0378] Intermediate 14
[0379] 1-Methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid
[0380]
[0381] (A) Methyl 6-oxo-1,6-dihydropyrimidine-5-carboxylate
[0382] In a reaction flask, dimethyl 2-(methoxymethylene)malonate (0.87 g, 5.0 mmol), formamidin (0.22 g, 5.0 mmol), sodium methoxide (0.27 g, 5.0 mmol), and anhydrous methanol (10 mL) were added sequentially, and the mixture was refluxed under nitrogen protection for 7 hours. The concentrated reaction solution was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0–0:100 gradient elution) to give 0.51 g of the title product as a white solid. MS (m / z): 155.1 [M+H] + .
[0383] (B) Methyl 1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate
[0384] In a reaction flask, methyl 6-oxo-1,6-dihydropyrimidine-5-carboxylate (0.51 g, 3.31 mmol), methyl iodoform (0.94 g, 6.62 mmol), potassium carbonate (0.69 g, 4.97 mmol), and DMSO (10 mL) were added sequentially, and the reaction was carried out at 50 °C for 1 h. The reaction solution was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 0.44 g of the title product as a pale yellow solid. MS (m / z): 169.1 [M+H] + .
[0385] (C) 1-Methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid
[0386] In a reaction flask, methyl 1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate (0.44 g, 2.61 mmol), lithium hydroxide monohydrate (0.22 g, 5.22 mmol), methanol (10 mL), and water (2 mL) were added sequentially, and the reaction was carried out at 50 °C for 1 h. The pH of the reaction solution was adjusted to 3-4, and the mixture was extracted with ethyl acetate. The crude product was concentrated and purified by rapid column chromatography (water / methanol = 100:0-0:100 gradient elution) to give 0.37 g of the title product as a white solid. MS (m / z): 155.1 [M+H] + .
[0387] The following intermediates were prepared using the same intermediates and reagents as intermediate 14, under conditions recognized by those skilled in the art.
[0388]
[0389] Intermediate 17
[0390] (2-Methyl-2H-1,2,3-triazol-4-yl)boronic acid
[0391]
[0392] (A) 4,5-Dibromo-1H-1,2,3-triazole
[0393] In a reaction flask, 1H-1,2,3-triazole (10.0 g, 145 mmol) and water (150 mL) were added and cooled in an ice bath. Then, liquid bromine (10 mL) was slowly added dropwise. After the addition was complete, the mixture was heated to room temperature and stirred overnight. The reaction mixture was filtered, and the resulting solid was washed with water and dried to give 18.9 g of the title product.
[0394] (B) 4,5-Dibromo-2-methyl-2H-1,2,3-triazole
[0395] In a reaction flask, 18.9 g (83.3 mmol) of 4,5-dibromo-1H-1,2,3-triazole, 23.04 g (166.7 mmol) of K2CO3, and 150 mL of DMF were added. The mixture was cooled to -10 °C, and then 23.67 g (166.7 mmol) of iodomethane was slowly added dropwise. After the addition was complete, the mixture was slowly brought to room temperature and stirred overnight. 500 mL of water was added, and the mixture was extracted three times with ethyl acetate. The organic phase was washed with saturated brine, dried, and concentrated. The residue was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0-0:100 gradient elution) to give 9.2 g of the white solid product 4,5-dibromo-2-methyl-2H-1,2,3-triazole. 1¹H NMR (400 MHz, CDCl₃) δ 4.16 (s, 3H). 4.66 g of the isomer 4,5-dibromo-1-methyl-1H-1,2,3-triazole. MS (m / z): 239.9, 241.9, 243.9 [M+H] + . 1 H NMR (400MHz, CDCl3) δ4.06 (s, 3H).
[0396] (C)4-Bromo-2-methyl-2H-1,2,3-triazole
[0397] In a reaction flask, 9.2 g (38.19 mmol) of 4,5-dibromo-2-methyl-2H-1,2,3-triazole and 150 mL of THF were added. The mixture was cooled to -78 °C, and then 19.0 mL (45.83 mmol) of 2.5N-butyllithium was slowly added dropwise. After the addition was complete, the mixture was stirred for one hour. The solution was quenched with 50 mL of water, and the mixture was extracted three times with ethyl acetate. The organic phase was washed with saturated brine, dried, and concentrated. The residue was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0–0:100 gradient elution) to give 2.5 g of the liquid title product. MS (m / z): 162.0, 164.0 [M+H] + .
[0398] (D)(2-methyl-2H-1,2,3-triazol-4-yl)boronic acid
[0399] In a reaction flask, 2.5 g (15.43 mmol) of 4-bromo-2-methyl-2H-1,2,3-triazole and 50 mL of THF were added. Under nitrogen protection, 1.3N isopropyl magnesium chloride and lithium chloride (14.2 mL, 18.52 mmol) were added dropwise. After the addition was complete, the mixture was stirred for 2 hours. The reaction solution was then cooled to -20°C, and trimethyl borate was added. The mixture was stirred for 1.5 hours, then brought to room temperature, quenched with water, and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried, and concentrated to give 1.02 g of the title product as a white solid. MS (m / z): 128.1 [M+H] + .
[0400] Intermediate 18
[0401] 5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0402]
[0403] (A) 2-Chloro-4-((6-nitro-pyridin-3-yl)oxy)pyridine
[0404] 2-Chloro-4-hydroxypyridine (12.9 g, 0.1 mol), 5-fluoro-2-nitropyridine (14.2 g, 0.1 mol), and potassium carbonate (27.6 g, 0.2 mol) were dissolved in DMSO (130 mL), and the mixture was heated at 80 °C for 2 days. The reaction mixture was cooled to room temperature and diluted with water (100 mL) and ethyl acetate (200 mL). The organic phase was separated, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined and concentrated to obtain a crude product, which was purified by rapid column chromatography (eluting with petroleum ether / ethyl acetate = 1:1) to give 10.8 g of the title product. MS (m / z): 251.9 [M+H] + .
[0405] (B) 2-(1-methyl-1H-pyrazol-4-yl)-4-((6-nitro-pyridin-3-yl)oxy)pyridine
[0406] 2-Chloro-4-((6-nitro-pyridin-3-yl)oxy)pyridine (10.8 g, 42.9 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxoborhexacyclopentan-2-yl)-1H-pyrazole (10.7 g, 52.0 mmol), Pd(dppf)Cl2 (3.14 g, 4.3 mmol), and K2CO3 (11.9 g, 86.0 mmol) were dissolved in a mixture of 1,4-dioxane (110 mL) and water (11 mL). The mixture was heated to 80 °C and stirred for 5 hours under nitrogen protection. The reaction was cooled to room temperature, quenched with water, and concentrated to obtain a crude product. This crude product was purified by rapid column chromatography (elution using a gradient of petroleum ether / ethyl acetate = 100:0–0:100 and dichloromethane / methanol = 100:0–90:10) to give 8.2 g of the title product. MS (m / z): 298.0 [M+H] + .
[0407] (C)5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine
[0408] 2-(1-methyl-1H-pyrazol-4-yl)-4-((6-nitro-pyridin-3-yl)oxy)pyridine (4.8 g, 16.1 mmol) and palladium on carbon (1.0 g) were dissolved in methanol (50 mL) and stirred at room temperature under hydrogen atmosphere for 15 hours. The palladium on carbon was removed by filtration, and the liquid was concentrated to obtain a crude product, which was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 3.6 g of the title product. MS (m / z): 268.0 [M+H] + .
[0409] The following intermediates were prepared using the same intermediates and reagents as intermediate 18, under conditions recognized by those skilled in the art.
[0410]
[0411] Intermediate 24
[0412] 5-((2-(2-methylthiazo-5-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0413]
[0414] (A) 2-Methyl-5-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)thiazole
[0415] In a reaction flask under nitrogen protection, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (200 mg, 0.79 mmol), 2-methyl-5-(tributyltinyl)thiazole (339 mg, 0.87 mmol), Pd(PPh3)4 (46 mg, 0.04 mmol), and DMF (5 mL) were added sequentially, and the reaction was carried out overnight at 100 °C. The reaction solution was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 120 mg of the title product as a solid. MS (m / z): 315.1 [M+H] + .
[0416] (B) 5-((2-(2-methylthiazo-5-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0417] In a reaction flask under nitrogen protection, 2-methyl-5-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)thiazole (120 mg, 0.38 mmol), ammonium chloride (102 mg, 1.91 mmol), iron powder (85 mg, 1.52 mmol), ethanol (20 mL), and water (5 mL) were added sequentially, and the reaction was carried out at 90 °C for 3 h. The reaction solution was filtered, the filtrate was concentrated, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 88 mg of the title product as a solid. MS (m / z): 285.1 [M+H] + .
[0418] The following intermediates were prepared using the same intermediates and reagents as intermediate 24, under conditions recognized by those skilled in the art.
[0419]
[0420] Intermediate 26
[0421] 4-((6-aminopyridin-3-yl)oxy)-N-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine
[0422]
[0423] (A)N-(1-methyl-1H-pyrazol-4-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine-2-amine
[0424] In a reaction flask under nitrogen protection, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (150 mg, 0.6 mmol), 1-methyl-1H-pyrazole-4-amine hydrochloride (96 mg, 0.72 mmol), p-toluenesulfonic acid monohydrate (103 mg, 0.6 mmol), and isopropanol (5 mL) were added sequentially, and the reaction was carried out at 150 °C for 16 h. The reaction solution was concentrated, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 90 mg of the title product as a brown solid. MS (m / z): 313.1 [M+H] + .
[0425] (B) 4-((6-aminopyridin-3-yl)oxy)-N-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine
[0426] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 283.1 [M+H] + .
[0427] Intermediate 27
[0428] 4-((6-aminopyridin-3-yl)oxy)-N-(pyridin-2-yl)pyridin-2-amine
[0429]
[0430] (A) 4-((6-nitropyridin-3-yl)oxy)-N-(pyridin-2-yl)pyridin-2-amine
[0431] In a reaction flask under nitrogen protection, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (300 mg, 1.2 mmol), 2-aminopyridine (123 mg, 1.3 mmol), BINAP (150 mg, 0.24 mmol), Pd2(dba)3 (69 mg, 0.12 mmol), cesium carbonate (782 mg, 2.4 mmol), and DMA (5 mL) were added sequentially. The mixture was microwaved at 145 °C for 10 min. The reaction solution was filtered, the filtrate was concentrated, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 210 mg of the title product as a brown solid. MS (m / z): 310.1 [M+H] + .
[0432] (B) 4-((6-aminopyridin-3-yl)oxy)-N-(pyridin-2-yl)pyridin-2-amine
[0433] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 280.1 [M+H] + .
[0434] Intermediate 28
[0435] 5-((2-(imidazo[1,2-a]pyridin-7-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0436]
[0437] (A) 4-((6-nitropyridin-3-yl)oxy)-[2,4'-bipyridine]-2'-amine
[0438] In a reaction flask under nitrogen protection, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (300 mg, 1.2 mmol), (2-aminopyridin-4-yl)boronic acid (197 mg, 1.4 mmol), Pd(dppf)Cl2 (98 mg, 0.12 mmol), 2M potassium carbonate solution (1.5 mL), and 1,4-dioxane (6 mL) were added sequentially, and the reaction was carried out overnight at 90 °C. The reaction solution was concentrated, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 187 mg of the title product as a yellow solid. MS (m / z): 310.1 [M+H] + .
[0439] (B)7-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)imidazo[1,2-a]pyridine
[0440] In a reaction flask under nitrogen protection, 187 mg (0.61 mmol) of 4-((6-nitropyridin-3-yl)oxy)-[2,4'-bipyridine]-2'-amine, 1 mL of 40% chloroacetaldehyde aqueous solution, 84 mg (0.61 mmol) of potassium carbonate, and 5 mL of ethanol were added sequentially, and the mixture was refluxed overnight. The reaction solution was concentrated, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 130 mg of the title product as a yellow solid. MS (m / z): 334.0 [M+H] + .
[0441] (C)5-((2-(imidazo[1,2-a]pyridin-7-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0442] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 304.1 [M+H] + .
[0443] Intermediate 29
[0444] 4-((6-aminopyridin-3-yl)oxy)-N-(1-(difluoromethyl)-1H-pyrazol-3-yl)pyridin-2-amine
[0445]
[0446] (A) 1-(difluoromethyl)-3-nitro-1H-pyrazole
[0447] In a reaction flask under nitrogen protection, 3-nitro-1H-pyrazole (5 g, 44.2 mmol), sodium 2-chloro-2,2-difluoroacetate (8.1 g, 53.0 mmol), potassium carbonate (9.2 g, 66.3 mmol), 18-crown-6 (2.3 g, 8.8 mmol), and acetonitrile (20 mL) were added sequentially, and the mixture was refluxed overnight. The reaction solution was filtered, the filtrate was concentrated, the residue was dissolved in water (200 mL), extracted with ethyl acetate (100 mL × 3), the organic layers were combined, concentrated, and the residue was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0–0:100 gradient elution) to give 5 g of the yellow oily title product. MS (m / z): 164.1 [M+H] + .
[0448] (B) 1-(difluoromethyl)-1H-pyrazole-3-amine
[0449] In a reaction flask, 5 g (30.7 mmol) of 1-(difluoromethyl)-3-nitro-1H-pyrazole, 500 mg of Pd / C, and 15 mL of methanol were added sequentially, and the reaction was carried out overnight at room temperature under hydrogen atmosphere. The reaction solution was filtered, and the filtrate was concentrated to give 4 g of a yellow oily crude product. MS (m / z): 134.0 [M+H] + .
[0450] (C)N-(1-(difluoromethyl)-1H-pyrazol-3-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine-2-amine
[0451] In a reaction flask under nitrogen protection, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (500 mg, 2.59 mmol), 1-(difluoromethyl)-1H-pyrazole-3-amine (345 mg, 1.3 mmol), XantPhos (231 mg, 0.40 mmol), Pd2(dba)3 (183 mg, 0.20 mmol), cesium carbonate (1.3 g, 3.88 mmol), and 1,4-dioxane (10 mL) were added sequentially, and the reaction was carried out overnight at 100 °C. The reaction solution was concentrated, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 600 mg of the title product as a solid. MS (m / z): 349.0 [M+H] + .
[0452] (D)4-((6-aminopyridin-3-yl)oxy)-N-(1-(difluoromethyl)-1H-pyrazol-3-yl)pyridin-2-amine
[0453] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 319.0 [M+H] + .
[0454] Intermediate 30
[0455] 5-((2-(1-methyl-1H-imidazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0456]
[0457] (A) 2-(1-methyl-1H-imidazol-4-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine
[0458] In a reaction flask, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (300 mg, 1.19 mmol), 1-methyl-4-(tributyltinyl)-1H-imidazolium (663 mg, 1.79 mmol), Pd(PPh3)4 (137 mg, 0.119 mmol), and DMF (5.0 mL) were added. Under nitrogen protection, the mixture was heated to 100 °C and stirred for 3 hours. After cooling, the reaction solution was purified by rapid column chromatography (H2O / MeOH = 100:0–0:100 gradient elution) to give 220 mg of the title product as a white solid. MS (m / z): 298.1 [M+H] + .
[0459] (B) 5-((2-(1-methyl-1H-imidazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0460] In a reaction flask, 2-(1-methyl-1H-imidazol-4-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine (220 mg, 0.74 mmol), Pd / C (30 mg), and methanol (15.0 mL) were added. The mixture was stirred overnight under hydrogen pressure, filtered, and the filtrate was concentrated to give 152 mg of the yellow oily title product. MS (m / z): 268.1 [M+H] + .
[0461] The following intermediates were prepared using the same intermediates and reagents as intermediate 30, under conditions recognized by those skilled in the art.
[0462]
[0463] Intermediate 32
[0464] 5-((2-(1H-1,2,4-triazol-1-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0465]
[0466] (A) 4-((6-nitropyridin-3-yl)oxy)-2-(1H-1,2,4-triazol-1-yl)pyridine
[0467] In a sealed tube, 2-chloropyridin-4-ol (500 mg, 3.86 mmol), 1H-1,2,4-triazole (400 mg, 5.79 mmol), Cs₂CO₃ (4.71 mg, 14.48 mmol), CuI (73 mg, 0.386 mmol), and DMF (20.0 mL) were added. The mixture was heated to 130 °C and stirred for 2 days under nitrogen protection. After cooling, 5-fluoro-2-nitropyridine (1.1 g, 7.72 mmol) was added, and the mixture was heated to 100 °C and stirred overnight. The reaction mixture was filtered, and the filtrate was purified by rapid column chromatography (H₂O / MeOH = 100:0–0:100 gradient elution) to give 396 mg of the title product as a pale yellow solid. MS (m / z): 285.1 [M+H] + .
[0468] (B) 5-((2-(1H-1,2,4-triazol-1-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0469] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 255.1 [M+H] + .
[0470] Intermediate 33
[0471] 5-((2-(4-methyl-1H-imidazol-1-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0472]
[0473] (A) 2-(4-methyl-1H-imidazol-1-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine
[0474] In a sealed tube, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (500 mg, 2.0 mmol), 4-methyl-1H-imidazolium (490 mg, 5.97 mmol), Pd2(dba)3 (36.5 mg, 0.04 mmol), Me4tBuXPhos (38 mg, 0.08 mmol), K3PO4 (845 mg, 3.98 mmol), dioxane (4.0 mL), and toluene (20.0 mL) were added. The mixture was heated to 120 °C and stirred overnight under nitrogen protection. The reaction solution was concentrated, and the residue was purified by rapid column chromatography (H2O / MeOH = 100:0–0:100 gradient elution) to give 280 mg of the title product as a pale yellow solid. MS (m / z): 298.1 [M+H] + (B) 5-((2-(4-methyl-1H-imidazol-1-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0475] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 268.1 [M+H] + .
[0476] Intermediate 34
[0477] 5-([2,3'-bipyridine]-4-yloxy)pyridine-2-amine
[0478]
[0479] (A) 4-((6-nitropyridin-3-yl)oxy)-2,3'-bipyridine
[0480] In a reaction flask, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (500 mg, 0.2 mmol), pyridin-3-ylboronic acid (367 mg, 0.3 mmol), Na₂CO₃ (640 mg, 6.0 mmol), Pd(dppf)Cl₂·CH₂Cl₂ (163 mg, 0.02 mmol), dioxane (25.0 mL), and water (3.0 mL) were added. The mixture was heated to 100 °C and stirred overnight. After cooling, the reaction solution was concentrated, and the residue was purified by rapid column chromatography (H₂O / MeOH = 100:0–0:100 gradient elution) to give 441 mg of the title product as a yellow solid. MS (m / z): 295.0 [M+H] + .
[0481] (B) 5-([2,3'-bipyridine]-4-yloxy)pyridine-2-amine
[0482] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 265.1 [M+H] + .
[0483] The following intermediates were prepared using the same intermediates and reagents as intermediate 34, under conditions recognized by those skilled in the art.
[0484]
[0485]
[0486] Intermediate 35
[0487] 4-((6-aminopyridin-3-yl)oxy)-N-(6-methylpyridin-2-yl)pyridin-2-amine
[0488]
[0489] (A) 6-Methyl-N-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)pyridin-2-amine
[0490] In a sealed tube, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (500 mg, 2.0 mmol), 6-methylpyridin-2-amine (432 mg, 4.0 mmol), Pd2(dba)3 (183 mg, 0.2 mmol), Xantphos (231 mg, 0.4 mmol), Cs2CO3 (1.63 g, 5.0 mmol), and dioxane (50.0 mL) were added. The mixture was heated to 100 °C and stirred for 4 hours under nitrogen protection. The reaction solution was concentrated, and the residue was purified by rapid column chromatography (H2O / MeOH = 100:0–0:100 gradient elution) to give 550 mg of a pale yellow solid. MS (m / z): 324.1 [M+H] + .
[0491] (B) 4-((6-aminopyridin-3-yl)oxy)-N-(6-methylpyridin-2-yl)pyridin-2-amine
[0492] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 294.1 [M+H] + .
[0493] Intermediate 36
[0494] 5-((2-(1H-pyrazol-1-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0495]
[0496] (A)2-(1H-pyrazol-1-yl)pyridin-4-ol
[0497] In a sealed tube, 2-chloro-4-hydroxypyridine (500 mg, 3.9 mmol), pyrazole (527 mg, 7.8 mmol), Cs₂CO₃ (2.5 g, 7.8 mmol), CuI (76 mg, 0.4 mmol), and DMF (10 mL) were added sequentially, and the reaction was carried out at 130 °C for 12 h. The reaction solution was concentrated, and the residue was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0–50:50 gradient elution) to give 300 mg of the title product as a pale yellow solid. MS (m / z): 162 [M+H] + .
[0498] (B) 4-((6-nitropyridin-3-yl)oxy)-2-(1H-pyrazol-1-yl)pyridine
[0499] In a reaction flask, 2-(1H-pyrazol-1-yl)pyridin-4-ol (250 mg, 1.6 mmol), 5-fluoro-2-nitropyridine (220 mg, 1.6 mmol), K₂CO₃ (321 mg, 2.4 mmol), and DMF (10 mL) were added sequentially, and the reaction was carried out at 100 °C for 12 h. The reaction mixture was then diluted with water, extracted with ethyl acetate, washed with saturated brine, and dried over anhydrous sodium sulfate. The solution was concentrated to give 250 mg of a pale yellow solid. MS (m / z): 284 [M+H] + .
[0500] (C)5-((2-(1H-pyrazol-1-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0501] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 254 [M+H] + .
[0502] Intermediate 37
[0503] 5-((2-(1-ethyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine
[0504]
[0505] (A) 2-(1-Ethyl-1H-pyrazole-4-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine
[0506] In a reaction flask under nitrogen protection, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (300 mg, 1.2 mmol), 1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)-1H-pyrazole (398 mg, 1.8 mmol), Pd(PPh3)4 (138 mg, 0.12 mmol), Cs2CO3 (779 mg, 2.4 mmol), dioxane (8 mL), and water (2 mL) were added sequentially, and the reaction was carried out at 100 °C for 3 hours. The reaction solution was concentrated, and the residue was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0-50:50 gradient elution) to give 300 mg of the title product as a pale yellow solid. MS (m / z): 312 [M+H] + (B) 5-((2-(1-ethyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0507] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 282 [M+H] + .
[0508] The following intermediates were prepared using the same intermediates and reagents as intermediate 37, under conditions recognized by those skilled in the art.
[0509]
[0510] Intermediate 39
[0511] 5-([2,4'-bipyridine]-4-yloxy)pyridine-2-amine
[0512]
[0513] (A) 4-((6-nitropyridin-3-yl)oxy)-2,4'-bipyridine
[0514] In a reaction flask under nitrogen protection, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (300 mg, 1.2 mmol), 4-pyridineboronic acid (220 mg, 1.8 mmol), Pd(PPh3)4 (138 mg, 0.12 mmol), Cs2CO3 (779 mg, 2.4 mmol), dioxane (8 mL), and water (2 mL) were added sequentially, and the reaction was carried out at 100 °C for 3 hours. The reaction solution was concentrated, and the residue was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0–0:100 gradient elution) to give 300 mg of the title product as a pale yellow solid. MS (m / z): 295 [M+H] + .
[0515] (B) 5-([2,4'-bipyridine]-4-yloxy)pyridine-2-amine
[0516] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 265 [M+H] + .
[0517] The following intermediates were prepared using the same intermediates and reagents as intermediate 39, under conditions recognized by those skilled in the art.
[0518]
[0519] Intermediate 42
[0520] 4-((6-aminopyridin-3-yl)oxy)-N-(1-methyl-1H-pyrazol-3-yl)pyridin-2-amine
[0521] (A)N-(1-methyl-1H-pyrazol-3-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine-2-amine
[0522] In a reaction flask under nitrogen protection, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (400 mg, 1.6 mmol), 1-methyl-1H-pyrazole-3-amine (309 mg, 3.2 mmol), Pd₂(dba)₃ (145 mg, 0.16 mmol), Xantphos (184 mg, 0.32 mmol), Cs₂CO₃ (779 mg, 2.4 mmol), and dioxane (10 mL) were added sequentially, and the reaction was carried out at 100 °C for 16 h. The reaction solution was concentrated, and the residue was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0–0:100 gradient elution) to give 200 mg of the title product as a pale yellow solid. MS (m / z): 313 [M+H] + .
[0523] (B) 4-((6-aminopyridin-3-yl)oxy)-N-(1-methyl-1H-pyrazol-3-yl)pyridin-2-amine
[0524] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 283 [M+H] + .
[0525] The following intermediates were prepared using the same intermediates and reagents as intermediate 42, under conditions recognized by those skilled in the art.
[0526]
[0527] Intermediate 45
[0528] 5-((2-(1-(difluoromethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0529]
[0530] (A) 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxoborhecyclopentan-2-yl)-1H-pyrazole
[0531] In a reaction flask, 4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)-1H-pyrazole (1 g, 5.1 mmol), sodium 2-chloro-2,2-difluoroacetate (0.94 g, 6.2 mmol), 18-crown-6 (0.27 g, 1.02 mmol), and acetonitrile (20 mL) were added sequentially, and the reaction was carried out at 85 °C for 20 h. The reaction mixture was then diluted with water, extracted with ethyl acetate, washed with saturated brine, and dried over anhydrous sodium sulfate. The concentrate was concentrated to obtain 900 mg of crude product, which was used directly in the next step. MS (m / z): 245 [M+H] + .
[0532] (B)2-(1-(difluoromethyl)-1H-pyrazol-4-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine
[0533] The title compound was prepared using the same intermediates and reagents as intermediate 37(A). MS (m / z): 334 [M+H] + .
[0534] (C)5-((2-(1-(difluoromethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine
[0535] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 304 [M+H] + .
[0536] Intermediate 46
[0537] 2-Chloro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)aniline
[0538]
[0539] (A) 2-Chloro-4-(3-Chloro-4-nitrophenoxy)pyridine
[0540] In a reaction flask, 2-chloro-4-hydroxypyridine (294 mg, 2.28 mmol), 2-chloro-4-fluoro-1-nitrobenzene (400 mg, 2.28 mmol), K₂CO₃ (473 mg, 3.42 mmol), and DMF (8 mL) were added sequentially, and the mixture was reacted at 80 °C for 4 hours. The reaction solution was then diluted with water, extracted with ethyl acetate, washed with saturated brine, and dried over anhydrous sodium sulfate. The product was concentrated to give 500 mg of the title product as a pale yellow solid. MS (m / z): 285 [M+H] + .
[0541] (B) 4-(3-chloro-4-nitrophenoxy)-2-(1-methyl-1H-pyrazol-4-yl)pyridine
[0542] The title compound was prepared using the same intermediates and reagents as intermediate 37(A). MS (m / z): 331 [M+H] + .
[0543] (C)2-Chloro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)aniline
[0544] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 301 [M+H] + .
[0545] Intermediate 47
[0546] 5-((2-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0547]
[0548] (A) 4-((6-nitropyridin-3-yl)oxy)-2-(1H-pyrazol-4-yl)pyridine
[0549] 2-Chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (1.0 g, 4.0 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)-1H-pyrazole (1.55 g, 8.0 mmol), Pd(dppf)Cl2 (0.29 g, 0.4 mmol), and K2CO3 (0.83 g, 6.0 mmol) were dissolved in a mixture of 1,4-dioxane (16 mL) and water (4 mL). The mixture was heated to 80 °C overnight under nitrogen protection. The reaction mixture was concentrated to obtain a crude product, which was purified by rapid column chromatography (dichloromethane / methanol = 100:0–90:10 gradient elution) to give 0.57 g of the title product. MS (m / z): 284.1 [M+H] + .
[0550] (B)N,N-Dimethyl-2-(4-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)ethyl-1-amine
[0551] 4-((6-nitropyridin-3-yl)oxy)-2-(1H-pyrazol-4-yl)pyridine (100 mg, 0.35 mmol), 2-chloro-N,N-dimethylethyl-1-amine (72 mg, 0.70 mmol), and cesium carbonate (170 mg, 0.52 mmol) were dissolved in acetonitrile (10 mL) and stirred at 80 °C for 5 hours. The crude product was concentrated and purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 88 mg of the title product. MS (m / z): 355.1 [M+H] + .
[0552] (C)5-((2-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine
[0553] N,N-dimethyl-2-(4-(4-(((6-nitropyridin-3-yl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)ethyl-1-amine (88 mg, 0.25 mmol) and palladium on carbon (10 mg) were dissolved in methanol (10 mL) and stirred at room temperature under hydrogen atmosphere for 5 hours. The reaction mixture was filtered to remove the palladium on carbon, and the liquid was concentrated to give 67 mg of the crude product of the title compound. MS (m / z): 325.2 [M+H] + .
[0554] Intermediate 48
[0555] 5-((2-(1-methyl-1H-1,2,4-triazol-3-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0556]
[0557] (A) 4-((6-aminopyridin-3-yl)oxy)pyridin-2-carboxynitrile
[0558] 4-Chloropyridinecarboxynitrile (1.38 g, 10.0 mmol), 6-aminopyridine-3-ol (1.1 g, 10.0 mmol), potassium tert-butoxide (1.12 g, 10.0 mmol), and potassium carbonate (1.38 g, 10.0 mmol) were dissolved in 20 mL of DMSO and stirred at 80 °C for 15 hours. The reaction solution was quenched with saturated ammonium chloride solution, extracted with ethyl acetate, and concentrated to obtain a crude product. This crude product was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 1.12 g of the title product. MS (m / z): 213.0 [M+H] + .
[0559] (B) 4-((6-aminopyridin-3-yl)oxy)-N'-methylpyridinic acid iminehydrazine
[0560] 4-((6-aminopyridin-3-yl)oxy)pyridin-2-carboxynitrile (1.12 g, 5.28 mmol) and methylhydrazine (1.21 g, 26.4 mmol) were dissolved in ethanol (20 mL) and reacted at room temperature for 15 h. The reaction mixture was concentrated to obtain a crude product, which was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 430 mg of the title product. MS (m / z): 259.1 [M+H] + .
[0561] (C)5-((2-(1-methyl-1H-1,2,4-triazol-3-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0562] 258 mg of 4-((6-aminopyridin-3-yl)oxy)-N'-methylpyridinecarboxylic acid imine hydrazine (1.0 mmol) was dissolved in formic acid (5 mL) and refluxed for 4 h. The reaction mixture was concentrated to obtain a crude product, which was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 88 mg of the title product. MS (m / z): 269.1 [M+H] + .
[0563] Intermediate 49
[0564] N-(4-((6-aminopyridin-3-yl)oxy)pyridin-2-yl)-5-methylthiazolyl-2-amine
[0565]
[0566] (A) 5-Methyl-N-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)thiazolyl-2-amine
[0567] 2-Chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (300 mg, 1.20 mmol), 5-methylthiazol-2-amine (200 mg, 1.80 mmol), Pd2(dba)3 (100 mg, 0.12 mmol), Xantphos (60 mg, 0.12 mmol), and potassium carbonate (331 mg, 2.40 mmol) were dissolved in dioxane (15 mL), and the mixture was stirred at 90 °C for 6 hours. The crude product was concentrated and purified by rapid column chromatography (dichloromethane / methanol = 100:0–90:10 gradient elution) to give 370 mg of the title product. MS (m / z): 330.1 [M+H] + .
[0568] (B)N-(4-((6-aminopyridin-3-yl)oxy)pyridin-2-yl)-5-methylthiazolyl-2-amine
[0569] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 300.0 [M+H] + .
[0570] Intermediate 50
[0571] 3-Fluoro-5-((2-(1-methyl-1H-imidazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0572]
[0573] (A) 5-((2-chloropyridin-4-yl)oxy)-3-fluoropyridin-2-amine
[0574] 6-Amino-5-fluoropyridin-3-ol (1.70 g, 13.3 mmol), 2-chloro-4-fluoropyridinium (1.74 g, 13.3 mmol), and cesium carbonate (6.50 g, 20.0 mmol) were dissolved in 50 mL of DMSO and reacted at 90 °C with stirring for 2 h. The crude product was concentrated and purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 1.41 g of the title product. MS (m / z): 240.1 [M+H] + .
[0575] (B) 3-Fluoro-5-((2-(1-methyl-1H-imidazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0576] The title compound was prepared using the same intermediates and reagents as intermediate 30(A). MS (m / z): 286.0 [M+H] + .
[0577] Intermediate 51
[0578] 3-Fluoro-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0579]
[0580] The title compound was prepared using the same procedure as intermediate 18(B), employing 5-((2-chloropyridin-4-yl)oxy)-3-fluoropyridin-2-amine and appropriate reagents. MS (m / z): 286.0 [M+H] + .
[0581] Intermediate 52
[0582] 2-Amino-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)nicotinonitrile
[0583]
[0584] (A) 2-Amino-5-((2-chloropyridin-4-yl)oxy)nicotinonitrile
[0585] The title compound was prepared using 6-amino-5-cyanopyridine-3-ol and appropriate reagents, following the preparation procedure for intermediate 50(A). MS (m / z): 247.1 [M+H] + .
[0586] (B) 2-Amino-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)nicotinonitrile
[0587] 2-Amino-5-((2-chloropyridin-4-yl)oxy)nicotinonitrile (150 mg, 0.61 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)-1H-pyrazole (253 mg, 1.22 mmol), Pd(dppf)Cl2 (43 mg, 0.06 mmol), and sodium carbonate (95 mg, 0.92 mmol) were dissolved in dioxane (5 mL) and water (1 mL), and reacted at 80 °C for 5 h under nitrogen protection. The crude product was concentrated and purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 93 mg of the title product. MS (m / z): 293.0 [M+H] + .
[0588] Intermediate 53
[0589] 5-((2-(2-methylthiazo-4-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0590]
[0591] (A) 2-(1-ethoxyvinyl)-4-((6-nitropyridin-3-yl)oxy)pyridine
[0592] Under nitrogen protection, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (252 mg, 1.0 mmol), tributyl(1-ethoxyvinyl)stanane (722 mg, 2.0 mmol), and Pd(PPh3)4 (58 mg, 0.05 mmol) were dissolved in 10 mL of DMF. The reaction mixture was heated at 100 °C for 15 hours. After cooling to room temperature, 20 mL of water and 50 mL of ethyl acetate were added. The mixture was extracted and concentrated, and the crude product was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0-0:100 gradient elution) to give the title product (162 mg) as a pale yellow solid. MS (m / z): 288.0 [M+H]+ .
[0593] (B)2-Bromo-1-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)acetoone
[0594] In a reaction flask, 162 mg (0.564 mmol) of 2-(1-ethoxyvinyl)-4-((6-nitropyridin-3-yl)oxy)pyridine and 100 mg (0.564 mmol) of NBS were dissolved in a mixed solvent of 10 mL tetrahydrofuran and 1 mL water. The reaction mixture was stirred at room temperature for 1 hour. After concentration, the crude product was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give the title product (136 mg) as a pale yellow solid. MS (m / z): 338.0 [M+H] + .
[0595] (C)2-Methyl-4-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)thiazole
[0596] In a reaction flask, 136 mg (0.402 mmol) of 2-bromo-1-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)acet-1-one and acetylthioamide (151 mg, 2.01 mmol) were dissolved in 5 mL of ethanol, and the reaction mixture was heated under reflux for 1 hour. The crude product was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) after concentration to give the title product (98 mg) as a pale yellow solid. MS (m / z): 315.0 [M+H] + .
[0597] (D)5-((2-(2-methylthiazo-4-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0598] The title compound was prepared using the same intermediates and reagents as intermediate 24(B). MS (m / z): 285.0 [M+H] + .
[0599] Example 2
[0600] Preparation of compound 1-135
[0601] Compound 1
[0602] 6-(dimethylamino)-1-isopropyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0603]
[0604] (A) 6-Chloro-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0605] In a reaction flask under nitrogen protection, 5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine (500 mg, 1.87 mmol), 6-chloro-2-oxo-1,2-dihydropyridine-3-carboxylic acid (487 mg, 2.81 mmol), HATU (1.07 g, 2.81 mmol), and DMF (5 mL) were added sequentially, followed by TEA (0.76 mL, 5.61 mmol). The reaction was allowed to proceed overnight at room temperature. The reaction mixture was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 320 mg of the title product as a brown solid. MS (m / z): 423.1 [M+H] + .
[0606] (B) 6-(dimethylamino)-1-isopropyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0607] In a reaction flask under nitrogen protection, 6-chloro-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (70 mg, 0.17 mmol), 2-bromopropane (41 mg, 0.33 mmol), potassium carbonate (69 mg, 0.50 mmol), and DMF (3 mL) were added, and the reaction was carried out overnight at 80 °C. The reaction solution was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) and p-TLC (dichloromethane / methanol = 15:1) to give 12 mg of the title product as a pale yellow solid. MS (m / z): 474.2 [M+H] + .
[0608] 1H NMR (400MHz, DMSO-d6) δ10.48 (s, 1H), 8.36 (d, J = 3.1Hz, 1H), 8.35 (s, 1H), 8.27 (d,J=2.9Hz,1H),8.25(s,1H),8.12(d,J=8.7Hz,1H),7.95(s,1H),7.72(dd,J= 9.0,2.9Hz,1H),7.22(d,J=2.4Hz,1H),6.70(dd,J=5.7,2.3Hz,1H),6.36(d,J= 8.8Hz, 1H), 5.53-5.41 (m, 1H), 3.82 (s, 3H), 3.09 (s, 6H), 1.44 (d, J = 6.2Hz, 6H).
[0609] The following compounds were prepared using the same preparation process as compound 1, with appropriate intermediates and reagents, under conditions deemed suitable by those skilled in the art.
[0610]
[0611] Compound 2
[0612] 6-(dimethylamino)-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-
[0613] Dihydropyridine-3-carboxamide
[0614]
[0615] In a reaction flask under nitrogen protection, 6-chloro-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (100 mg, 0.24 mmol), methyl iodoform (30 μL, 0.47 mmol), potassium carbonate (100 mg, 0.72 mmol), and DMF (4 mL) were added, and the reaction was carried out overnight at 80 °C. Then, dimethylamine hydrochloride (38 mg, 0.47 mmol) was added, and the reaction was carried out overnight at room temperature. The reaction mixture was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) and p-TLC (dichloromethane / methanol = 15:1) to give 16 mg of the title product as a pale yellow solid. MS (m / z): 446.2 [M+H] + .
[0616] 1H NMR (400MHz, DMSO-d6) δ12.48(s,1H),8.36(dd,J=7.4,4.3Hz,2H),8.29(d,J=8.5Hz,1H),8.25(m,2H),7.95(d,J=0.6Hz,1H),7.71(dd ,J=9.0,2.9Hz,1H),7.22(d,J=2.4Hz,1H),6.70(dd,J=5.7,2.4Hz,1H),6.16(d,J=8.6Hz,1H),3.82(s,3H),3.49(s,3H),2.87(s,6H).
[0617] Compound 3
[0618] 6-Methoxy-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0619]
[0620] (A) 6-Chloro-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0621] In a reaction flask under nitrogen protection, 6-chloro-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (320 mg, 0.76 mmol), methyl iodoforme (71 μL, 1.14 mmol), potassium carbonate (540 mg, 1.42 mmol), and DMF (5 mL) were added, and the reaction was carried out overnight at 80 °C. The reaction solution was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 130 mg of the title product as a brown solid. MS (m / z): 437.1 [M+H] + .
[0622] (B) 6-Methoxy-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0623] In a reaction flask under nitrogen protection, 30 mg of 6-chloro-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (0.07 mmol) and 7 M ammonia-methanol solution (3 mL) were added, and the mixture was sealed and reacted at 80 °C for 2 h. The reaction solution was then concentrated, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) and p-TLC (dichloromethane / methanol = 15:1) to give 3 mg of the title product as a pale yellow solid. MS (m / z): 433.2 [M+H] + .
[0624] 1 H NMR (400MHz, DMSO-d6) δ12.39(s,1H),8.46(d,J=8.6Hz,1H),8.38-8.33(m,2H),8.29-8.20(m,2H),7.95(d,J=0.5Hz,1H),7.72(dd, J=9.0, 2.9Hz, 1H), 7.23 (d, J= 2.3Hz, 1H), 6.70 (dd, J= 5.7, 2.4Hz, 1H), 6.25 (d, J= 8.7Hz, 1H), 4.04 (s, 3H), 3.82 (s, 3H), 3.45 (s, 3H).
[0625] Compound 4
[0626] N-(3-Fluoro-5-((2-((1-methyl-1H-pyrazol-4-yl)amino)pyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
[0627]
[0628] (A) 5-((2-bromopyridin-4-yl)oxy)-3-fluoropyridin-2-amine
[0629] In a reaction flask under nitrogen protection, 6-amino-5-fluoropyridin-3-ol (1.28 g, 10 mmol), 2-bromo-4-fluoropyridinium (1.76 g, 10 mmol), cesium carbonate (4.9 g, 15 mmol), and DMSO (10 mL) were added sequentially, and the reaction was carried out at 80 °C for 2 h. The reaction mixture was cooled to room temperature and added to water (100 mL) with stirring. Extraction was performed with ethyl acetate (100 mL × 3), the organic layers were combined, concentrated, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 2.7 g of the title product as a yellow solid. MS (m / z): 285.9 [M+H] + .
[0630] (B)N-(5-((2-bromopyridin-4-yl)oxy)-3-fluoropyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridin-3-carboxamide
[0631] In a reaction flask, 5-((2-bromopyridin-4-yl)oxy)-3-fluoropyridin-2-amine (200 mg, 0.70 mmol), 1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (118 mg, 0.77 mmol), HATU (322 mg, 0.85 mmol), TEA (148 μL, 1.05 mmol), and DMF (6 mL) were added sequentially, and the reaction was carried out overnight at 45 °C. The reaction solution was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 133 mg of the title product as a brown solid. MS (m / z): 419.0 [M+H] + .
[0632] (C)N-(3-fluoro-5-((2-((1-methyl-1H-pyrazol-4-yl)amino)pyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
[0633] In a reaction flask under nitrogen protection, N-(5-((2-bromopyridin-4-yl)oxy)-3-fluoropyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (133 mg, 0.32 mmol), 1-methyl-1H-pyrazole-4-amine (37 mg, 0.38 mmol), XantPhos (37 mg, 0.064 mmol), Pd2(dba)3 (29 mg, 0.032 mmol), cesium carbonate (261 mg, 0.8 mmol), and 1,4-dioxane (10 mL) were added sequentially, and the reaction was carried out overnight at 100 °C. The reaction solution was concentrated, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) and p-TLC (dichloromethane / methanol / formic acid = 10:1:0.1) to give 15 mg of the title product as a yellow solid. MS (m / z): 436.1 [M+H] + .
[0634] 1H NMR (400MHz, DMSO-d6) δ12.22(s,1H),8.83(s,1H),8.46(dd,J=7.3,2.1Hz,1H), 8.25(d,J=2.3Hz,1H),8.21(dd,J=6.5,2.1Hz,1H),8.16(s,2H),8.05(d,J=5.8H z,1H),7.94(dd,J=10.5,2.4Hz,1H),7.90(s,1H),7.35(s,1H),6.66-6.58(m,1H ), 6.39 (dd, J = 5.8, 2.2Hz, 1H), 6.12 (d, J = 2.1Hz, 1H), 3.78 (s, 3H), 3.65 (s, 3H).
[0635] Compound 5
[0636] 1,2-Dimethyl-N-(5-((6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidin-5-carboxamide
[0637]
[0638] (A) 5-((6-chloropyrimidin-4-yl)oxy)pyridine-2-amine
[0639] In a reaction flask under nitrogen protection, 4,6-dichloropyrimidine (530 mg, 3.56 mmol), 6-aminopyridin-3-ol (390 mg, 3.56 mmol), potassium tert-butoxide (800 mg, 7.12 mmol), and DMSO (18 mL) were added sequentially, and the reaction was carried out overnight at 100 °C. The reaction solution was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 494 mg of the title product as a solid. MS (m / z): 233.0 [M+H] + .
[0640] (B) 5-((6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridine-2-amine
[0641] In a reaction flask under nitrogen protection, 5-((6-chloropyrimidin-4-yl)oxy)pyridine-2-amine (300 mg, 1.35 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)-1H-pyrazole (336 mg, 1.62 mmol), Pd(dppf)Cl2 (110 mg, 0.135 mmol), cesium carbonate (660 mg, 2.03 mmol), water (2 mL), and 1,4-dioxane (8 mL) were added sequentially, and the reaction was carried out overnight at 50 °C. The reaction solution was concentrated, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 160 mg of the title product as a solid. MS (m / z): 269.1 [M+H] + .
[0642] (C)1,2-Dimethyl-N-(5-((6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidin-5-carboxamide
[0643] The title compound was prepared using the same intermediates and reagents as compound 1(A). MS (m / z): 419.1 [M+H] + .
[0644] 1 H NMR (400MHz, DMSO-d6) δ11.85(s,1H),8.76(s,1H),8.65(d,J=0.7Hz,1H),8.49(s,1H),8.38-8.27(m,2H) ,8.18(s,1H),7.82(dd,J=8.9,2.8Hz,1H),7.46(d,J=0.7Hz,1H),3.91(s,3H),3.60(s,3H),2.65(s,3H).
[0645] Compound 6
[0646] 1-Isopropyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0647]
[0648] (A) 5-((2-chloropyrimidin-4-yl)oxy)pyridine-2-amine
[0649] In a reaction flask, 2,4-dichloropyrimidine (1.49 g, 10.0 mmol), 6-aminopyridin-3-ol (1.1 g, 10.0 mmol), K₂CO₃ (3.45 g, 25.0 mmol), and DMF (15.0 mL) were added. The mixture was heated to 100 °C and stirred for 4 hours. After cooling, the mixture was filtered, and the filtrate was purified by rapid column chromatography (H₂O / MeOH = 100:0–0:100 gradient elution) to give 1.3 g of the title product as a pale yellow solid. MS (m / z): 223.0, 225.0 [M+H] + .
[0650] (B)N-(5-((2-chloropyrimidin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide
[0651] The title compound was prepared using the same preparation procedure as compound 1(A), employing the corresponding intermediates and reagents. MS (m / z): 386.0, 388.0 [M+H] + .
[0652] (C)1-Isopropyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0653] In a reaction flask, N-(5-((2-chloropyrimidin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide (100 mg, 0.26 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxoborhexacyclopentan-2-yl)-1H-pyrazole (65 mg, 0.311 mmol), Na2CO3 (83 mg, 0.78 mmol), Pd(dppf)Cl2·CH2Cl2 (22 mg, 0.026 mmol), dioxane (25.0 mL), and water (3.0 mL) were added. The mixture was heated to 100 °C and stirred overnight. After cooling, the reaction solution was purified by rapid column chromatography (H2O / MeOH = 100:0-0:100 gradient elution) to give 40 mg of the title product as a white solid. MS(m / z): 432.2 [M+H] + .
[0654] 1H NMR(400MHz,DMSO-d6)δ12.70(s,1H),8.70-8.56(m,1H),8.55-8.44(m,1H),8.44-8.31(m,2H),8.24(s,1H),8.11(s, 1H),7.93-7.72(m,2H),7.00-6.82(m,1H),6.79-6.56(m,1H),5.35-5.11(m,1H),3.83(s,3H),1.37(d,J=5.3Hz,6H).
[0655] Compound 7
[0656] 1,2-Dimethyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidin-5-carboxamide
[0657]
[0658] (A) 5-((2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridine-2-amine
[0659] In a reaction flask, 5-((2-chloropyrimidin-4-yl)oxy)pyridine-2-amine (1.9 g, 8.56 mmol), (1-methyl-1H-pyrazol-4-yl)boronic acid (1.18 g, 9.41 mmol), Na₂CO₃ (2.72 g, 25.68 mmol), Pd(dppf)Cl₂·CH₂Cl₂ (1.05 g, 1.284 mmol), dioxane (25.0 mL), and water (3.0 mL) were added. The mixture was heated to 100 °C and stirred for 4 hours. After cooling, the reaction solution was concentrated and purified by rapid column chromatography (H₂O / MeOH = 100:0–0:100 gradient elution) to give 1.72 g of the title product as a yellow solid. MS (m / z): 269.1 [M+H] + .
[0660] (B) 1,2-Dimethyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidin-5-carboxamide
[0661] The title compound was prepared using the same intermediates and reagents as compound 1(A). MS (m / z): 419.1 [M+H] + .
[0662] 1H NMR (400MHz, DMSO-d6) δ11.85(s,1H),8.75(s,1H),8.62(d,J=6.2Hz,1H),8.40-8.31(m,2H),8.11(s ,1H),7.89-7.76(m,1H),7.81(s,1H),6.90(d,J=5.3Hz,1H),3.83(s,3H),3.58(s,3H),2.64(s,3H).
[0663] Compound 8
[0664] 1,2-Dimethyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide
[0665]
[0666] In a reaction flask, 5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine (158 mg, 0.59 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (100 mg, 0.59 mmol), HATU (224 mg, 0.59 mmol), triethylamine (178 mg, 1.77 mmol), and DMF (5 mL) were added sequentially, and the mixture was heated to 40 °C and reacted for 15 hours. The reaction solution was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 22 mg of a pale yellow solid product. MS (m / z): 418.1 [M+H] + .
[0667] 1 H NMR (400MHz, DMSO-d6) δ11.85(s,1H),8.73(s,1H),8.36(d,J=5.7Hz,1H),8.33(d,J=9.0Hz,1H),8.29(d,J=2.6Hz,1H),8.25(s,1H), 7.95(s,1H),7.76(dd,J=9.0,2.6Hz,1H),7.23(d,J=1.9Hz,1H),6.71(dd,J=5.5,2.2Hz,1H),3.83(s,3H),3.57(s,3H),2.62(s,3H).
[0668] The following compounds were prepared using the same preparation process as compound 8, with appropriate intermediates and reagents, under conditions deemed suitable by those skilled in the art.
[0669]
[0670] Compound 9
[0671] N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide)
[0672]
[0673] In a reaction flask under nitrogen protection, 5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine (100 mg, 0.37 mmol), 2-hydroxynicotinic acid (78 mg, 0.56 mmol), HATU (213 mg, 0.56 mmol), dichloromethane (20 mL), and TEA (155 μL, 1.1 mmol) were added sequentially. The mixture was stirred overnight at room temperature, and then concentrated after adding water (5 mL). The residue was purified by rapid column chromatography (water (0.5% formic acid):methanol = 100:0-0:100 gradient elution) and p-TLC to give 45 mg of the title product as a white solid. MS (m / z): 389.2 [M+H] + .
[0674] 1 H NMR (400MHz, DMSO-d6) δ12.86 (s, 1H), 12.69 (s, 1H), 8.52 (dd, J = 7.2, 2.2Hz, 1H ),8.40(d,J=2.6Hz,1H),8.38(s,1H),8.31(d,J=2.9Hz,1H),8.28(s,1H),7.98 (s,1H),7.86(dd,J=6.2,2.2Hz,1H),7.77(dd,J=9.0,2.9Hz,1H),7.26(d,J=2. 4Hz, 1H), 6.74 (dd, J = 5.7, 2.4Hz, 1H), 6.60 (dd, J = 7.1, 6.3Hz, 1H), 3.85 (s, 3H).
[0675] The following compounds were prepared using the same preparation process as compound 9, with appropriate intermediates and reagents, under conditions deemed suitable by those skilled in the art.
[0676]
[0677]
[0678]
[0679]
[0680]
[0681]
[0682]
[0683]
[0684]
[0685]
[0686]
[0687]
[0688]
[0689]
[0690]
[0691]
[0692]
[0693]
[0694]
[0695]
[0696]
[0697]
[0698] Compound 79
[0699] 4-Methoxy-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0700]
[0701] (A) 4-Methoxy-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0702] In a reaction flask under nitrogen protection, 5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine (100 mg, 0.37 mmol), 2-hydroxy-4-methoxynicotinic acid (76 mg, 0.45 mmol), HATU (213 mg, 0.56 mmol), DMF (5 mL), and TEA (155 μL, 1.1 mmol) were added sequentially, and the mixture was heated to 40 °C and stirred overnight. The reaction solution was purified by rapid column chromatography (water (0.5% formic acid): methanol = 100:0-0:100 gradient elution) to give 80 mg of the title product as a white solid. MS (m / z): 419.2 [M+H] + .
[0703] (B) 4-Methoxy-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0704] In a reaction flask under nitrogen protection, 4-methoxy-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (80 mg, 0.2 mmol), methyl iodoformate (74 mg, 0.52 mmol), potassium carbonate (72 mg, 0.52 mmol), and DMF (5 mL) were added sequentially. The reaction mixture was stirred at room temperature for 1 hour until complete. The reaction solution was purified by rapid column chromatography (water (0.5% formic acid):methanol = 100:0-0:100 gradient elution) and p-TLC to give 60 mg of the title product as a white solid. MS (m / z): 433.2 [M+H] + .
[0705] 1 H NMR (400MHz, DMSO-d6) δ11.33(s,1H),8.38(d,J=5.7Hz,1H),8.31(d,J=9.0Hz,1H),8.28(s,1H),8.26(d,J=2.9Hz,1H),7.98(s,1H),7.93(d,J=7.7H z,1H),7.72(dd,J=9.0,2.9Hz,1H),7.25(d,J=2.4Hz,1H),6.73(dd,J=5.7 ,2.4Hz,1H),6.42(d,J=7.8Hz,1H),3.86(s,3H),3.85(s,3H),3.45(s,3H).
[0706] The following compounds were prepared using the same preparation process as compound 79, with appropriate intermediates and reagents, under conditions deemed suitable by those skilled in the art.
[0707]
[0708] Compound 81
[0709] 1-(2-(dimethylamino)ethyl)-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo
[0710] -1,2-Dihydropyridine-3-carboxamide
[0711]
[0712] In a reaction flask under nitrogen protection, N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (80 mg, 0.21 mmol), 2-bromo-N,N-dimethylethyl-1-amine hydrochloride (144 mg, 0.63 mmol), cesium carbonate (267 mg, 0.82 mmol), and DMF (5 mL) were added sequentially. The mixture was heated to 80 °C and stirred overnight. After cooling to room temperature, the reaction solution was purified by rapid column chromatography (water (0.5% ammonia): methanol = 100:0-0:100 gradient elution) to give 50 mg of the title product as a white solid. MS (m / z): 460.2 [M+H] + .
[0713] 1 H NMR (400MHz, DMSO-d6) δ12.66(s,1H),8.50(dd,J=7.4,2.2Hz,1H),8.40(s,1H),8.38(d,J =3.7Hz, 1H), 8.31 (d, J = 2.8Hz, 1H), 8.28 (s, 1H), 8.13 (dd, J = 6.5, 2.2Hz, 1H), 7.98 (d, J = 0. 5Hz,1H),7.77(dd,J=9.0,2.9Hz,1H),7.26(d,J=2.4Hz,1H),6.74(dd,J=5.7,2.4Hz,1H), 6.66-6.59(m,1H),4.19(t,J=6.1Hz,2H),3.85(s,3H),2.59(t,J=6.1Hz,2H),2.20(s,6H).
[0714] The following compounds were prepared using the same preparation process as compound 81, with appropriate intermediates and reagents, under conditions deemed suitable by those skilled in the art.
[0715]
[0716]
[0717]
[0718] Compound 92
[0719] 1-Isopropyl-N-(3-methoxy-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0720]
[0721] (A) N-(5-bromo-3-methoxypyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridin-3-carboxamide
[0722] The title compound was prepared using the same intermediates and reagents as compound 79(A). MS (m / z): 366.0 [M+H] + .
[0723] (B)(6-(1-isopropyl-2-oxo-1,2-dihydropyridine-3-formylamino)-5-methoxypyridine-3-yl)boronic acid
[0724] In a reaction flask under nitrogen protection, N-(5-bromo-3-methoxypyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide (360 mg, 1.0 mmol), pinacol borate (508 mg, 2 mmol), potassium acetate (294 mg, 3 mmol), dioxane (10 mL), and Pd(dppf)Cl2 (73 mg, 0.1 mmol) were added sequentially, and the mixture was refluxed and stirred overnight. After cooling to room temperature, the mixture was concentrated, and the residue was purified by rapid column chromatography (elution of water (0.5% formic acid): methanol = 100:0-0:100 gradient) to give 330 mg of the title product as a white solid. MS (m / z): 332.1 [M+H] + .
[0725] (C)N-(5-hydroxy-3-methoxypyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide
[0726] In a reaction flask under nitrogen protection, (6-(1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamido)-5-methoxypyridine-3-yl)boronic acid (330 mg, 1.0 mmol) and tetrahydrofuran (20 mL) were added sequentially, followed by dropwise addition of 1N sodium hydroxide aqueous solution (2 mL) and 30% hydrogen peroxide (567 mg, 5 mmol). The mixture was stirred at room temperature for half an hour. After adjusting the pH to 4 with 1N hydrochloric acid aqueous solution, saturated sodium thiosulfate aqueous solution (1 mL) was added dropwise, and the mixture was concentrated. The residue was purified by rapid column chromatography (water (0.5% formic acid):methanol = 100:0-0:100 gradient elution) to give 240 mg of the title product as a pale yellow solid. MS (m / z): 304.1 [M+H] + .
[0727] (D)N-(5-((2-chloropyridin-4-yl)oxy)-3-methoxypyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridin-3-carboxamide
[0728] In a reaction flask under nitrogen protection, N-(5-hydroxy-3-methoxypyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide (240 mg, 0.8 mmol), 2-chloro-4-fluoropyridine (126 mg, 0.96 mmol), potassium tert-butoxide (135 mg, 1.2 mmol), and DMSO (6 mL) were added sequentially. The mixture was heated to 90 °C and stirred for 6 hours. After cooling to room temperature, water (40 mL) was added, and the mixture was stirred for half an hour before filtration. The solid was washed with water and dried to give 180 mg of the title product as a brown solid. MS (m / z): 415.1 [M+H] + .
[0729] (E)1-Isopropyl-N-(3-methoxy-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0730] In a reaction flask under nitrogen protection, N-(5-(((2-chloropyridin-4-yl)oxy)-3-methoxypyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide (90 mg, 0.22 mmol), 1-methyl-4-pyrazolpinacol boronic acid ester (69 mg, 0.33 mmol), potassium carbonate (59 mg, 0.43 mmol), dioxane / water (10 mL / 2 mL), and Pd(dppf)Cl2 (15 mg, 0.02 mmol) were added sequentially, and the mixture was refluxed and stirred overnight. After cooling to room temperature, the mixture was concentrated, and the residue was purified by rapid column chromatography (elution of water (0.5% formic acid):methanol = 100:0-0:100 gradient) to give 70 mg of the title product as a white solid. MS (m / z): 461.2 [M+H] + .
[0731] 1 H NMR (400MHz, DMSO-d6) δ12.38(s,1H),8.43(dd,J=7.2,1.9Hz,1H),8.40(d,J=5.7 Hz,1H),8.29(s,1H),8.22(dd,J=6.7,2.0Hz,1H),7.99(s,1H),7.90(d,J=2.3Hz,1 H),7.48(d,J=2.2Hz,1H),7.28(d,J=2.2Hz,1H),6.76(dd,J=5.7,2.3Hz,1H),6.70 -6.59(m,1H),5.35-5.18(m,1H),3.89(s,3H),3.86(s,3H),1.38(d,J=6.8Hz,6H).
[0732] Compound 93
[0733] 1-Isopropyl-N-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0734]
[0735] (A) 3-((2-bromopyridin-4-yl)oxy)-2-methyl-6-nitropyridine
[0736] In a reaction flask under nitrogen protection, 2-methyl-6-nitropyridin-3-ol (616 mg, 4 mmol), 2-bromo-4-fluoropyridine (739 mg, 4.2 mmol), cesium carbonate (1.95 g, 6 mmol), and DMF (15 mL) were added sequentially. The mixture was heated to 90 °C and stirred for 6 hours. After cooling to room temperature, water (80 mL) was added, and the mixture was stirred for half an hour before filtration. The solid was washed with water and dried to give 460 mg of the title product as a brown solid. MS (m / z): 310.0 [M+H] + .
[0737] (B) 2-Methyl-3-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)-6-nitropyridine
[0738] The title compound was prepared using the same intermediates and reagents as compound 92(E). MS (m / z): 312.1 [M+H] + .
[0739] (C)6-Methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0740] In a reaction flask, 2-methyl-3-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)-6-nitropyridine (250 mg, 0.8 mmol), methanol (20 mL), and palladium on carbon (100 mg) were added sequentially. The hydrogen gas was replaced with a hydrogen balloon, and the mixture was stirred overnight at room temperature under normal pressure. The filtrate was concentrated after filtration, and the residue was purified by rapid column chromatography (elution gradient of water (0.5% formic acid):methanol = 100:0–0:100) to give 180 mg of the title product as a brown solid. MS (m / z): 282.1 [M+H] + .
[0741] (D) 1-Isopropyl-N-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0742] The title compound was prepared using the same intermediates and reagents as compound 79(A). MS (m / z): 445.2 [M+H] + .
[0743] 1H NMR (400MHz, DMSO-d6) δ12.65(s,1H),8.49(dd,J=7.2,2.0Hz,1H),8.37(d,J=5.7Hz,1H),8.32-8.17(m,3H),7.98(s,1H),7.66 (d,J=8.8Hz,1H),7.20(d,J=2.3Hz,1H),6.74-6.58(m,2H),5.30-5.14(m,1H),3.85(s,3H),2.30(s,3H),1.40(d,J=6.8Hz,6H).
[0744] Compound 94
[0745] N-(5-((2-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide)
[0746]
[0747] (A)N-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridin-3-carboxamide
[0748] In a reaction flask under nitrogen protection, 5-((2-chloropyridin-4-yl)oxy)pyridin-2-amine (850 mg, 3.84 mmol), 2-hydroxynicotinic acid (640 mg, 4.6 mmol), HATU (2.2 g, 5.8 mmol), DMF (12 mL), and TEA (1.3 mL, 9.6 mmol) were added sequentially. The mixture was heated to 40 °C and stirred overnight. After cooling to room temperature, water (80 mL) was added, and the mixture was stirred for two hours before filtration. The solid was washed with water and dried to give 900 mg of the title product as a pale yellow solid. MS (m / z): 343.0 [M+H] + .
[0749] (B)N-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridin-3-carboxamide
[0750] In a reaction flask under nitrogen protection, N-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (900 mg, 2.6 mmol), methyl iodoforme (479 μL, 7.7 mmol), potassium carbonate (1.06 g, 7.7 mmol), and DMF (10 mL) were added sequentially. The mixture was stirred at room temperature for 1 hour until the reaction was complete. Water (80 mL) was added, and the mixture was stirred for 1 hour before filtration. The solid was washed with water and dried to give 800 mg of the title product as a pale yellow solid. MS (m / z): 357.0 [M+H] + .
[0751] (C)N-(5-((2-(1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide)
[0752] In a reaction flask under nitrogen protection, N-(5-(((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (100 mg, 0.28 mmol), 4-pyrazolpinacol borate (82 mg, 0.42 mmol), potassium carbonate (77 mg, 0.56 mmol), dioxane / water (10 mL / 2 mL), and Pd(dppf)Cl2 (21 mg, 0.03 mmol) were added sequentially, and the mixture was refluxed and stirred for 2 hours. After cooling to room temperature, the mixture was concentrated, and the residue was purified by rapid column chromatography (elution of water (0.5% formic acid):methanol = 100:0-0:100 gradient) to give 80 mg of the title product as a pale yellow solid. MS (m / z): 389.1 [M+H] + .
[0753] (D)N-(5-((2-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide)
[0754] In a reaction flask under nitrogen protection, N-(5-((2-(1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (80 mg, 0.21 mmol), 2-bromoethyl acetate (167 mg, 1 mmol), cesium carbonate (326 mg, 1 mmol), and DMF (5 mL) were added sequentially. The mixture was heated to 80 °C and stirred overnight. After cooling to room temperature, 2 mL of 2N sodium hydroxide aqueous solution was added dropwise, and the mixture was stirred at room temperature for 2 hours. The reaction solution was purified by rapid column chromatography (water (0.5% formic acid): methanol = 100:0-0:100 gradient elution) to give 40 mg of the title product as a white solid. MS (m / z): 433.1 [M+H]+ .
[0755] 1 H NMR (400MHz, DMSO-d6) δ12.66 (s, 1H), 8.50 (dd, J = 7.3, 1.9Hz, 1H), 8.43-8.35 (m ,2H),8.35-8.25(m,2H),8.20(dd,J=6.4,1.9Hz,1H),8.01(s,1H),7.77(dd,J=9. 0,2.8Hz,1H),7.29(d,J=2.1Hz,1H),6.74(dd,J=5.6,2.3Hz,1H),6.67-6.57(m,1 H), 4.94 (t, J = 5.2Hz, 1H), 4.15 (t, J = 5.5Hz, 2H), 3.80-3.69 (m, 2H), 3.64 (s, 3H).
[0756] The following compounds were prepared using the same intermediates and reagents as compound 94 (step AC) under conditions deemed suitable by those skilled in the art.
[0757]
[0758] Compound 95
[0759] N-(5-((2-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide)
[0760]
[0761] (A)N-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridin-3-carboxamide
[0762] The title compound was prepared using the same intermediates and reagents as compound 94(A). MS (m / z): 385.1 [M+H] + .
[0763] (B)N-(5-((2-(1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide
[0764] The title compound was prepared using the same intermediates and reagents as compound 94(C). MS (m / z): 417.1 [M+H] + .
[0765] (C)N-(5-((2-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide)
[0766] The title compound was prepared using the same intermediates and reagents as compound 94(D). MS (m / z): 461.2 [M+H] + .
[0767] 1 H NMR (400MHz, DMSO-d6) δ12.72(s,1H),8.50(dd,J=7.3,2.1Hz,1H),8.40(s,1H),8.39(d,J=2.5H z,1H),8.31(d,J=2.9Hz,1H),8.29(s,1H),8.26(dd,J=6.7,2.1Hz,1H),8.01(s,1H),7.77(dd,J= 9.0,2.9Hz,1H),7.29(d,J=2.3Hz,1H),6.74(dd,J=5.7,2.4Hz,1H),6.72-6.66(m,1H),5.30-5.1 8(m,1H),4.93(t,J=5.3Hz,1H),4.15(t,J=5.6Hz,2H),3.79-3.70(m,2H),1.39(d,J=6.8Hz,6H).
[0768] Compound 96
[0769] 1-Isopropyl-N-(5-((2-((1-methyl-1H-pyrazol-4-yl)amino)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0770]
[0771] In a reaction flask under nitrogen protection, N-(5-(((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide (50 mg, 0.13 mmol), 1-methyl-1H-pyrazole-4-amine (38 mg, 0.39 mmol), BINAP (8 mg, 0.013 mmol), sodium tert-butoxide (25 mg, 0.26 mmol), dioxane (10 mL), and Pd2(dba)3 (12 mg, 0.013 mmol) were added sequentially, and the mixture was stirred under reflux for 2 hours. After cooling to room temperature, the mixture was concentrated, and the residue was purified by rapid column chromatography (water (0.5% formic acid): methanol = 100:0-0:100 gradient elution) and p-TLC to give 25 mg of the title product as a pale yellow solid. MS (m / z): 446.2 [M+H] + .
[0772] 1 H NMR (400MHz, DMSO-d6) δ12.71(s,1H),8.78(s,1H),8.49(dd,J=7.3,2.1Hz,1H),8.38(d, J=9.0Hz,1H),8.28(d,J=2.8Hz,1H),8.25(dd,J=6.7,2.1Hz,1H),8.02(d,J=5.8Hz,1H),7 .89(s,1H),7.76(dd,J=9.0,2.9Hz,1H),7.32(s,1H),6.73-6.64(m,1H),6.34(dd,J=5.8, 2.2Hz, 1H), 6.04 (d, J = 2.2Hz, 1H), 5.29-5.18 (m, 1H), 3.77 (s, 3H), 1.39 (d, J = 6.8Hz, 6H).
[0773] The following compounds were prepared using the same preparation process as compound 96, with appropriate intermediates and reagents, under conditions deemed suitable by those skilled in the art.
[0774]
[0775] Compound 98
[0776] N-(5-((2-(4-ethylpiperazin-1-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide)
[0777]
[0778] In a microwave-safe tube, N-(5-(((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-isopropyl-2-oxo-1,2-dihydropyridin-3-carboxamide (50 mg, 0.13 mmol), 1-ethylpiperazine (74 mg, 0.65 mmol), and NMP (4.0 mL) were added. The mixture was microwave-safe at 160 °C for 1.5 h. The reaction solution was purified by rapid column chromatography (H₂O / MeOH = 100:0–0:100 gradient elution) to give 25 mg of the title product as a yellow solid. MS (m / z): 463.2 [M+H] + .
[0779] 1 H NMR(400MHz,DMSO-d6)δ12.64(s,1H),8.44(s,1H),8.39-8.26(m,1H),8.26-8.11(m,2H),7.97(s,1H),7.78-7.56(m,1H), 6.75-6.54(m,1H),6.31(s,1H),6.17(s,1H),5.19(s,1H),3.36-3.30(m,4H),2.41-2.20(m,6H),1.35(s,6H),0.97(s,3H).
[0780] Compound 99
[0781] Methyl-N-(5-((2-(2-methyl-2H-1,2,3-triazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine
[0782] -3-Formamide
[0783]
[0784] In a reaction flask, N-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (120 mg, 0.336 mmol), (2-methyl-2H-1,2,3-triazol-4-yl)boronic acid (85 mg, 0.673 mmol), Na₂CO₃ (106 mg, 1.008 mmol), Pd(dppf)Cl₂·CH₂Cl₂ (27 mg, 0.0336 mmol), dioxane (23.0 mL), and water (3.0 mL) were added. The mixture was heated to 110 °C and stirred overnight. After cooling, the reaction solution was purified by rapid column chromatography (H₂O / MeOH = 100:0–0:100 gradient elution) to give 65 mg of the title product as a white solid. MS (m / z): 404.2 [M+H] + .
[0785] 1 H NMR (400MHz, DMSO-d6) δ12.67(s,1H),8.51(d,J=5.7Hz,1H),8.48(dd,J=7.4,2.2Hz,1H),8.39(d,J=9.0Hz,1H),8.34(d,J=2.9Hz,1H),8.20 -8.15(m,2H),7.81(dd,J=9.0,2.9Hz,1H),7.28(d,J=2.5Hz,1H),7.02(dd,J=5.7,2.5Hz,1H),6.64-6.55(m,1H),4.15(s,3H),3.61(s,3H).
[0786] The following compounds were prepared using the same preparation process as compound 99, with appropriate intermediates and reagents, under conditions deemed suitable by those skilled in the art.
[0787]
[0788]
[0789] Compound 104
[0790] 1-Cyclopropyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0791] In a reaction flask, N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (100 mg, 0.26 mmol), cyclopropylboronic acid (66 mg, 0.78 mmol), 2,2'-bipyridine (8 mg, 0.05 mmol), copper acetate (55 mg, 0.30 mmol), triethylamine (53 mg, 0.52 mmol), molecular sieve (200 mg), and 1,2-dichloroethane (10 mL) were added sequentially. The reaction was carried out at 70 °C for 24 hours under oxygen protection. The mixture was filtered, and the filtrate was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 10.1 mg of the title product as a pale yellow solid. MS (m / z): 429.2 [M+H] + .
[0792] 1¹H NMR (400 MHz, mixed solution of CD₃OD and CDCl₃) δ 8.54 (dd, J = 7.3, 2.1 Hz, 1H), 8.40 (d, J = 9.0 Hz, 1H), 8.32 (d, J = 5.8 Hz, 1H), 8.19 (d, J = 2.9 Hz, 1H), 8.02 (s, 1H), 7.93–7.85 (m, 2H), 7.60 (dd,J=9.0,2.9Hz,1H),7.13(d,J=2.4Hz,1H),6.73(dd,J=5.8,2.4Hz,1H),6.55(t, J=7.0Hz,1H),3.90(s,3H),3.49-3.38(m,1H),1.22-1.13(m,2H),0.99-0.95(m,2H).
[0793] Compound 105
[0794] 6-Amino-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0795]
[0796] In a reaction flask, 6-chloro-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (80 mg, 0.18 mmol), ammonium chloride (46 mg, 0.90 mmol), potassium carbonate (50 mg, 0.36 mmol), and DMSO (5 mL) were added sequentially, and the reaction was carried out at room temperature for 15 hours. The mixture was filtered, and the filtrate was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 6.3 mg of the title product as a pale yellow solid. MS (m / z): 418.1 [M+H] + .
[0797] 1 H NMR (400MHz, DMSO-d6) δ12.41(s,1H),8.36-8.33(m,2H),8.24(s,1H),8.20(d,J=2.7Hz,1H),8.05(d,J=8.8Hz,1H),7.95(s, 1H),7.76-7.61(m,3H),7.21(d,J=2.1Hz,1H),6.68(dd,J=5.6,2.3Hz,1H),5.81(d,J=8.8Hz,1H),3.82(s,3H),3.39(s,3H).
[0798] Compound 106
[0799] 1-Methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-(methylamino)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0800]
[0801] In a reaction flask, 80 mg of 6-chloro-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (0.18 mmol) and methylamine solution (5 mL) were added sequentially, and the reaction was carried out at 80 °C for 2 h. The mixture was filtered, and the filtrate was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 23.0 mg of the title product as a pale yellow solid. MS (m / z): 432.1 [M+H] + .
[0802] 1 H NMR (400MHz, DMSO-d6) δ12.43(s,1H),8.40-8.30(m,2H),8.24(s,1H),8.21(d,J=2.9Hz,1H),8.17(d,J=8.9Hz,1H),7.95(s,1H),7 .68-7.65(m,2H),7.21(d,J=2.3Hz,1H),6.68(dd,J=5.6,2.2Hz,1H),5.80(d,J=9.0Hz,1H),3.82(s,3H),3.41(s,3H),2.85(s,3H).
[0803] Compound 107
[0804] 1-Methyl-N-(5-((2-(1-methyl-1H-imidazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0805] (A)N-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridin-3-carboxamide
[0806] The title compound was prepared using the same intermediates and reagents as compound 79(A). MS (m / z): 343.0 [M+H] + .
[0807] (B)N-(5-((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridin-3-carboxamide
[0808] In a reaction flask under nitrogen protection, N-(5-(((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide (387 mg, 1.13 mmol), methyl iodide (241 mg, 1.70 mmol), potassium carbonate (312 mg, 2.26 mmol), and DMSO (5 mL) were added sequentially, and the reaction was carried out at 60 °C for 1 h. The reaction solution was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 203 mg of the title product as a pale yellow solid. MS (m / z): 356.7 [M+H] + (C) 1-Methyl-N-(5-((2-(1-methyl-1H-imidazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxo-1,2-dihydropyridine-3-carboxamide
[0809] In a reaction flask under nitrogen protection, N-(5-(((2-chloropyridin-4-yl)oxy)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (130 mg, 0.37 mmol), 1-methyl-4-(tributyltinyl)-1H-imidazolium (208 mg, 0.56 mmol), Pd(PPh3)4 (13 mg, 0.01 mmol), and DMF (5 mL) were added sequentially, and the reaction was carried out at 100 °C for 2 h. The reaction solution was concentrated, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 64.5 mg of the title product as a pale yellow solid. MS (m / z): 403.0 [M+H] + .
[0810] 1 H NMR (400MHz, DMSO-d6) δ12.65(s,1H),8.47(d,J=6.9Hz,1H),8.39-8.35(m,2H),8.30(s,1H),8.18(d,J=5.6Hz,1H),7. 78(d,J=7.7Hz,1H),7.67(s,1H),7.58(s,1H),7.25(s,1H),6.81(s,1H),6.61-6.57(m,1H),3.66(s,3H),3.61(s,3H).
[0811] The following compounds were prepared using the same preparation process as compound 107, with appropriate intermediates and reagents, under conditions deemed suitable by those skilled in the art.
[0812]
[0813] Compound 109
[0814] N-(5-((2-(1-(2-aminoethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidin-5-carboxamide)
[0815]
[0816] (A)(2-(4-(4-((6-nitropyridin-3-yl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)ethyl)tert-butyl carbamate
[0817] In a reaction flask, 4-((6-nitropyridin-3-yl)oxy)-2-(1H-pyrazol-4-yl)pyridine (350 mg, 1.24 mmol), tert-butyl (2-bromoethyl)carbamate (415 mg, 1.85 mmol), cesium carbonate (601 mg, 1.85 mmol), and acetonitrile (20 mL) were added sequentially, and the reaction was carried out at 80 °C for 5 h. The concentrated reaction solution was purified by rapid column chromatography (dichloromethane / methanol = 100:0–0:100 gradient elution) to give 362 mg of the title product as a pale yellow solid. MS (m / z): 427.2 [M+H] + .
[0818] (B)(2-(4-(4-((6-aminopyridin-3-yl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)ethyl)tert-butyl carbamate
[0819] (110 mg, 0.26 mmol) of tert-butyl (2-(4-(4-(((6-nitropyridin-3-yl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)ethyl)carbamate (10 mL) and palladium on carbon (11 mg) were dissolved in methanol and stirred at room temperature under hydrogen for 5 hours. The reaction mixture was filtered to remove the palladium on carbon, and the filtrate was concentrated and purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 93 mg of the title product. MS (m / z): 397.2 [M+H] + .
[0820] (C)(2-(4-(4-((6-(1,2-dimethyl-6-oxo-1,6-dihydropyrimidin-5-carbamate)pyridin-3-yl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)ethyl)tert-butyl carbamate
[0821] In a reaction flask, tert-butyl (2-(4-(4-((6-aminopyridin-3-yl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)ethyl)carbamate (93 mg, 0.23 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (35 mg, 0.23 mmol), HATU (86 mg, 0.23 mmol), triethylamine (70 mg, 0.69 mmol), and DMF (4 mL) were added sequentially, and the reaction was carried out at 45 °C for 15 h. The reaction solution was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 37 mg of the title product as a pale yellow solid. MS (m / z): 547.2 [M+H] + .
[0822] (D)N-(5-((2-(1-(2-aminoethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidin-5-carboxamide)
[0823] In a reaction flask, tert-butyl (2-(4-(4-((6-(1,2-dimethyl-6-oxo-1,6-dihydropyrimidin-5-carbamate)pyridin-3-yl)oxy)pyridin-2-yl)-1H-pyrazol-1-yl)ethyl)carbamate (37 mg, 0.07 mmol) was dissolved in concentrated hydrochloric acid (1 mL) and methanol (5 mL). The reaction was carried out at room temperature for half an hour. The reaction solution was concentrated at 50 °C and purified by rapid column chromatography (water / methanol = 100:0-0:100 gradient elution) to give 7 mg of the title product as a pale yellow solid. MS (m / z): 447.1 [M+H] + .
[0824] 1 H NMR (400MHz, CD3OD) δ8.89(s,1H),8.71(s,1H),8.58(d,J=6.5Hz,1H),8.49-8.45(m,2H),8.35(s,1H),7.97(d,J=8. 5Hz,1H),7.77(s,1H),7.36(d,J=6.0Hz,1H),4.62-4.57(m,2H),3.77(s,3H),3.53-3.48(m,2H),2.90-2.67(m,3H).
[0825] The following compounds were prepared using the same preparation process as compound 109, with appropriate intermediates and reagents, under conditions deemed suitable by those skilled in the art.
[0826]
[0827] Compound 111
[0828] 1,2-Dimethyl-N-(5-((2-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide
[0829]
[0830] (A)N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine-2-amine
[0831] In a reaction flask, 2-chloro-4-((6-nitropyridin-3-yl)oxy)pyridine (500 mg, 2.0 mmol), 5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-amine (540 mg, 3.0 mmol), Pd2(dba)3 (186 mg, 0.2 mmol), Xantphos (116 mg, 0.2 mmol), potassium carbonate (420 mg, 3.0 mmol), and dioxane (20 mL) were added sequentially. The reaction was carried out at 100 °C for 15 hours under nitrogen protection. The concentrated reaction solution was purified by rapid column chromatography (dichloromethane / methanol = 100:0–0:100 gradient elution) to give 320 mg of the title product as a pale yellow solid. MS (m / z): 397.0 [M+H] + .
[0832] (B) 4-((6-aminopyridin-3-yl)oxy)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyridin-2-amine
[0833] N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine-2-amine (320 mg, 0.81 mmol), iron powder (168 mg, 3.24 mmol), and ammonium chloride (214 mg, 4.05 mmol) were dissolved in ethanol (8 mL) and water (2 mL), and the mixture was refluxed for 1 h. The reaction solution was filtered to remove the iron powder, and the concentrated filtrate was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 227 mg of the title product. MS (m / z): 367.1 [M+H] + .
[0834] (C)1,2-Dimethyl-N-(5-((2-((5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)amino)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidin-5-carboxamide
[0835] The title compound was prepared using the same intermediates and reagents as compound 1(A). MS (m / z): 517.2 [M+H] + .
[0836] (D)1,2-Dimethyl-N-(5-((2-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidin-5-carboxamide
[0837] The title compound was prepared using the same intermediates and reagents as compound 109(D). MS (m / z): 433.1 [M+H] + .
[0838] 1 H NMR (400MHz, DMSO-d6) δ11.83(s,1H),9.09(s,1H),8.73(s,1H),8.32(d,J=9.0Hz,1H),8.26(d,J=2.8Hz,1H),7.99(d,J=5. 7Hz,1H),7.73(dd,J=9.0,2.9Hz,1H),6.88(s,1H),6.35-6.28(m,1H),5.93(s,1H),3.57(s,3H),2.63(s,3H),2.13(s,3H).
[0839] The following compounds were prepared using the same preparation process as compound 111, with appropriate intermediates and reagents, under conditions deemed suitable by those skilled in the art.
[0840]
[0841] Compound 113
[0842] N-(5-((2-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidin-5-carboxamide)
[0843]
[0844] (A)2-(1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-pyrazol-4-yl)-4-((6-nitropyridin-3-yl)oxy)pyridine
[0845] 4-((6-nitropyridin-3-yl)oxy)-2-(1H-pyrazol-4-yl)pyridine (100 mg, 0.35 mmol), (2-bromoethoxy)(tert-butyl)dimethylsilane (101 mg, 0.42 mmol), and cesium carbonate (172 mg, 0.53 mmol) were dissolved in acetonitrile (10 mL) and stirred at 80 °C for 5 hours. The crude product was concentrated and purified by rapid column chromatography (dichloromethane / methanol = 100:0–90:10 gradient elution) to give 139 mg of the title product. MS (m / z): 442.2 [M+H] + .
[0846] (B)5-((2-(1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0847] The title compound was prepared using the same intermediates and reagents as compound 111(B). MS (m / z): 412.2 [M+H] + .
[0848] (C)N-(5-((2-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidin-5-carboxamide)
[0849] In a reaction flask, 5-((2-(1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine (83 mg, 0.20 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (34 mg, 0.20 mmol), HATU (76 mg, 0.20 mmol), triethylamine (60 mg, 0.60 mmol), and DMF (3 mL) were added sequentially, and the reaction was carried out at 40 °C for 15 h. The reaction solution was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give 23.3 mg of the title product as a pale yellow solid. MS (m / z): 448.2 [M+H] + .
[0850] 1H NMR(400MHz,DMSO-d6)δ11.85(s,1H),8.74(s,1H),8.43-8.22(m,4H),8.00(s,1H),7.79-7.75(m,1H),7.29- 7.25(m,1H),6.75-6.72(m,1H),4.93(s,1H),4.17-4.14(m,2H),3.77-3.72(m,2H),3.59(s,3H),2.64(s,3H).
[0851] Compound 117
[0852] 1,2-Dimethyl-N-(5-((2-(1-methyl-1H-pyrrolo-3-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide
[0853] (A) 2-Bromo-4-((6-nitro-pyridin-3-yl)oxy)pyridine
[0854] 2-Bromo-4-hydroxypyridine (5.22 g, 30 mmol), 5-fluoro-2-nitropyridine (4.263 g, 30 mmol), and potassium carbonate (4.975 g, 36 mmol) were dissolved in DMF (40 mL), and the mixture was heated at 90 °C for 4 hours. The reaction was cooled to room temperature and quenched with water (200 mL). The mixture was filtered, and the solid was collected to give 8.1 g of the title product. MS (m / z): 296.0, 298.0 [M+H] + .
[0855] (B) 5-((2-bromopyridin-4-yl)oxy)pyridin-2-amine
[0856] In a reaction flask, 2-bromo-4-((6-nitro-pyridin-3-yl)oxy)pyridine (5 g, 16.89 mmol), iron powder (3.773 g, 67.56 mmol), ammonium chloride (4.517 g, 84.45 mmol), ethanol (60 mL), and water (15 mL) were added sequentially, and the mixture was heated to reflux for 1 hour. The reaction solution was concentrated, and the residue was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0–0:100 gradient elution) to give 4.3 g of the title product. MS (m / z): 266.0, 268.0 [M+H] + .
[0857] (C)5-((2-(1-methyl-1H-pyrrolo-3-yl)pyridin-4-yl)oxy)pyridine-2-amine
[0858] In a reaction flask, 5-((2-bromopyridin-4-yl)oxy)pyridine-2-amine (532 mg, 2.0 mmol), 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)-1H-pyrrole (414 mg, 2.0 mmol), Pd(dppf)Cl2 (73 mg, 0.1 mmol), K2CO3 (552 mg, 4.0 mmol), dioxane (20 mL), and water (4 mL) were added sequentially. The reaction mixture was heated to 100 °C for 15 hours under nitrogen protection. After concentration, the product was purified by rapid column chromatography (petroleum ether / ethyl acetate = 100:0-0:100 gradient elution) to give 410 mg of the title product. MS (m / z): 267.1 [M+H] + .
[0859] (D) 1,2-Dimethyl-N-(5-((2-(1-methyl-1H-pyrrolo-3-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidin-5-carboxamide
[0860] In a reaction flask, 5-((2-(1-methyl-1H-pyrrolo-3-yl)pyridin-4-yl)oxy)pyridine-2-amine (410 mg, 1.54 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (388 mg, 2.31 mmol), HATU (878 mg, 2.31 mmol), DMAP (282 mg, 2.31 mmol), and DMF (3 mL) were added sequentially, and the mixture was heated to 40 °C and reacted for 15 hours. The reaction solution was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution), and the crude product was further purified by rapid column chromatography (dichloromethane / methanol = 100:0–70:30 gradient elution) to obtain the title product (180 mg). MS (m / z): 417.1 [M+H] + .
[0861] 1H NMR (400MHz, DMSO-d6) δ11.84(s,1H),8.73(s,1H),8.35-8.25(m,3H),7.74(dd,J=9.1,2.9Hz,1H),7.34(s,1H),7.08(d, J=2.4Hz,1H),6.72-6.67(m,1H),6.61(dd,J=5.7,2.4Hz,1H),6.53-6.48(m,1H),3.60(s,3H),3.56(s,3H),2.62(s,3H).
[0862] The following compounds were prepared using the same intermediates and reagents as compound 117(D) under conditions deemed suitable by those skilled in the art.
[0863]
[0864]
[0865] Compound 123
[0866] 1,2-Dimethyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)methyl)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide
[0867]
[0868] (A)2-(1-methyl-1H-pyrazole-4-yl)isoniazonel
[0869] In a reaction flask under nitrogen protection, 2-chloroisononal (1 g, 7.1 mmol), 1-methylpyrazole-4-boronic acid pinacol ester (1.8 g, 8.5 mmol), cesium carbonate (1.95 g, 14.2 mmol), dioxane / water (20 mL / 2 mL), and Pd(dppf)Cl2 (512 mg, 0.7 mmol) were added sequentially. The mixture was heated to 90 °C and stirred overnight. After cooling to room temperature, the mixture was concentrated, and the residue was purified by rapid column chromatography (elution of water (0.5% formic acid):methanol = 100:0-0:100 gradient) to give 1 g of the title product as a brown solid. MS (m / z): 220.1 [M + MeOH + H] + .
[0870] (B)(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)methanol
[0871] In a reaction flask under nitrogen protection, 1 g (5.3 mmol) of 2-(1-methyl-1H-pyrazol-4-yl)isoniamaldehyde and 20 mL of methanol were added, followed by the slow addition of sodium borohydride (1 g, 26.5 mmol) in portions. The reaction was stirred at room temperature for 1 hour until complete. Water (2 mL) was slowly added dropwise to quench the reaction, and the mixture was concentrated. The residue was purified by rapid column chromatography (water:methanol = 100:0–0:100 gradient elution) to give 800 mg of the title product as a pale yellow solid. MS (m / z): 190.1 [M+H] + .
[0872] (C)4-(bromomethyl)-2-(1-methyl-1H-pyrazol-4-yl)pyridine
[0873] In a reaction flask under nitrogen protection, 800 mg (4.2 mmol) of (2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)methanol, 2.1 g (6.3 mmol), and 30 mL of dichloromethane were added sequentially, followed by the addition of triphenylphosphine (1.7 g, 6.3 mmol). The reaction was stirred at room temperature for 1 hour until complete. The concentrated residue was purified by rapid column chromatography (dichloromethane:methanol = 100:0–90:10 gradient elution) to give 1.06 g of the title product as a pale yellow solid. MS (m / z): 252.0 [M+H] + .
[0874] (D)5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)methyl)pyridin-2-amine
[0875] In a reaction flask under nitrogen protection, 4-(bromomethyl)-2-(1-methyl-1H-pyrazol-4-yl)pyridine (200 mg, 0.79 mmol), 2-aminopyridine-5-boronic acid pinacol ester (262 mg, 1.2 mmol), tripotassium phosphate (503 mg, 2.4 mmol), dioxane / water (10 mL / 2 mL), and Pd(dppf)Cl2 (58 mg, 0.08 mmol) were added sequentially. The mixture was heated to 90 °C and stirred overnight. After cooling to room temperature, the mixture was concentrated, and the residue was purified by rapid column chromatography (water:methanol = 100:0–0:100 gradient elution) and rapid column chromatography (dichloromethane:methanol = 100:0–90:10 gradient elution) to give 50 mg of the title product as a white solid. MS (m / z): 266.1 [M+H] + .
[0876] (E)1,2-Dimethyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)methyl)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidin-5-carboxamide
[0877] In a reaction flask under nitrogen protection, 5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)methyl)pyridin-2-amine (50 mg, 0.19 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (64 mg, 0.38 mmol), HATU (144 mg, 0.38 mmol), DMF (5 mL), and DMAP (116 mg, 0.95 mmol) were added sequentially. The mixture was heated to 40 °C and stirred for two days. After adding water (2 mL), the mixture was purified by rapid column chromatography (water (0.5% formic acid):methanol = 100:0-0:100 gradient elution) to give 30 mg of the title product as a white solid. MS (m / z): 416.1 [M+H] + .
[0878] 1H NMR (400MHz, DMSO-d6) δ11.73(s,1H),8.72(s,1H),8.38(d,J=5.0Hz,1H),8.34(d,J=2.1Hz,1H),8.24(s,1H),8.19(d,J=8.5Hz,1H) ,7.96(s,1H),7.76(dd,J=8.4,2.0Hz,1H),7.57(s,1H),7.04(d,J=4.9Hz,1H),3.96(s,2H),3.87(s,3H),3.57(s,3H),2.63(s,3H).
[0879] Compound 128
[0880] 2-Methyl-1-(trideuteratedmethyl)-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide
[0881]
[0882] (A) 2-Methyl-1-(trideuterated methyl)-6-oxo-1,6-dihydropyrimidine-5-carboxynitrile
[0883] In a reaction flask, 2-methyl-6-oxo-1,6-dihydropyrimidin-5-carboxynitrile (2702 mg, 20.0 mmol), deuterated iodomethane (3189 mg, 22.0 mmol), and potassium carbonate (4146 mg, 30.0 mmol) were dissolved in dimethyl sulfoxide (10 mL). After stirring at room temperature for 15 hours, the mixture was purified by rapid column chromatography (water:methanol = 100:0–0:100 gradient elution) to give the title product (2.05 g, yield 67.3%) as a white solid. MS (m / z): 153.0 [M+H] +
[0884] (B) 2-Methyl-1-(trideuterated methyl)-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid
[0885] 2-Methyl-1-(trideuteratedmethyl)-6-oxo-1,6-dihydropyrimidin-5-carboxynitrile (2.05 g, 13.47 mmol) was dissolved in concentrated hydrochloric acid (10 mL) in a reaction flask, and the reaction mixture was heated under reflux for 2 hours. The reaction mixture was concentrated to dryness, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give the title product (1.6 g, yield 69.4%) as a white solid. MS (m / z): 172.0 [M+H] +
[0886] (C)2-Methyl-1-(trideuteratedmethyl)-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide
[0887] 5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine (1.92 g, 7.18 mmol), 2-methyl-1-(trideuterated methyl)-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (1.60 g, 9.34 mmol), HATU (3.55 g, 9.34 mmol), 4-dimethylaminopyridine (1.14 g, 9.34 mmol), and N,N-dimethylformamide (20 mL) were added sequentially to the reaction flask, and the reaction was stirred at room temperature for 15 hours. After the reaction was complete, water (2 mL) was added and the mixture was concentrated. The residue was purified by rapid column chromatography (elution of water (0.05% formic acid) / methanol = 100:0-0:100 gradient) to give a white solid. The white solid was recrystallized from dichloromethane and methanol to give the title product (2.4 g, yield 79.5%). MS (m / z): 421.0 [M+H] +
[0888] 1 H NMR (400MHz, DMSO-d6) δ11.85(s,1H),8.73(d,J=0.7Hz,1H),8.36(d,J=5.7Hz,1H),8.33(d,J=9.0Hz,1H),8.29(d,J=2.9Hz,1 H),8.25(s,1H),7.96(s,1H),7.76(dd,J=9.0,2.9Hz,1H),7.24(d,J=2.4Hz,1H),6.76-6.67(m,1H),3.83(s,3H),2.62(s,3H).
[0889] Compound 129
[0890] 1,2-Dimethyl-N-(5-((2-(1-(trideuteratedmethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide
[0891]
[0892] (A) 1-(trideuterated methyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxoborhexacyclopentan-2-yl)-1H-pyrazole
[0893] In a reaction flask, 4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)-1H-pyrazole (582 mg, 3.0 mmol) was dissolved in N,N-dimethylformamide (5 mL). Sodium hydride (132 mg, 3.3 mmol) was added fractionally to the reaction solution at room temperature. After the addition was complete, the reaction solution was stirred at room temperature for 10 minutes, followed by the addition of deuterated iodomethane (522 mg, 3.6 mmol). The reaction solution was then stirred at room temperature for 4 hours. After the reaction was complete, the reaction solution was quenched with water and extracted with ethyl acetate. The organic phases were combined, concentrated, and purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give the title product (420 mg, 66% yield) as a white solid. MS (m / z): 212.1 [M+H] +
[0894] (B) 5-((2-(1-(trideuterated methyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine
[0895] 1-(trideuteratedmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxoborhexacyclopentan-2-yl)-1H-pyrazole (441 mg, 1.99 mmol), 5-((2-bromopyridin-4-yl)oxy)pyridin-2-amine (447 mg, 1.66 mmol), Pd(dppf)Cl2 (124 mg, 0.17 mmol), and potassium carbonate (458 mg, 3.32 mmol) were dissolved in a mixture of 1,4-dioxane (20 mL) and water (5 mL). The mixture was heated to reflux and stirred for 15 hours. The reaction solution was cooled to room temperature and concentrated to obtain a crude product, which was purified by rapid column chromatography (water (0.05% formic acid) / methanol = 100:0-0:100 gradient elution) to give the title product (370 mg, 82.5% yield) as a white solid. MS(m / z): 271.1 [M+H] +
[0896] (C)1,2-Dimethyl-N-(5-((2-(1-(trideuteratedmethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide
[0897] 5-((2-(1-(trideuteratedmethyl)-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine (135 mg, 0.5 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (126 mg, 0.75 mmol), HATU (285 mg, 0.75 mmol), 4-dimethylaminopyridine (92 mg, 0.75 mmol), and N,N-dimethylformamide (3 mL) were added sequentially to the reaction flask. The reaction mixture was stirred at room temperature for 15 hours. After the reaction was completed, the reaction mixture was quenched with 2 mL of water, concentrated, and the crude product was purified by rapid column chromatography (water (0.05% formic acid) / methanol = 100:0-0:100 gradient elution) to give the title product as a white solid (85 mg, yield 40.47%). MS (m / z): 421.0 [M+H] +
[0898] 1 H NMR(400MHz,DMSO-d6)δ11.84(s,1H),8.72(s,1H),8.42-8.27(m,3H),8.24(s,1H),7.95(s ,1H),7.76(d,J=6.7Hz,1H),7.23(s,1H),6.71(d,J=3.6Hz,1H),3.56(s,3H),2.61(s,3H).
[0899] Compound 130
[0900] N-(5-((2-(1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidin-5-carboxamide
[0901]
[0902] (A) 5-((2-(1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine
[0903] In a reaction flask, 5-((2-chloropyridin-4-yl)oxy)pyridine-2-amine (222 mg, 1.0 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxoborhexacyclopentan-2-yl)-1H-pyrazole (388 mg, 2.0 mmol), Pd(dppf)Cl2 (73 mg, 0.1 mmol), and potassium carbonate (276 mg, 2.0 mmol) were dissolved in a mixture of 1,4-dioxane (20 mL) and water (5 mL). The mixture was heated to reflux and stirred for 15 hours. The reaction was cooled to room temperature, and the crude product was concentrated and purified by rapid column chromatography (water (0.05% formic acid) / methanol = 100:0-0:100 gradient elution) to give the title product (120 mg, yield 47.4%) as a white solid. MS (m / z): 254.0 [M+H] +
[0904] (B)N-(5-((2-(1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidin-5-carboxamide
[0905] 5-((2-(1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine (120 mg, 0.47 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (128 mg, 0.76 mmol), HATU (289 mg, 0.76 mmol), 4-dimethylaminopyridine (93 mg, 0.76 mmol), and N,N-dimethylformamide (3 mL) were added sequentially to a reaction flask. The reaction mixture was heated at 45 °C for 15 hours. After the reaction was completed, the reaction mixture was quenched with 2 mL of water and concentrated to obtain a crude product. The crude product was purified by rapid column chromatography (water (0.05% formic acid) / methanol = 100:0-0:100 gradient elution) to give the title product (18 mg, yield 9.5%) as a white solid. MS (m / z): 404.0 [M+H] +
[0906] 1 H NMR (400MHz, DMSO-d6) δ12.99(s,1H),11.85(s,1H),8.73(s,1H),8.37(d,J=5.7Hz,1H),8.34(d,J=9.0Hz,1H),8.30(d,J=2.9H z,1H),8.03(s,1H),7.76(dd,J=9.0,2.9Hz,1H),7.34(d,J=2.4Hz,1H),6.70(dd,J=5.7,2.4Hz,1H),3.57(s,3H),2.63(s,3H).
[0907] Compound 131
[0908] 2-Methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide
[0909]
[0910] (A) 2-Methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid
[0911] 2-Methyl-6-oxo-1,6-dihydropyrimidin-5-carboxynitrile (1.35 g, 10.0 mmol) was dissolved in concentrated hydrochloric acid (10 mL) in a reaction flask. The reaction mixture was heated under reflux for 2 hours. The reaction mixture was concentrated to dryness, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give the title product (1.1 g, yield 71.4%) as a white solid. MS (m / z): 155.0 [M+H] +
[0912] (B) 2-Methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidin-5-carboxamide
[0913] 5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine (134 mg, 0.5 mmol), 2-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (123 mg, 0.8 mmol), HATU (304 mg, 0.8 mmol), 4-dimethylaminopyridine (98 mg, 0.8 mmol), and N,N-dimethylformamide (3 mL) were added sequentially to the reaction flask. The reaction mixture was heated at 45 °C for 15 hours. After the reaction was completed, the reaction mixture was quenched with 2 mL of water, concentrated, and the crude product was purified by rapid column chromatography (water (0.05% formic acid) / methanol = 100:0-0:100 gradient elution) to give the title product (130 mg, yield 64%) as a white solid. MS (m / z): 404.0 [M+H] +
[0914] 1H NMR (400MHz, DMSO-d6) δ12.02(s,1H),8.71(s,1H),8.36(d,J=5.7Hz,1H),8.33(d,J=9.0Hz,1H),8.28(d,J=2.8Hz,1H),8.24( s,1H),7.95(s,1H),7.75(dd,J=9.0,2.9Hz,1H),7.23(d,J=2.3Hz,1H),6.71(dd,J=5.7,2.4Hz,1H),3.83(s,3H),2.40(s,3H).
[0915] Compound 132
[0916] 2-(2-hydroxyethyl)-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide
[0917]
[0918] 2-Methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide (100 mg, 0.248 mmol), formaldehyde aqueous solution (1 mL), and ethanol (3 mL) were added sequentially to a microwave tube. The microwave tube was sealed, and the reaction solution was reacted in a microwave reactor at 140 °C for 1 hour. After the reaction was completed, the reaction solution was concentrated to dryness, and the residue was purified by rapid column chromatography (water (0.05% formic acid) / methanol = 100:0-0:100 gradient elution), followed by preparative thin-layer chromatography to obtain the title product (9 mg, yield 8.4%) as a white solid. MS (m / z): 434.0 [M+H] +
[0919] 1 H NMR (400MHz, DMSO-d6) δ12.13(s,1H),8.74(s,1H),8.36(dd,J=9.9,7.4Hz,2H),8.28(d,J=2.9Hz,1H),8.25(s,1H),8.15(s,1H),7.96(s,1H ),7.75(dd,J=9.0,2.9Hz,1H),7.23(d,J=2.4Hz,1H),6.72(dd,J=5.7,2.4Hz,1H),3.83(s,3H),3.78(t,J=6.2Hz,2H),2.80(t,J=6.2Hz,2H).
[0920] Compound 133
[0921] 2-(hydroxymethyl)-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide
[0922]
[0923] (A) 2-Methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid
[0924] 2-Methyl-6-oxo-1,6-dihydropyrimidine-5-carboxynitrile (6.0 g, 44.4 mmol) was dissolved in concentrated hydrochloric acid (15 mL) in a reaction flask. The reaction solution was heated under reflux for 2 hours. The reaction solution was concentrated to dryness, and the crude product was directly used for the next reaction without purification (6.84 g, 100% yield). MS (m / z): 155.2 [M+H] +
[0925] (B) Ethyl 2-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate
[0926] In a reaction flask, the acid intermediate 2-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (6.84 g, 44.4 mmol) prepared in the previous step was dissolved in ethanol (100 mL). The mixture was then added dropwise with thionyl chloride (5 mL) under ice bath conditions. After the addition was complete, the reaction mixture was refluxed for 15 hours. After the reaction was completed, the reaction mixture was concentrated, and the residue was purified by rapid column chromatography (elution of water (0.05% formic acid) / methanol = 100:0–0:100 gradient) to give the title product (4.5 g, 55.6% yield of the two-step reaction). MS (m / z): 183.2 [M+H] +
[0927] (C) ethyl 2-(chloromethyl)-6-oxo-1,6-dihydropyrimidine-5-carboxylate
[0928] Ethyl 2-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate (4500 mg, 24.7 mmol), N-chlorosuccinimide (3298 mg, 24.7 mmol), and dichloromethane (100 mL) were added sequentially to the reaction flask. The mixture was heated under reflux for 2.5 hours. After the reaction was complete, the reaction solution was cooled to room temperature and quenched with water. The reaction solution was concentrated to dryness, and the residue was purified by rapid column chromatography (elution of water (0.05% formic acid) / methanol = 100:0–0:100 gradient) to give the title product (1.7 g, yield 37.7%) as a white solid. MS (m / z): 217.0 [M+H] +
[0929] (D)2-(chloromethyl)-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid
[0930] Ethyl 2-(chloromethyl)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (1.7 g, 7.85 mmol) was dissolved in concentrated hydrochloric acid (15 mL) in a reaction flask, and the reaction mixture was heated under reflux for 2 hours. The reaction mixture was concentrated to dryness, and the residue was purified by rapid column chromatography (water / methanol = 100:0–0:100 gradient elution) to give the title product (1.2 g, 81% yield) as a white solid. MS (m / z): 189.0 [M+H] +
[0931] (E)2-(chloromethyl)-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidin-5-carboxamide
[0932] 5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine-2-amine (1742 mg, 6.52 mmol), 2-(chloromethyl)-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (1.23 g, 6.52 mmol), HATU (2.73 g, 7.17 mmol), 4-dimethylaminopyridine (876 mg, 7.17 mmol), and N,N-dimethylformamide (15 mL) were added sequentially to the reaction flask. The reaction mixture was stirred at room temperature for 15 hours. After the reaction was completed, the reaction mixture was quenched with 2 mL of water, concentrated, and the crude product was purified by rapid column chromatography (water (0.05% formic acid) / methanol = 100:0-0:100 gradient elution) to give the title product (1.8 g, 63% yield) as a white solid. MS (m / z): 438.1 [M+H] +
[0933] (F)(5-((5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)carbamoyl)-6-oxo-1,6-dihydropyrimidin-2-yl)methyl acetate
[0934] 2-(chloromethyl)-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidin-5-carboxamide (500 mg, 1.14 mmol), potassium acetate (500 mg, 5.1 mmol), and N,N-dimethylformamide (4 mL) were added sequentially to the reaction flask. The reaction mixture was heated at 80 °C for 15 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and quenched with water (1 mL). The reaction mixture was concentrated, and the crude product was purified by rapid column chromatography (water (0.05% formic acid) / methanol = 100:0-0:100 gradient elution) to give the title product (290 mg, yield 55.1%) as a white solid. MS (m / z): 462.2 [M+H]+
[0935] (G)2-(hydroxymethyl)-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidin-5-carboxamide
[0936] The following solutions were added sequentially to a reaction flask: methyl 5-((5-(((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)carbamoyl)-6-oxo-1,6-dihydropyrimidin-2-yl)acetate (30 mg, 0.065 mmol), methanol (3 mL), and sodium methoxide (14 mg, 0.26 mmol). The reaction mixture was stirred at room temperature for 1 hour. After the reaction was complete, the pH of the reaction mixture was adjusted to approximately 5 with dilute hydrochloric acid (2 M). The reaction mixture was concentrated, and the crude product was purified by rapid column chromatography (elution of water (0.05% formic acid) / methanol = 100:0-0:100 gradient) to give the title product (15 mg, yield 55.5%) as a white solid. MS (m / z): 420.1 [M+H] +
[0937] 1 H NMR (400MHz, DMSO-d6) δ12.19(s,1H),8.65(s,1H),8.36(d,J=5.7Hz,1H),8.33(d,J=9.0Hz,1H),8.28(d,J=2.8Hz,1H),8.24(s,1H), 7.95(s,1H),7.74(dd,J=9.0,2.9Hz,1H),7.22(d,J=2.3Hz,1H),6.71(dd,J=5.7,2.4Hz,1H),5.86(s,1H),4.44(s,2H),3.82(s,3H).
[0938] Compound 134
[0939] 2-Hydroxy-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidine-5-carboxamide
[0940]
[0941] (A)(methyl-5-((5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)carbamoyl)-6-oxo-1,6-dihydropyrimidin-2-yl)methyl acetate
[0942] To the reaction flask, methyl (5-((5-(((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)carbamoyl)-6-oxo-1,6-dihydropyrimidin-2-yl)acetate (200 mg, 0.433 mmol), potassium carbonate (72 mg, 0.519 mmol), N,N-dimethylformamide (3 mL), and methyl iodoformate (62 mg, 0.433 mmol) were added sequentially. The reaction mixture was stirred at room temperature for 4 hours. After the reaction was complete, the reaction mixture was quenched with water, extracted with ethyl acetate, and the organic phases were combined. The organic phase was concentrated and purified by rapid column chromatography (water / methanol = 100:0-0:100 gradient elution) to give the title product as a white solid (140 mg, yield 67.96%). MS (m / z): 476.1 [M+H] +
[0943] (B) 2-Hydroxy-1-methyl-N-(5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-6-oxo-1,6-dihydropyrimidin-5-carboxamide
[0944] (1-Methyl-5-((5-(((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)carbamoyl)-6-oxo-1,6-dihydropyrimidin-2-yl)methyl acetate (48 mg, 0.1 mmol), methanol (3 mL), and sodium methoxide (216 mg, 0.4 mmol) were added sequentially to the reaction flask. The reaction mixture was stirred at room temperature for 1 hour. After the reaction was complete, the pH of the reaction mixture was adjusted to approximately 5 with dilute hydrochloric acid (2 M). The reaction mixture was concentrated, and the crude product was purified by rapid column chromatography (elution of water (0.05% formic acid) / methanol = 100:0-0:100 gradient) to give the title product (10 mg, yield 23.8%) as a white solid. MS (m / z): 420.1 [M+H] +
[0945] 1 H NMR (400MHz, DMSO-d6) δ11.69(s,1H),8.45(s,1H),8.35(d,J=5.6Hz,1H),8.31(d,J=8.9Hz,1H),8.24(s,2H),7 .95(s,1H),7.70(d,J=9.0Hz,1H),7.22(d,J=2.0Hz,1H),6.70(dd,J=5.5,2.0Hz,1H),3.82(s,3H),3.21(s,3H).
[0946] Compound 135
[0947] N-(5-((2-(3-hydroxy-1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidin-5-carboxamide)
[0948]
[0949] (A) 3-(benzyloxy)-1-methyl-1H-pyrazole
[0950] In a reaction flask under nitrogen protection, 1-methyl-1H-pyrazole-3-ol (4 g, 41 mmol), potassium carbonate (6.8 g, 49 mmol), and DMF (50 mL) were added sequentially. Benzyl bromide (8.4 g, 49 mmol) was added dropwise under ice bath conditions. The mixture was heated to room temperature and stirred for 1.5 hours, then heated to 50 °C and stirred for another 4 hours. After cooling to room temperature, water (100 mL) and ethyl acetate (150 mL) were added. After separation, the organic phase was washed twice with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by rapid column chromatography (petroleum ether:ethyl acetate = 100:0-0:100 gradient elution) to give 4.7 g of the colorless oily title product. MS (m / z): 189.1 [M+H] +
[0951] (B) 3-(benzyloxy)-4-iodo-1-methyl-1H-pyrazole
[0952] In a reaction flask under nitrogen protection, 3-(benzyloxy)-1-methyl-1H-pyrazole (4.7 g, 25 mmol), acetonitrile (60 mL), cerium ammonium nitrate (8.22 g, 15 mmol), and elemental iodine (3.8 g, 15 mmol) were added sequentially, and the mixture was stirred at room temperature for 2 hours. After cooling in an ice bath, the mixture was extracted dropwise with 5% sodium bisulfite (100 mL) and ethyl acetate (100 mL). The organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by rapid column chromatography (petroleum ether:ethyl acetate = 100:0-0:100 gradient elution) to give 5.1 g of the brown oily title product. MS (m / z): 315.0 [M+H] +
[0953] (C)3-(benzyloxy)-1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)-1H-pyrazole
[0954] In a reaction flask under nitrogen protection, 3-(benzyloxy)-4-iodo-1-methyl-1H-pyrazole (5.1 g, 16 mmol) and anhydrous tetrahydrofuran (80 mL) were added sequentially. After cooling to -10°C in an ice-salt bath, isopropyl magnesium chloride (12 mL, 24 mmol) was added dropwise. The mixture was then heated to 0°C and stirred for 1.5 hours. After cooling to -10°C again in an ice-salt bath, 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxoboronylcyclopentane (5.95 g, 32 mmol) was added dropwise, followed by slow heating to room temperature and stirring for 4 hours. The mixture was extracted with saturated ammonium chloride (100 mL) and ethyl acetate (100 mL). The organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by rapid column chromatography (petroleum ether:ethyl acetate = 100:0-0:100 gradient elution) to give 4.6 g of the title product as a colorless oil. MS (m / z): 315.2 [M+H] +
[0955] (D)5-((2-(3-(benzyloxy)-1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine
[0956] In a reaction flask under nitrogen protection, 3-(benzyloxy)-1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)-1H-pyrazole (1.57 g, 5 mmol), 5-((2-chloropyridin-4-yl)oxy)pyridin-2-amine (742 mg, 3.33 mmol), cesium carbonate (2.7 g, 8.3 mmol), tetrakis(triphenylphosphine)palladium (380 mg, 0.33 mmol), and DMF / H₂O (18 mL / 6 mL) were added sequentially. The mixture was heated to 90 °C and stirred overnight. After cooling to room temperature, the mixture was concentrated, and the residue was purified by rapid column chromatography (elution of water (0.1% formic acid):acetonitrile = 100:0-0:100 gradient) to give 1.2 g of the title product as a pale yellow solid. MS (m / z): 374.2 [M+H] +
[0957] (E)4-(4-((6-aminopyridin-3-yl)oxy)pyridin-2-yl)-1-methyl-1H-pyrazol-3-ol
[0958] In a reaction flask, 1.2 g (3.33 mmol) of 5-((2-(3-(benzyloxy)-1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine, 60 mL of methanol, 6 mL of dichloromethane, and 600 mg of palladium hydroxide were added sequentially. After purging with hydrogen, the mixture was stirred overnight at room temperature. The mixture was filtered, the filter cake was washed with methanol, the filtrates were combined and concentrated, and the residue was purified by rapid column chromatography (dichloromethane:methanol = 100:0-90:10 gradient elution) to give 590 mg of the title product as a white solid. MS (m / z): 284.1 [M+H] +
[0959] (F)N-(5-((2-(3-hydroxy-1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-1,2-dimethyl-6-oxo-1,6-dihydropyrimidin-5-carboxamide)
[0960] In a reaction flask under nitrogen protection, 4-(4-((6-aminopyridin-3-yl)oxy)pyridin-2-yl)-1-methyl-1H-pyrazol-3-ol (283 mg, 1 mmol), 1,2-dimethyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (202 mg, 1.2 mmol), HATU (570 mg, 1.5 mmol), DMF (10 mL), and DMAP (183 mg, 1.5 mmol) were added sequentially. The mixture was heated to 40 °C and stirred overnight. Water (2 mL) was added, and the mixture was purified by rapid column chromatography (water (0.1% formic acid):acetonitrile = 100:0-0:100 gradient elution) and preparative thin-layer chromatography to give 75 mg of the title product as a white solid. MS (m / z): 434.2 [M+H] +
[0961] 1 H NMR(400MHz,DMSO-d6)δ11.89(s,1H),10.96(s,1H),8.76(s,1H),8.45-8.28(m,3H),8.07(s,1H),7.81(dd,J =9.0, 2.9Hz, 1H), 7.24 (d, J = 2.4Hz, 1H), 6.76 (dd, J = 5.8, 2.5Hz, 1H), 3.65 (s, 3H), 3.59 (s, 3H), 2.65 (s, 3H).
[0962] Example 3
[0963] Determining CSF1R kinase activity at the molecular level
[0964] 1. Reagents and materials:
[0965] Z-LYTE TMTyr 1 substrate peptide: Invitrogen, PV3190;
[0966] 5X kinase buffer: Invitrogen, PV3189;
[0967] 10mM ATP: Invitrogen, PV3227;
[0968] Development reagent B: Invitrogen, PV3295;
[0969] Development buffer: Invitrogen, P3127;
[0970] Termination solution: Invitrogen, P3094;
[0971] Recombinant human CSF1R kinase: Invitrogen, PR4598A;
[0972] 384-hole blackboard: Corning, 3575;
[0973] Envision: Perkin Elmer.
[0974] 2. Preparation of reaction solution
[0975] 1) 1.33X Kinase Buffer: Dilute 5X kinase buffer to 1.33X with ddH2O.
[0976] 2) 4X dilution of the test compound: The test compound was serially diluted to a 4-fold reaction concentration while maintaining the DMSO concentration at 8%. The final reaction concentrations of the compounds were: 1, 0.33, 0.11, 0.037, 0.012, 0.004, 0.0014, and 0.00046 μM, with a final DMSO concentration of 2%.
[0977] 3) Kinase / substrate peptide mixture: In 1.33X kinase buffer, mix the kinase and Z-LYTE... TM The Tyr 1 substrate peptide was diluted to 0.12 μg / mL and 4 μM, respectively, to prepare kinase / substrate peptide mixtures. The mixtures were then gently mixed using a pipette.
[0978] 4) Phosphorylated substrate peptide solution (PP solution): Add 0.4 μL of Z-LYTE... TM Tyr1 phosphorylated substrate peptide was added to 99.6 μL of 1.33X kinase buffer.
[0979] 5) ATP solution: Dilute 10 mM ATP with 1.33X kinase buffer to 760 μM to prepare ATP solution.
[0980] 6) Development solution: Dilute Development reagent B with Development buffer at a ratio of 1:200.
[0981] 3. Methods
[0982] 1) Kinase reaction (10μL system)
[0983] Add 2.5 μL of the 4X test compound to each well of a 384 plate, and add the corresponding volume of 8% DMSO to each control well. Place the plate on ice. Add 5 μL of the kinase / substrate peptide mixture, 2.5 μL of kinase buffer, and ATP solution to each well sequentially. Set up three control groups: Group C1 contains only kinase buffer, Group C2 contains the kinase / substrate peptide mixture, kinase buffer, and ATP, and Group C3 contains 5 μL of PP solution. After adding the reaction components, seal the 384-well plate in the dark and incubate at 25–30 °C for 1 hour.
[0984] 2) Development response
[0985] Add 5 μL of Development solution to each well, seal the wells to protect them from light, and incubate at 25-30°C for 1 hour.
[0986] 3) Termination of reaction and plate reading
[0987] Add 5 μL of stop solution to each well. Measure the Coumarin value (excitation wavelength 400 nm).
[0988] The emitted light wavelength is 445nm) and the Fluorescein value (excitation light wavelength is 400nm, emitted light wavelength is 520nm).
[0989] 4. Data Analysis
[0990] % phosphorylation rate = 100% - 100% × [ER × C3 520nm - C3 445nm] / [(C1 445nm - C3 445nm) + ER × (C3 520nm - C1 520nm)]
[0991] in:
[0992] ER (Emission Ratio): Coumarin emission reading (445nm) / Fluorescein emission reading (520nm);
[0993] C3 445nm: Emission reading of 100% phosphorylated Coumarin;
[0994] C3 520nm: Emission reading of 100% phosphorylated Fluorescein;
[0995] C1 445nm: Emission reading of 0% phosphorylated Coumarin;
[0996] C1 520nm: Emission reading of 0% phosphorylated Fluorescein.
[0997] Inhibition rate % (IR) = [1 - % phosphorylation rate] 待测样品 / 100% phosphorylation rate 对照 ]×100%
[0998] in:
[0999] % phosphorylation rate 待测样品 Phosphorylation rate of the compound to be tested;
[1000] 100% phosphorylation rate 对照 Phosphorylation rate of C3 control group.
[1001] 5.IC 50 Value: XL-Fit software bundled with Microsoft Excel by ID Business Solutions (Guildford, UK) TM (Version 5.3) Calculation.
[1002] 6. Test Results
[1003]
[1004]
[1005] Example 4
[1006] Detection of CSF1R phosphorylation activity at the cellular level
[1007] 1. Cell lines
[1008] THP-1 (ATCC) is a human acute monocytic leukemia cell line. These cells are cultured in RPMI containing 10% FBS.
[1009] In 1640 culture medium.
[1010] 2. Reagents and Instruments
[1011] Human phosphorylated-CSF1R ELISA kit: R&D, #DYC3268-2;
[1012] • RPMI 1640 culture medium: GIBCO, #10491;
[1013] • Human M-CSF recombinant cytokine: R&D, #216-MC-500;
[1014] • Cell lysis buffer: Cell Signal, #9803S;
[1015] • 1XPBS buffer (1L): Dissolve 8.0g NaCl, 0.2g KCl, 3.58g Na2HPO4-12H2O, and 0.24g KH2PO4 in 1L dd H2O and adjust the pH to 7.4;
[1016] • Blocking solution: PBS buffer containing 1% BSA;
[1017] • PBST washing buffer: PBS buffer containing 0.05% Tween-20;
[1018] • Developing substrate: R&D, #DY999;
[1019] ·2N H2SO4;
[1020] • Microplate reader: Labsystems Multiskan K3: Thermo; Envision: Perkin Elmer;
[1021] ·ELISA plate: Corning, #9018;
[1022] • Cell culture plate: Facol, #353027.
[1023] 3. Cell processing and lysis buffer preparation
[1024] THP-1 cells were resuspended in RPMI-1640 medium containing 2% FBS at a concentration of 5 × 10⁻⁶ cells / mL. 4 Add 50 μL of the compound to each well of a 96-well plate and incubate overnight at 37°C with 5% CO2. Dilute the compound to be tested with serum-free RPMI-1640 medium to 3, 1.1, 0.37, 0.12, 0.04, 0.014, 0.005, and 0.002 μM, with 5% DMSO. Add 5 μL of the diluted compound to 50 μL of cell culture medium and incubate for 60 min at 37°C with 5% CO2. Then add 300 ng / mL M-CSF to the cells and stimulate for 1 min at 37°C. Add 50 μL of cell lysis buffer and store at -80°C.
[1025] 4. ELISA testing steps
[1026] Add 100 μL / well of p-CSF1R capture antibody diluted to 0.8 μg / mL with PBS to the ELISA plate and coat overnight on a shaker at room temperature. After washing with PBST, add blocking buffer and incubate at room temperature for 2 h. Wash with PBST, add 90 μL of cell lysis buffer, and incubate on a shaker at 25°C for 2 h. Wash three times with PBST, add 100 μL of anti-p-tyrosine-HRP detection antibody diluted with 0.1% PBS-BSA, and incubate on a shaker at 25°C for 2 h. After washing with PBST, add 100 μL of chromogenic substrate and incubate at room temperature for 10–20 min. Stop the reaction by adding 50 μL of 2N H2SO4. Detect the optical density signal (450 / 570 nm) of each well using a Labsystems Multiskan K3 or Envision.
[1027] 5. Data Analysis
[1028]
[1029] in:
[1030] • Drug treatment well reading: Represents the optical density signal of the cell pore affected by the test compound.
[1031] • Background reading: Represents the optical density signal of a cell-free pore containing cell lysis buffer.
[1032] • Cell pore reading: Represents the optical density signal of cell pores that have not been treated with the compound.
[1033] 6.IC 50 Calculation: Obtained using XL-Fit 5.3 software.
[1034] 7. Test Results
[1035]
[1036]
[1037] Example 5
[1038] Cell proliferation experiment 1. Cell line
[1039] Ba / F3 BCR-FMS-11 Mouse proto-B lymphocytes stably expressing the BCR-FMS fusion gene were cultured in RPMI 1640 medium containing 10% FBS.
[1040] 2. Reagents and Instruments
[1041] • cckit-8 kit: Dojindo, #CK04;
[1042] Envision: Perkin Elmer;
[1043] • Cell culture plate: Facol, #353027.
[1044] 3. Experimental Procedure
[1045] Ba / F3 cells were transfected with the BCR-FMS fusion gene to screen for a stable BCR-FMS cell line that grows in dependence on CSF-1R. BCR-FMS-11 Ba / F3 BCR-FMS-11 Cell proliferation assays were performed using the CCKit-8 cell counting kit in 96-well plates. Ba / F3 cells were seeded at 100 μL / well in each well of the 96-well plate. BCR-FMS-11 5000 cells / well. After 24 hours, the test compound was diluted to 10, 3.33, 1.11, 0.37, 0.12, 0.037, 0.012, and 0.004 μM, maintaining the DMSO concentration at 5%. 10 μL of each of the eight dilutions was added to the cell culture wells. Cells were incubated at 37°C and 5% CO2 for 72 hours. 10 μL of the cckit-8 cell counting kit was added to each well, and the cells were incubated for another hour at 37°C and 5% CO2. The absorbance at 450 nm was measured in each well using a Perkin Elmer Envision instrument.
[1046] 4. Data Analysis
[1047]
[1048] in:
[1049] • Drug treatment well reading: Represents the optical density signal of the cell pore affected by the test compound.
[1050] • Cell pore reading: Represents the optical density signal of cell pores that have not been treated with the analyte compound (only 0.5% DMSO).
[1051] • Background reading: Represents the optical density signal of the pores in the cell culture medium.
[1052] 5.IC 50 Calculation: Obtained using XL-Fit 5.3 software.
[1053] 6. Test Results
[1054]
[1055]
Claims
1. Use of a compound selected from the following or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a disease mediated by CSF-1R in an individual, wherein said disease is cancer, an autoimmune disease, an inflammatory disease, or a neurodegenerative disease:
2. The use as described in claim 1, wherein the cancer is selected from solid tumors or hematologic malignancies; and the autoimmune disease or inflammatory disease is selected from arthritis, pigmented villonodular synovitis (PVNS), systemic lupus erythematosus, multiple sclerosis, autoimmune nephritis, Crohn's disease, asthma, or chronic obstructive pulmonary disease.
3. The use as described in claim 1, wherein the cancer is selected from ovarian cancer, lung cancer, brain tumor, giant cell tumor of the tendon sheath, gastrointestinal stromal tumor (GIST), gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, melanoma, mesothelioma, mesothelial endometrial carcinoma, kidney cancer, liver cancer, thyroid cancer, squamous cell carcinoma of the head and neck, urothelial carcinoma, bladder cancer, endometrial cancer, choriocarcinoma, adrenal carcinoma, leukemia, lymphoma, or myeloma; and the autoimmune disease or inflammatory disease is selected from rheumatoid arthritis and collagen-induced arthritis.
4. The use as described in claim 1, wherein the autoimmune disease or inflammatory disease is osteoarthritis.
5. The use as claimed in claim 1, wherein the cancer is selected from non-small cell lung cancer and glioblastoma (GBM).
Citation Information
Patent Citations
Vehicle composition containing 1-substituted azacycloheptan-2-ones
US3989816A
Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4444762A
N-hydroxyamide derivatives and use thereof
KR1020120104395A
Novel compounds advantageous in the treatment of central nervous system diseases and disorders
US20160137592A1
